About the Therapeutic Goods Administration (TGA)

• The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices.

• TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary.

• The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices.

• The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action.

• To report a problem with a medicine or medical device, please see the information on the TGA website <www.tga.gov.au>.

About AusPARs

• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.

• AusPARs are prepared and published by the TGA.

• An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications.

• An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time.

• A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
Contents

I. Introduction to product submission ________________________________ 5

   Submission Details ____________________________________________ 5
   Product background ____________________________________________ 5
   Regulatory status ______________________________________________ 5
   Product information ____________________________________________ 6

II. Quality findings _________________________________________________ 6

   Drug substance (active ingredient) ________________________________ 6
   Drug product __________________________________________________ 7
   Quality summary and conclusions ___________________________________ 8

III. Nonclinical findings _____________________________________________ 8

   Introduction ___________________________________________________ 8
   Pharmacology ___________________________________________________ 9
   Pharmacokinetics ________________________________________________ 10
   Toxicology ______________________________________________________ 11
   Major findings __________________________________________________ 13
   Nonclinical summary and conclusions __________________________________ 16

IV. Clinical findings ________________________________________________ 17

   Introduction ____________________________________________________ 17
   Pharmacokinetics ________________________________________________ 18
   Pharmacodynamics _______________________________________________ 23
   Efficacy _________________________________________________________ 27
   Safety __________________________________________________________ 47
   List of questions ________________________________________________ 65
   Clinical summary and conclusions __________________________________ 65

V. Pharmacovigilance findings ________________________________________ 69

   Risk management plan __________________________________________ 69

VI. Overall conclusion and risk/benefit assessment _________________ 72

   Quality _________________________________________________________ 72
   Nonclinical _____________________________________________________ 73
   Clinical _________________________________________________________ 74
   Pharmacodynamics _______________________________________________ 78
   Risk management plan ____________________________________________ 86
   Risk-benefit analysis _____________________________________________ 86
   Outcome _________________________________________________________ 91
Attachment 1. Product Information __________________________ 92
I. Introduction to product submission

Submission Details

Type of Submission: New chemical entity

Decision: Approved

Date of Decision: 17 February 2012

Active ingredient(s): Aflibercept

Product Name(s): Eylea

Sponsor’s Name: Bayer Australia Limited
875 Pacific Highway
Pymble NSW 2073

Dose form(s): Solution for Intravitreal Injection

Strength(s): 40 mg/mL

Container(s): Pre-filled syringe and vial

Pack size(s): One unit per package

Approved Therapeutic use: Eylea (aflibercept) is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Route(s) of administration: Intravitreal

Dosage: Injection volume is 50 μL of Eylea (equivalent to 2 mg aflibercept); one injection intravitreally monthly for three months followed by two monthly injections.

ARTG Number (s): AUST R 180859 and AUST R 180860

Product background

Aflibercept (VEGF Trap-Eye, also abbreviated to VTE) is a new chemical entity, a biological substance that is a recombinant fusion glycoprotein consisting of sequences derived from human vascular endothelial growth factor (VEGF) receptor extracellular domains 1 and 2 are fused to the Fc portion of humanimmunoglobulin subtype G1 (IgG1). For more information on the structure of aflibercept, please refer to the separate quality findings below.

This AusPAR describes the application by Bayer Australia Ltd to register aflibercept (as Eylea) for

The treatment of neovascular (wet) age-related macular degeneration (AMD).

The proposed treatment regimen is intravitreal (IVT) injection of 50 μL solution (containing 2 mg aflibercept) once per month for three consecutive months, followed by one injection every two months.

Regulatory status

At the time of application, Eylea had also been submitted for registration in the European Union, Switzerland and the USA. These applications are all currently under evaluation with their
respective health authorities, with the exception of the USA, where the product was approved by FDA on the 18 November 2011.

Product information

The approved product information (PI) current at the time this AusPAR was prepared can be found as Attachment 1.

II. Quality findings

Drug substance (active ingredient)

Aflibercept is a recombinant protein consisting of sequences derived from human vascular endothelial growth factor (VEGF) receptor extracellular domains fused to the Fc portion of human IgG1. The extracellular domain sequences come from two different VEGF receptors, VEGFR1 (also known as Flt-1) and VEGFR2 (also known as KDR or Flk-1). Each of the VEGF receptors are composed of seven Ig domains in their extracellular regions, with Ig domains 2 and 3 contributing the majority of the binding energy for VEGF. Thus, the amino acid sequence of a single aflibercept subunit comprises Ig domain 2 from VEGFR1, fused to Ig domain 3 from VEGFR2, which is in turn fused to a Fc domain fragment of IgG1. There are no extraneous linker sequences between any of the peptide domains. The schematic structure of the drug substance is shown below:

Figure 1. Schematic structure

Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa) (C_{4318}H_{6788}N_{1164}O_{1304}S_{32}, 2 x 431 amino acids). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain.

The disulfide bond structure of aflibercept determined by peptide mapping matches the known disulfide patterns of the VEGFR1 (Ig domain 2), VEGFR2 (Ig domain 3) and the IgG Fc domain. The C-terminus lacks the predicted lysine residue on the Fc moiety as expected.
Manufacture

The manufacturing of aflibercept drug substance involves growth of a suspension culture of Chinese Hamster Ovary cells (CHO K1) engineered to express aflibercept. The recombinant product is secreted into the culture medium and subsequently purified by chromatographic (Protein A affinity, cation exchange, anion exchange, hydrophobic interaction and size-exclusion chromatography), virus inactivation/filtration and membrane filtration techniques. Cell banking processes are satisfactory.

All viral/prion safety issues have been addressed, including use of animal-derived excipient supplements in the fermentation process and in cell banking.

Physical and chemical properties

Product related impurities include aggregates, truncated species, deamidated variants, charged variants and oxidised forms. The first four forms of impurity are controlled at drug substance release. It is well justified to exclude the testing of oxidised form at the drug substance release.

Specifications

Appropriate validation data were submitted in support of the test procedures.

Drug product

The drug product, 40 mg/mL, is formulated in 10 mM sodium phosphate buffer containing 40 mM NaCl, 0.03% (w/v) polysorbate 20 and 5% (w/v) sucrose, pH 6.2. Two presentations are available:

The vial presentation is supplied in a 2R ISO injection vial. The target fill volume for each vial is 278 µL (100 µL extractable volume) to ensure a single 50 µL injectable dose containing 2 mg aflibercept. One package includes one vial and one filter needle. The injection needle is not supplied.

The syringe presentation is supplied in glass 1 mL syringes. The target fill volume for each syringe is 165 µL (90 µL extractable volume). The syringe, when equipped with a 30 gauge, 0.5 inch needle, can deliver a single 50 µL injectable dose containing 2 mg aflibercept. One blister package contains one syringe. The injection needle is not supplied.

Manufacture

The drug product is sterilised by filtration.

Blisters containing the syringe are either hydrogen peroxide (H₂O₂)-sterilised or ethylene oxide (ETO)-sterilised.

Specifications

Appropriate validation data have been submitted in support of the test procedures.

Stability

Stability data have been generated under real time/stressed conditions to characterise the stability profile of the product. Photostability data shows the product is not photostable and should be stored in its original package.
The real time stability data support a shelf life of “12 months when stored at 2°C to 8°C, protected from light”, for both vial and syringe presentation.

**Quality summary and conclusions**

The draft PI, Consumer Medicine Information (CMI) and container/primary packaging labels are acceptable.

**Summary of evaluation**

The administrative, product usage, chemical, pharmaceutical and microbiological data submitted in support of this application have been evaluated in accordance with the Australian legislation, pharmacopoeial standards and relevant technical guidelines adopted by the TGA.

**Batch release conditions of registration for clinical delegate**

It is a condition of registration that the first five independent batches of Eylea are not released for sale until samples and/or the manufacturer’s release data have been assessed and endorsed for release by the TGA Office of Laboratories and Scientific Services (OLSS).

The sponsor should supply:

1. Certificates of Analysis of all active ingredient (drug substance) and final product.
2. Information on the number of doses to be released in Australia with accompanying expiry dates for the product and diluents (if included).
3. Evidence of the maintenance of registered storage conditions during transport to Australia.
4. 3 vials or 3 syringes of each batch for testing by the Therapeutic Goods Administration OLSS together with any necessary standards, impurities and active pharmaceutical ingredients (with their Certificates of Analysis) required for method development and validation.

These batch release conditions will be reviewed and may be modified on the basis of actual batch quality and consistency.

**III. Nonclinical findings**

**Introduction**

**General comments**

The overall quality of the nonclinical dossier was adequate. All pivotal safety-related studies were conducted under Good Laboratory Practice (GLP) conditions. A safety pharmacology study examining effects of aflibercept on cardiovascular parameters in rodents was non-GLP compliant; nevertheless, the study was well documented, and cardiovascular parameters were also examined as part of GLP compliant general repeat-dose toxicity studies in monkeys. Reports for several non-pivotal, non GLP repeat-dose toxicity studies in mice and rats were of poor quality in some respects; no group means were calculated, clinical signs and the histopathological findings were not tabulated, nor incidences per dose group calculated; the absence of group summary data (such that the results were not presented in a clear and concise
manner) is at odds with the TGA adopted EU guideline on repeated dose toxicity\(^1\). The pivotal toxicity studies were conducted with drug substance manufactured using the commercial process.

**Pharmacology**

**Primary pharmacology**

**Rationale and mechanism of action**

Vascular endothelial growth factor (VEGF or VEGF-A) plays a critical role in angiogenesis. In age-related macular degeneration, VEGF promotes ocular neovascularisation and excessive vascular permeability and oedema. Aflibercept is designed to act as a soluble decoy receptor for VEGFR ligands.

**Efficacy**

*In vitro*, aflibercept was shown to bind to human VEGF-A with subpicomolar affinity (Kd for VEGF-A165, 0.497 pM; Kd for VEGF-A121, 0.360 pM). High affinity was also found for the related angiogenic molecule, PlGF-2 (placental growth factor 2; Kd value, 38.8 pM), which acts through VEGFR-1. Binding to aflibercept occurs with higher affinity than to the ligands’ endogenous receptors (compared to respective Kd values for VEGF-A binding to VEGFR-1 and VEGFR-2, 10–30 pM and 75–760 pM\(^2\) and ~170 pM for PlGF-2 binding to VEGFR-1\(^3\)). The drug’s ability to bind to PlGF may contribute to its pharmacological activity as PlGF is also implicated in the development of neovascular AMD\(^4\). Aflibercept also displayed affinity for PlGF-1 (placental growth factor 1; Kd value, 392 pM); in this case, though, affinity is below that for the endogenous receptor (170 pM for binding to VEGFR-13). The drug’s affinity was similar for the animal and human VEGF isoforms among the species tested (mouse, rat, rabbit). Binding studies were not performed with monkey VEGF as its amino acid sequence is identical to human VEGF. *In vitro* functional studies, aflibercept blocked VEGF-induced phosphorylation of VEGFR-2 and the resultant calcium mobilisation in human umbilical vein endothelial cells (HUVECs). *In vivo*, intravitreal (IVT) injection of aflibercept inhibited retinal neovascularisation in the mouse (oxygen-induced retinopathy model) and choroidal neovascularisation in the monkey (laser-induced), and normalised retinal vascular permeability in the rat (diabetic model).

**Secondary pharmacodynamics and safety pharmacology**

Aflibercept did not to bind to human VEGF-C or VEGF-D. In an immunohistochemical study examining potential cross-reactivity, no specific staining was found for aflibercept (≤25 μg/mL) against a panel of 33 normal human tissues. The Fc region of the aflibercept molecule did not mediate any complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) *in vitro*.

---

\(^1\) CPMP/SWP/1042/99 Rev 1. Guideline on repeated dose toxicity.  


Specialised safety pharmacology studies were limited in scope. Instead, the sponsor has mostly relied on various general repeat-dose toxicity studies that incorporated relevant end points. This approach is acceptable under the applicable TGA adopted EU guideline. Aflibercept had no effect on respiration in rats following IV administration (≤250 mg/kg over 30 min). There was no evidence of particular central nervous system (CNS) toxicity in the repeat-dose toxicity studies; lethargy in rats (at ≥2 mg/kg subcutaneously (SC) administered three times weekly) and reduced activity in monkeys (≥3 mg/kg intravenous (IV) once weekly) were observed, but occurred at doses beyond the maximum tolerated dose (MTD; based on body weight loss or substantial inhibition of body weight gain). Intravitreal (IVT) treatment produced no clinical signs in monkeys (≤4 mg/eye bilateral). Increases in blood pressure were observed in monkeys given aflibercept SC (15–30 mg/kg, twice weekly, but not IV (≤30 mg/kg once weekly). In a specialised study in mice and rats, SC administration of aflibercept increased systolic and diastolic blood pressure in both species that persisted until plasma concentrations of free aflibercept fell below 1 μg/mL. In addition to its function as a vascular growth factor, VEGF is involved in the regulation of blood pressure by modulating available nitric oxide and prostacyclin levels to promote vasodilatation; these results therefore presumably reflect inhibition of circulating VEGF by aflibercept. No electrocardiogram (ECG) abnormalities were observed in monkeys treated with aflibercept SC or IV. Aflibercept did not affect thrombus formation or coagulation parameters in the rabbit (≤30 mg/kg IV). Wound healing was inhibited by aflibercept in rabbits at all doses tested (incisional and excisional models; reductions in blood vessel density, tensile strength, fibrous response and/or epidermal hyperplasia seen at ≥0.3 mg/kg IV); the finding is consistent with the known role of VEGF in wound repair (reviewed by Bao et al., 20097).

Pharmacokinetics

Free aflibercept, and sometimes also VEGF-bound aflibercept, were assayed in pharmacokinetic/toxicokinetic studies. The bound form is pharmaco logically inactive. Following IVT administration in monkeys, levels of free aflibercept in the vitreous were dose-proportional and declined with an estimated half-life of 40–64 h (independent of dose). Peak levels of free aflibercept in plasma were generally reached within 1–3 days post-dose and were detectable for up to 2 or 3 weeks. Bound aflibercept was detected in plasma with 24 h of dosing, peaking at 1–3 weeks post-dose; its apparent clearance was much slower compared to free aflibercept, remaining detectable in plasma in some animals for up to 18 weeks post-dose. Note, however, that the continuous formation of endogenous VEGF obfuscates the determination of the true half-life for bound aflibercept. The proportion of free:bound aflibercept increased with dose, consistent with saturable binding of endogenous VEGF. In rabbits given aflibercept IVT, half-lives for free aflibercept were determined to be 115 h in the vitreous and 157 h in plasma; peak plasma concentration (Cmax) and overall exposure (area under the plasma concentration versus time response curve from time zero to infinity (AUC0–∞)) to free aflibercept in plasma was 950- and 310-times lower, respectively, compared to in the vitreous.

Greater than dose-proportional exposure was observed for free aflibercept in serum in rats and monkeys following SC administration. This may reflect that clearance comprises a saturable component, possibly related to VEGF binding. Again, long half-lives were observed for free

---


aflibercept in serum following IV and SC dosing (~40–50 h in the mouse and rat, and up to ~50–100 h in the monkey). Bioavailability by the SC route was high in mice (94%) and monkeys (85%) and moderate in rats (33%). No sex differences in pharmacokinetic profiles were observed for any route/species.

Distribution to the retina and choroid after IVT administration was shown in the rabbit, with peak and overall exposure to free aflibercept in these tissues ~5% of the corresponding values for the vitreous; half-lives were comparable for all three matrices (115–132 h). With IV dosing in mice, rats and monkeys, steady-state volumes of distribution were only slightly greater than the whole blood volume, consistent with limited distribution outside of the central compartment (as is typical for large molecular weight, protein-based drugs). Results from a tissue distribution study in rats with radioactively labelled (125I)-aflibercept, administered IV, support this. Highest tissue concentrations of radioactivity were found in the liver, followed by other highly perfused tissues. The liver (and not the kidney) was identified as having the major role in the clearance of aflibercept. Consistent with this, functional nephrectomy did not significantly affect the serum kinetics of aflibercept in rats. Given aflibercept’s protein nature, no classical biotransformation studies were conducted; this is in accordance with the relevant TGA adopted EU guideline8.

Anti-aflibercept antibodies were formed in mice, rats and rabbits, and less commonly in monkeys. Their development was associated with decreased drug exposure in rabbits and the rodent species but rarely in monkeys. The aflibercept molecule contains multiple N-linked glycosylation sites. Differences in the extent of sialic acid occupancy were found to affect the drug’s serum kinetics (in rats) but not its potency (assessed in in vitro binding and functional assays).

Pharmacokinetic drug interactions
No nonclinical studies were performed.

Toxicology

Acute toxicity
Single-dose toxicity studies, performed by the IV route in rats, revealed a low order of acute toxicity for aflibercept, with no deaths observed up to the highest dose tested (500 mg/kg).

Repeat-dose toxicity
Repeat-dose toxicity studies by the clinical route (IVT) were conducted in the cynomolgus monkey only (up to 8 months duration). To better characterise the systemic toxicological profile, SC studies were performed in mice (up to 8 weeks duration), rats (up to 13 weeks) and monkeys (up to 13 weeks), and IV studies were performed in the rabbit (2 weeks; in non-pregnant animals as a pilot study for reproductive toxicity) and monkey (up to 6 months). Aflibercept is pharmacologically active in all of these species. IVT dosing was once per 4 weeks in the pivotal and most other studies (consistent with the initial phase of the clinical treatment regimen), or else once per 2 weeks or 6 weeks. The proposed clinical formulation was used in the pivotal IVT study; the strength of aflibercept varied with dose though, being the same as that for Eylea at the mid-dose level and double it at the high-dose level. SC and IV doses were administered more frequently than is proposed clinically for IVT administration, ranging from once per 2 weeks to up to 3 times weekly.

Based on their short duration (≤3 months) and non-ocular route of administration, no rodent study sufficient to be regarded as pivotal has been provided with the current submission (this is not to say that they provided no useful information). A 6-month study in rodents was found not to be feasible due to the development of anti-aflibercept antibodies; repeated intravitreal administration is largely impractical in mice and rats. Considering this, the pre-eminence of the primate over the rodent as a relevant and feasible model for the assessment of the toxicity of the proposed product, and that there is existing experience with the pharmacological class, the reliance on the cynomolgus monkey as a single species for which there is a pivotal study is deemed to be acceptable. Group sizes were adequate; the small group size used in the monkey studies is typical but does limit their predictive value.

**Relative exposure**

Relative systemic exposure in selected toxicity studies has been calculated based on animal:human C\text{max} and AUC for free aflibercept in plasma/serum (see Table 1 below). The human reference values used are from Clinical Study VGFT-OD-0702, obtained following IVT administration of 2 mg aflibercept (clinical formulation) to one eye of patients. The values have been doubled for the calculation here to reflect that Eylea may be administered to both eyes in clinical use.

Relative ocular exposure is considered based on dose adjusted for species differences in vitreous volume\(^9\); the IVT doses used in the pivotal monkey study (0.5, 2 and 4 mg/eye) are 0.3, 1.25 and 2.5-times the proposed human dose (2 mg/eye).

---

\(^9\) Values for vitreous volumes of 3.2 mL in cynomolgus monkeys and 4.0 mL in humans have been used for the calculation here, in accordance with the approach to safety evaluation of Short (2008). Less conservative values (1.5 mL and 4.5 mL, respectively) were used by the author of the Nonclinical Expert Report.
### Table 1. Relative exposure to free aflibercept in selected toxicity studies

<table>
<thead>
<tr>
<th>Species</th>
<th>Study</th>
<th>Route; frequency</th>
<th>Dose</th>
<th>( C_{\text{max}} ) (( \mu \text{g/mL} ))</th>
<th>AUC(_0–28) (( \mu \text{g} \cdot \text{h/mL} ))</th>
<th>Exposure ratio(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mouse (CD-1)</strong></td>
<td>4 weeks PK01017(^a)</td>
<td>SC; three times weekly</td>
<td>10 mg/kg</td>
<td>33.8</td>
<td>–</td>
<td>875</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15 mg/kg</td>
<td>82.2</td>
<td>–</td>
<td>213</td>
</tr>
<tr>
<td><strong>Rat (SD)</strong></td>
<td>13 weeks VGFT-TX-02006(^b)</td>
<td>SC; three times weekly</td>
<td>0.1 mg/kg</td>
<td>77.1</td>
<td>–</td>
<td>199</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.5 mg/kg</td>
<td>235</td>
<td>–</td>
<td>609</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 mg/kg</td>
<td>1701</td>
<td>–</td>
<td>440</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 mg/kg</td>
<td>915</td>
<td>–</td>
<td>237</td>
</tr>
<tr>
<td><strong>Monkey (Cynomolgus)</strong></td>
<td>3 months VGFT-TX-02037(^c)</td>
<td>SC; twice weekly</td>
<td>1.5 mg/kg</td>
<td>31.9</td>
<td>–</td>
<td>825</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 mg/kg</td>
<td>109</td>
<td>–</td>
<td>282</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15 mg/kg</td>
<td>286</td>
<td>–</td>
<td>741</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 mg/kg</td>
<td>721</td>
<td>–</td>
<td>186</td>
</tr>
<tr>
<td></td>
<td>3 months, juvenile VGFT-TX-05010(^d)</td>
<td>IV; once weekly</td>
<td>0.5 mg/kg</td>
<td>9.54</td>
<td>1776</td>
<td>245</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 mg/kg</td>
<td>73.8</td>
<td>19296</td>
<td>338</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 mg/kg</td>
<td>830</td>
<td>16382</td>
<td>286</td>
</tr>
<tr>
<td></td>
<td>6 months VGFT-TX-05009(^e)</td>
<td>IV; once per 1–2/weeks</td>
<td>3 mg/kg</td>
<td>93.2</td>
<td>8832</td>
<td>241</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 mg/kg</td>
<td>305</td>
<td>35952</td>
<td>790</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 mg/kg</td>
<td>730</td>
<td>72336</td>
<td>189</td>
</tr>
<tr>
<td></td>
<td>8 months VGFT-TX-05011(^f)</td>
<td>IVT(^2); once/4 weeks</td>
<td>0.5 mg/eye</td>
<td>0.936</td>
<td>157.6</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 mg/eye</td>
<td>6.97</td>
<td>1394</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 mg/eye</td>
<td>16.9</td>
<td>3360</td>
<td>440</td>
</tr>
<tr>
<td><strong>Human (AMD patients)</strong></td>
<td>VGFT-0D-0702</td>
<td>IVT(^1)</td>
<td>2 mg/eye</td>
<td>0.019</td>
<td>2.856</td>
<td>–</td>
</tr>
</tbody>
</table>

\(^a\) = calculated as animal:human values, following doubling of the clinical reference values to reflect bilateral use; exposure ratios greater than 100 are rounded to the nearest 5; \( = \) no data/not applicable;

\(^1\) = unilateral administration; \(^2\) = bilateral administration; data are the means of male and female values;

\(^x\) = parameters obtained on day 22; \(^y\) = parameters obtained on day 83; \(^z\) = parameters obtained after dosing in week 13;

\(^{x+y}\) = parameters obtained after dosing in week 13 (AUC\(_0–168\) is multiplied by 4, accounting for dosing frequency)

\(^{x+y+z}\) = parameters obtained after dosing in week 21; dosing was once per week to week 15, then once per 2 weeks;

(AUC\(_0–168\) is multiplied by 2 to account for dosing frequency);

\(^{x+y+z+f}\) = parameters obtained after the 7th dose.

### Major findings

IVT administration of aflibercept was associated with an anterior segment/vitreous inflammatory response in monkeys. This was generally mild, usually peaked at 2 days post dose and was completely (anterior) or mostly (vitreous) reversed by 4 weeks post dose.
Administration of the vehicle alone also produced some inflammation. No angiographic or electro-retinographic changes were found in treated monkeys, nor were any ocular abnormalities observed in imaging and microscopic evaluations. Intraocular pressure was unaffected by the drug. Several-fold increases in intraocular pressure (IOP) occurred immediately post dose, though, including following administration of the vehicle only, consistent with injection of a fluid bolus. No animal developed glaucomatous optic nerve head cupping in response to these IOP spikes. The only findings of toxicological significance in the IVT studies involved the nasal turbinates, with microscopic erosion and ulceration of the respiratory epithelium, often accompanied by chronic-active inflammation, seen at 2 and 4 mg/eye in the pivotal study. These lesions were generally mild and demonstrated to be reversible. Based on the absence of effects on other tissues, the nasal turbinate findings are considered more likely to result from local rather than systemic exposure (that is, by way of anastamotic connections between the ophthalmic and nasal venous plexuses or leakage into the nasal lacrimal duct). Cross-species exposure comparisons for such an effect are probably best made on a mg/kg basis: assuming 4 kg body weight for a monkey and 50 kg for a human (as a conservative measure), the lowest-observable-effect level (LOEL; 2 mg/eye) is more than 6 times the human dose and the no-observable-effect level (NOEL; 0.5 mg/eye) is >1.5 times the human dose. More pronounced effects on the nasal cavity were seen with systemic administration in monkeys, along with changes in numerous additional tissues, consistent with the very much higher exposure levels achieved. The nasal cavity findings included atrophy/loss of the septum and/or turbinates associated with necrotising inflammation. The other principal organs targeted were bone (such as osteocartilaginous exostoses of vertebrae; interference with growth plate maturation), kidney (increased glomerular mesangial matrix; glomerulopathy with tubular dilatation and cast formation), adrenals (decreased vacuolisation with eosinophilia of the cortex) and ovary (decreased number of maturing follicles, granulosa cells and/or theca cells). The vertebral changes were accompanied by myofibre atrophy of the overlying axial musculature along the vertebral arches or proliferation/regeneration of the microvasculature adjacent to the exostoses; kyphosis was observed in monkeys treated IV at ≥10 mg/kg/week for 13 weeks and at all dose levels (≥3 mg/kg every 1–2 weeks) in the 6-month study. Renal histopathological changes were associated with decreased serum albumin and/or total protein and increased blood urea nitrogen and urine protein levels. Vascular alterations in various tissues (proliferation/regeneration/fibrosis in duodenum, stomach, rectum, gallbladder, pancreas, heart and/or brain) and hepatic portal inflammation and periportal necrosis were also seen. No NOEL was established for systemic toxicity in the pivotal IV study in monkeys (<3 mg/kg every 1–2 weeks) but a NOEL was established in the IVT study (0.5 mg/eye/4 weeks for 8 months; relative exposure based on AUC was 28).

Mice and rats treated with aflibercept SC commonly and rapidly developed anti-aflibercept antibodies, leading to decreased drug exposure. The kidney was identified as the principal target organ for toxicity in the two rodent species, with glomerulonephritis routinely observed. This finding is consistent with deposition of circulating antigen-antibody complexes in the glomerulus. Other findings in treated mice and/or rats included vascular changes (haemorrhage, congestion and/or dilatation) in various tissues (kidney, liver, lungs and gastrointestinal tract), and changes in teeth (broken, thickened and altered colour) and bone (osteoporosis of femur).

Anti-aflibercept antibodies developed in monkeys at low frequency only in short term studies (4–13 weeks; SC, IV and IVT routes) but their development was more common in the 6 month IV study (39% of treated animals) and the 8 month IVT study (21% of treated animals). This was associated with toxicity in only one case; the sole animal that exhibited anti-aflibercept antibodies in a 13-week IVT study was the only one to show a severe ocular inflammatory response to treatment. Animals are poor models for immunogenicity in humans; the potential immunogenicity of the drug therefore requires particular clinical focus.
**Genotoxicity and carcinogenicity**

No genotoxicity or carcinogenicity studies were included in the submission. Their omission is acceptable in accordance with the TGA adopted EU guideline and justified on the basis that as a large protein the drug is not expected to interact directly with deoxyribonucleic acid (DNA) or other chromosomal material, that chronic rodent studies are not feasible due to immunogenicity, that the drug does not have growth factor activity and did not display immunosuppressant activity in the general repeat-dose toxicity studies.

**Reproductive toxicity**

No specialised fertility study was conducted. Relevant data were obtained, though, as part of the 6 month IV general repeat-dose toxicity study in monkeys. In that study, females showed absent or irregular menses, associated with profound reductions in ovarian hormones (oestradiol, progesterone, and inhibin B) and increases in follicle stimulating hormone (FSH) levels, at all dose levels tested (≥3 mg/kg). Ovarian weight was reduced, accompanied by compromised luteal development and reduction of maturing follicles. Uterine and vaginal atrophy were also found. Following recovery, all aflibercept-treated females exhibited normal ovarian folliculogenesis and presence of medium to large sized corpora lutea; uterine and vaginal atrophy were also reversed. There were no aflibercept-related effects on male reproductive hormone levels (FSH, luteinizing hormone LH and testosterone). Decreased sperm motility and increased sperm abnormalities were evident at all doses; these effects were considered consequential upon fertility but were seen to be fully reversible after the treatment free phase. Due to adverse effects occurring at all the tested doses, No Observable Adverse Effect Levels (NOAELs) for effects on male and female fertility could not be established in the study (relative exposure at the lowest observable effect levels (LOELs) was 1545). Although more limited in terms of the parameters assessed, there were no findings to suggest impairment of fertility in the IVT studies in monkeys (relative exposure based on AUC in the pivotal study, ≤590).

Specialised reproductive toxicity studies conducted by the sponsor covered embryofetal development only. These were conducted in a single species (rabbit) and involved IV administration once every 3 days during the period of organogenesis. Placental transfer was demonstrated by the finding of free aflibercept in the amniotic fluid of pregnant rabbits. Abortions and increased post implantation loss were seen with dosing at 45 and 60 mg/kg. Maternotoxicity was evident at ≥15 mg/kg (as transient body weight loss). Treatment-related external and visceral fetal abnormalities, including malformations, were observed at all dose levels studied (≥3 mg/kg); skeletal malformations and variations were observed at 60 mg/kg and the incidence of incomplete ossification was increased at ≥3 mg/kg. Such effects are unsurprising given the critical role played by angiogenesis in fetal development. No NOEL was established for effects on embryofetal development. Plasma C<sub>max</sub> and AUC values for free aflibercept at the lowest dose tested (3 mg/kg IV) were 56.1 μg/mL and 1935 μg·h/mL, respectively. These are 2907 times and 678 times higher than the C<sub>max</sub> and AUC in patients after IVT administration of 2 mg aflibercept to one eye (Clinical Study VGFT-OD-0702).

No pre-/postnatal development study was conducted. Excretion of aflibercept in milk was not investigated in animals.

**Pregnancy classification**

The sponsor has proposed Pregnancy Category D. This categorisation was considered appropriate based on the drug’s anti-angiogenic activity and the demonstration of teratogenicity in the rabbit. It matches the category for the related anti-VEGF IVT agent ranibizumab (Lucentis®).
**Local tolerance**

Local tolerance following IVT administration was evaluated in the general repeat-dose toxicity studies in monkeys. In a specialised study, no irritation or other local reactions attributable to aflibercept or the vehicle were found following IV, IM and SC administration in the rabbit; the study was adequately conducted. Compatibility with blood was demonstrated (human and monkey).

**Paediatric use**

Eylea is not proposed for use in children and adolescents. A repeat-dose toxicity study in juvenile monkeys (13 weeks duration; IV administration) revealed findings similar to those seen in mature animals, with the skeletal system a particular target of the drug. No study in juvenile animals by the IVT route has been conducted.

**Nonclinical summary and conclusions**

- The sponsor has conducted adequate nonclinical studies on the pharmacodynamics, pharmacokinetics and toxicity of aflibercept according to the relevant guidelines. All pivotal safety related studies were conducted according to GLP.

- Aflibercept acts as a soluble decoy receptor for vascular endothelial growth factor A (VEGF-A) and also placental growth factor 2 (PlGF-2), angiogenic ligands implicated in the pathophysiology of AMD. IVT injection of aflibercept was shown to inhibit retinal/choroidal neovascularisation in mouse and monkey models (oxygen- or laser-induced) and to normalise retinal vascular permeability in the rat (diabetic model).

- Secondary pharmacodynamic studies with aflibercept revealed high specificity. It did not bind to human VEGF-C or VEGF-D and did not exhibit cross-reactivity against a panel of human tissues. The Fc region of the molecule did not mediate complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity *in vitro*. Safety pharmacology examinations revealed increased blood pressure in rodents and monkeys and inhibition of wound healing in rabbits following systemic administration.

- Pharmacokinetic studies in rabbits and monkeys indicated a long half-life for free aflibercept (non-VEGF-bound) in the vitreous after IVT injection (115 h and 40–64 h in the respective species). Long half-lives were also evident in plasma. Distribution to the retina and choroid following IVT administration was shown in the rabbit. A major role was identified for the liver and not the kidney in the systemic clearance of aflibercept.

- Aflibercept displayed a low order of acute toxicity in rats by the IV route.

- Pivotal repeat-dose toxicity studies were conducted in the cynomolgus monkey only; chronic studies in rodents were not feasible due to the development of anti-aflibercept antibodies, which decreased drug exposure. The pivotal monkey studies involved IVT injection once every 4 weeks for 8 months and, to better characterise systemic toxicity, IV administration every 1–2 weeks for 6 months. IVT administration was associated with an anterior segment/vitreous inflammatory response in monkeys (as was the vehicle alone to a lesser degree; generally mild and completely or mostly reversed by 4 weeks post dose); among non-ocular tissues, the only treatment-related finding was erosion and ulceration of the respiratory epithelium of the nasal turbinates. Tissues identified as targets for toxicity in studies involving systemic administration (involving higher exposure) were bone, kidney, adrenals, ovary, and again the nasal cavity.

- Aflibercept was immunogenic in the laboratory animal species, though markedly less so in monkeys compared rodents or rabbits. In monkeys, this rarely affected pharmacokinetics and was associated with toxicity in only one case (finding of a severe ocular inflammatory response).
• No studies on genotoxicity or carcinogenicity were submitted.

• Effects consequent on male and female fertility were seen in monkeys treated with aflibercept IV (decreased sperm motility and increased abnormalities; irregular and absent menses associated with hormonal changes). In an embryofetal development study in rabbits, treatment with aflibercept (administered IV) produced abortions, increased post-implantation loss and caused fetal malformations (external, visceral and skeletal), variations and impairment of ossification.

• The nonclinical submission contained no major deficiencies. The scope of the nonclinical data set is consistent with EU guidelines for a protein-based drug.

• The nonclinical data provide reasonable, if limited evidence of efficacy.

• Increased blood pressure with aflibercept, identified following systemic administration in animals, is not considered likely to occur in patients with IVT treatment considering the lesser exposure.

• Ocular inflammation, seen in monkeys with IVT administration, being generally mild and reversible and partly attributable to the vehicle itself, is not considered to be a toxicologically significant finding in the context of therapy. Other findings in the repeat-dose toxicity studies are largely attributable to the drug’s pharmacological action, disrupting the role of VEGF in microvascular maintenance. The nasal cavity is identified as the principal target for toxicity, with erosions and ulcerations of the epithelium occurring at exposure margins ≥6 in monkeys (based on mg/kg IVT doses; relative exposure at the NOEL, 1.5). [It is noted that the sponsor’s Clinical Overview indicates that there was no evidence of such nasal effects in clinical trial participants.] Effects on the numerous other tissues that were seen in animals with repeated frequent systemic administration are not predicted to occur in patients treated with Eylea based on the existence of a large multiple of the maximum anticipated human exposure at the NOEL established in the monkey (that is, 28 times the clinical AUC).

• Given the limited predictivity of animals, assessment of the potential immunogenicity of aflibercept relies on clinical data.

• The absence of genotoxicity and carcinogenicity studies is acceptable; no particular concern for such effects is held.

• Teratogenicity was observed in the rabbit, beginning at a non maternotoxic dose. No NOEL was established for adverse effects on embryofetal development, the large exposure multiple at the LOEL notwithstanding. Considering these findings and given the pharmacological class (anti-angiogenic agent), placement in Pregnancy Category D is justified and the inclusion of appropriate precautionary statements in the Product Information document is warranted.

• There are no nonclinical objections to the registration of Eylea for the proposed indication.

• Amendments to the PI were also recommended.

IV. Clinical findings

Introduction

This application comprised a conventional clinical data set. All relevant individual patient data were supplied. There were 11 pharmacology/pharmacokinetic/dose finding studies. Two phase III pivotal studies were submitted. They were double blind, randomised, controlled two year
studies. The results submitted, however, were from the end of the first 12 months. There are long term studies that were only evaluable for safety information.

The studies contained in the submission appear to have been conducted according to good clinical practice (GCP).

Data from the following studies were provided:
Primarily pharmacokinetic and pharmacodynamic studies:
- Study VGFT-OD-0702.PK
- Study VGFT-OD-0307
- Study PDY6655
- Study PDY6656

Phase I studies:
- Study VGFT-OD-0502/14395 Part A (CLEAR-IT 1)
- Study VGFT-OD-0502/14395 Part C (CLEAR-IT 1)
- Study VGFT-OD-0603/14396 (CLEAR-IT 1b)
- Study VGFT-OD-0512/14805 (CLEAR-IT DME 1)
- Study VGFT-OD-0305
- Study VGFT-OD-0306

Phase II study:
- Study VGFT-OD-0508/14394 (CLEAR-IT AMD-2)

Pivotal efficacy studies:
- Study VGFT-OD-0605/14393 (VIEW 1)
- Study 311523 (VIEW 2)

Supportive studies:
- Study VGFT-OD-0702/14262
- Study VGFT-OD-0706/13336 (DAVINCI)

Safety studies:
- Study VGFT-OD-0502/14395 Part B (CLEAR-IT 1)

Ongoing studies with limited safety data:
- Study VGFT-OD-0910/14832
- Study VGFT-OD-0819/14232 (COPERNICUS)
- Study 14130 (GALILEO)

**Pharmacokinetics**

Eylea is intended for intravitreal administration and systemic exposure is anticipated to be minimal. The sponsor provided pharmacokinetic studies following intravitreal administration and also following intravenous administration.
Systemic exposure following intravitreal administration

Study VGFT-OD-0702.PK/14263 was a pharmacokinetic sub-study to Study VGFT-OD-0702 (an open-label, long term Phase II safety and tolerability study in subjects with neovascular AMD receiving aflibercept 2 mg every 8 weeks). The study included six subjects with neovascular AMD but the demographic characteristics were not provided. VEGF-trap (aflibercept) was administered as a single 2 mg (50 μL) dose by intravitreal injection. Blood samples were collected at Times 0, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 168 h, Day 15 and Day 29. VEGF-Trap concentrations were determined using an Enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantification (LLOQ) of free VEGF Trap, VEGF Trap:VEGF complex and anti-VEGF Trap antibody were equal to 0.0156 mg/L, 0.0439 mg/L, and 0.238 mg/L respectively. Exposure to free VEGF-trap, expressed as the area under the plasma concentration time curve from time zero to the last measurable time point (AUClast), was median (range) 0.0221 (0 to 0.474) mg.day/L. Exposure to VEGF-trap:VEGF complex expressed as AUClast was median (range) 4.67 (2.12 to 6.71) mg.day/L. The sponsor stated the exposure in terms of Cmax to be approximately 5 fold lower than the maximum mean concentrations in studies of large IV doses (1 mg/kg IV - 4 mg/kg IV) but the reference the sponsor provided does not report AUC data10 (Rudge 2007)11. Anti-VEGF Trap antibodies were unquantifiable in all subjects. Adverse events were not reported.

Study VGFT-OD-0603/14396 (CLEAR-IT 1b) was a double-masked, three arm (two randomised, one open-label) parallel group cohort study of the safety and tolerability of IVT-1 and IVT-2 formulations. VEGF-Trap was administered as a 4 mg intravitreal injection. Blood samples were collected for the measurement of VEGF-Trap concentrations. Cmax was at 12 weeks. Mean (standard error (SE)) VEGF Trap: VEGF complex concentrations at Week 12 were 0.236 (0.0302) mg/mL for ITV-1 and 0.215 (0.02) mg/mL for ITV-2.

Study VGFT-OD-0512/14805 (CLEAR-IT DME 1) was an open label safety and tolerability study in five subjects with DME. The treatment was VEGF Trap-Eye, 4 mg as a single intravitreal injection of 100 μL volume. On Days 3 and 8, mean concentrations of VEGF Trap were 0.0502 and 0.0272 mg/L, respectively.

Intravenous pharmacokinetics

Study VGFT-OD-0305 was a double-masked, placebo controlled, sequential group, dose escalating, (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 5 mg/kg, 7 mg/kg, and 10 mg/kg) study of safety and bioeffect. The study included subjects with a diagnosis of visual impairment associated with neovascular AMD. Subjects were required to have visual loss due to subfoveal choroidal neovascularization (CNV) secondary to AMD, be 50 years of age or older, with no history of Type I or Type II diabetes, without significant cardiac, liver or kidney disease, or congestive heart failure (CHF); and without confounding ophthalmic issues.

The study treatments were:
1. VEGF Trap 0.3 mg/kg
2. VEGF Trap 1 mg/kg
3. VEGF Trap 3 mg/kg

10 Rudge JS Proc Natl Acad Sci USA 2007:18363-18370
11 Sponsor comment: Free VEGF Trap plasma concentrations following IVT administration of doses of up to 4 mg/eye (approximately 0.57 mg/kg, based on a 70 kg body weight) were approximately 2 to 3 orders of magnitude lower than free VEGF Trap plasma concentrations observed following IV administration of doses ≥ 1 mg/kg. Concentrations of bound VEGF Trap in plasma following IVT administration of doses of up to 4 mg/eye were approximately 20-fold lower than plasma bound VEGF Trap concentrations determined following IV administration of doses of 1 to 4 mg/kg.
4. Placebo

The treatments were delivered as an intravenous infusion over 1 hour. Subjects were to receive four doses over 8 weeks, followed by a 4 week observation period. The study was halted at the 3 mg/kg dose because of dose limiting toxicity.

The measures of biological effect were: visual acuity and optical coherence tomography (OCT). The outcome measures of safety were: adverse events (AEs), clinical laboratory tests, ophthalmic exam and anti-VEGF Trap antibodies. The PK measures were: plasma VEGF Trap levels.

A total of 26 subjects were included in the study: seven treated with VEGF Trap 0.3 mg/kg, seven treated with 1 mg/kg, six treated with 3 mg/kg, and none treated with 5 mg/kg, 7 mg/kg or 10 mg/kg. Twenty five subjects were included in the analysis: 14 (56%) females, 11 (44%) males, with an age range of 58 to 88 years.

$C_{max}$ for free VEGF trap was 50 mg/L for the 3.0 mg/kg dose, around 16 mg/L for the 1.0 mg dose and 5 mg/L for the 0.3 mg/kg dose. Mean concentration to dose ratio of VEGF Trap: VEGF complex peaked at around 3.5 (Figure 2). $C_{max}$ for total VEGF reflected free VEGF levels and first dose trough concentrations and were 50 mg/L for the 3.0 mg/kg dose, around 15 mg/L for the 1.0 mg dose and 5 mg/L for the 0.3 mg/kg dose.

Figure 2. Median Log-scaled Concentration of Adjusted VEGF Trap:VEGF Complex by Nominal Day.

---

Study VGFT-OD-0307 was a double masked, placebo controlled; sequential group, dose escalating, safety, tolerability and bioeffect study of VEGF Trap in patients with diabetic macular edema. The study was planned to include 24 subjects with escalating dose of VEGF Trap: 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. However, due to the dose limiting toxicity observed in Study VGFT-OD-0305, only the 0.3 mg/kg dose level was examined. There were four intravenous infusions at 2 week intervals. The study included subjects €25 years of age, with a hemoglobin A1c between 9 and 10% and on a stable regimen of anti-diabetic medication; with nonproliferative or mild proliferative diabetic retinopathy; retinal edema; €2 prior focal, grid or panretinal photocoagulation treatments for which scars did not involve the center of the macula €12 weeks prior to Day 1; a best corrected visual acuity of 20/40 or worse according Early

---

AusPAR Eylea Aflibercept Bayer Australia Ltd
PM-2010-03802-3-5 Final 30 July 2012
Treatment Diabetic Retinopathy Study (ETDRS); and retinal thickness ≥ 250 μm in the macular region as measured by OCT. The study included nine subjects: six treated with 0.3 mg/kg, three treated with placebo. There were five females, four males, and the age range was 57 to 81 years. At the 0.3 mg/kg dose intravenously, mean (standard deviation (SD)) Cmax was 600 (202) ng/mL for free VEGF Trap, 1522 (659) ng/mL for VEGF Trap:VEGF and 1590 (699) ng/mL for total VEGF Trap.

Study PDY6655 was a Phase I, single centre, randomised, single dose, crossover, pharmacokinetic (PK) study in healthy volunteers to compare the pharmacokinetics and pharmacodynamic (PD) of intravenous and subcutaneous administration of aflibercept. The study included 40 healthy male subjects aged 18 to 45 years. The study treatments were: aflibercept 2.0 mg/kg as an intravenous infusion over 1 hour, and as a subcutaneous injection. The aflibercept was presented as 4 mL of 25 mg/mL solution. The treatments were administered as single doses followed by 6 week observation period. The treatment periods were separated by 1 to 2 weeks. The PK outcome measures were: Cmax, AUC, apparent volume of distribution at steady state (Vss), clearance and half life (t½). The PD outcome measures were: systolic blood pressure, diastolic blood pressure, heart rate, mean arterial pressure, plasma renin activity, angiotensin I, aldosterone, and free endogenous VEGF. The safety outcome measures were: AEs, clinical laboratory test, injection site reactions, and anti-aflibercept antibodies.

AUC and Cmax were slightly higher for Period 2, indicating some carry over. For Period 1, for free aflibercept mean (co-variance (CV%)) AUC was 177 (33) μg•day/mL and peak plasma concentration (Cmax) was 44.4 (36) μg/mL for intravenous and AUC was 84.9 (30) μg•day/mL and Cmax was 7.76 (39) μg/mL for subcutaneous (Table 2). For Period 1, for bound aflibercept mean (CV%) AUC was 57.7 (19) μg•day/mL and Cmax was 1.84 (22) μg/mL for intravenous and AUC was 47.3 (27) μg•day/mL and Cmax was 1.60 (27) μg/mL for subcutaneous (Table 3). The mean (90% CI) ratio for AUC, subcutaneous/ intravenous, was 0.51 (0.46 to 0.56).
Study PDY6656 was a single centre, Phase I, randomised, double blind, placebo controlled, sequential ascending dose study of intravenous aflibercept. The study included healthy male subjects 18 to 45 years of age; non-smoker; 18 ≤ body mass index (BMI) ≤ 28 kg/m²; with normal vital signs and no symptomatic hypotension. The study treatments were aflibercept 1 mg/kg, 2 mg/kg and 4 mg/kg, and placebo. There were three cohorts of 16 subjects: twelve treated with aflibercept and four treated with placebo. The treatments were administered as a single dose by intravenous infusion over 1 hour. The pharmacodynamic outcome measures were: systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), plasma active renin, aldosterone and angiotensin I; markers of endothelium dysfunction (plasma endothelin-1, E-selectin, cyclic guanosine 3’5’ monophosphate (cGMP), and urine nitrites/nitrates); renal function; and VEGF. The safety outcome measures were: AEs and laboratory tests. The study included 48 subjects: 12 treated with 1 mg/kg, 12 with 2 mg/kg, 12 with 4 mg/kg and 12 with placebo. The age range was 21 to 45 years. For free aflibercept mean (CV%) Cₘₐₓ was 18.2 (18) µg/mL for the 1 mg/kg dose, 39.7 (27) µg/mL for the 2 mg/kg dose and 78.6 (15) µg/mL for the 4 mg/kg dose; and mean (CV%) AUC was 64.8 (20) µg.day/mL for the 1 mg/kg dose, 180 (20) for the 2 mg/kg dose and 419 (21) for the 4 mg/kg dose. Bound aflibercept concentrations were not dose dependent and the proportion of bound aflibercept decreased with increasing dose. However, Cₘₐₓ and AUC for total aflibercept were dose proportional (Table 4).
Table 4. Mean (CV%) total (free + bound) aflibercept pharmacokinetic parameters.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>C_{max} (μg/mL)</th>
<th>AUC_{0-4h} (μg.day/mL)</th>
<th>AUC (μg.day/mL)</th>
<th>T_{1/2a} (day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>18.2 (18)</td>
<td>100 (16)</td>
<td>120 (16)</td>
<td>19.4 (20)</td>
</tr>
<tr>
<td>2</td>
<td>39.7 (27)</td>
<td>253 (17)</td>
<td>297 (17)</td>
<td>18.1 (10)</td>
</tr>
<tr>
<td>4</td>
<td>78.6 (15)</td>
<td>494 (18)</td>
<td>543 (17)</td>
<td>13.6 (26)</td>
</tr>
</tbody>
</table>

Evaluator’s overall conclusions on pharmacokinetics

Eylea (aflibercept) is intended for intravitreal administration and systemic exposure is important from a safety perspective but not from an efficacy perspective. The systemic exposure following intravitreal injection was minimal in comparison with studies of intravenous aflibercept. This would be expected given the differences in total dose: up to 4 mg intravitreal compared with up to 4 mg/kg intravenous.

Following intravitreal injection of 2 mg aflibercept the exposure to free aflibercept, expressed as median AUC_{last} was (range) 0.0221 (0 to 0.474) mg•day/L and exposure to aflibercept:VEGF complex expressed as median AUC_{last} was (range) 4.67 (2.12 to 6.71) mg•day/L (Study VGFT-OD-0702.PK). Following a 4 mg intravitreal injection, for the aflibercept: VEGF complex the time to peak plasma concentration (T_{max}) was 12 weeks and the C_{max} was (mean (SE)) 0.236 (0.0302) mg/mL (Study VGFT-OD-0603). Following 4 mg intravitreal injection, the mean concentrations of aflibercept were 0.0502 and 0.0272 mg/L on Days 3 and 8, respectively (Study VGFT-OD-0512).

Following intravenous administration, the C_{max} for free aflibercept was 50 mg/L for a 3.0 mg/kg dose, around 16 mg/L for a 1.0 mg dose and 5 mg/L for a 0.3 mg/kg dose. The C_{max} for total aflibercept was 50 mg/L for the 3.0 mg/kg dose, around 15 mg/L for the 1.0 mg dose and 5 mg/L for the 0.3 mg/kg dose (Study VGFT-OD-0305).

Following 2.0 mg/kg aflibercept, the mean AUC (CV%) and C_{max} for free aflibercept were 177 (33) μg.day/mL and 44.4 (36) μg/mL, respectively, for intravenous administration. For a 2.0 mg subcutaneous administration, the mean AUC was 84.9 (30) μg.day/mL and the C_{max} was 7.76 (39) μg/mL. For bound aflibercept, the mean (CV%) AUC was 57.7 (19) μg.day/mL and the mean C_{max} was 1.84 (22) μg/mL following intravenous administration. The AUC and C_{max} were 47.3 (27) μg.day/mL and 1.60 (27) μg/mL, respectively, for bound aflibercept following subcutaneous administration (Study PDY6655).

Following intravenous administration, the mean (CV%) C_{max} for free aflibercept was 18.2 (18) μg/mL for a 1 mg/kg dose, 39.7 (27) μg/mL for a 2 mg/kg dose and 78.6 (15) μg/mL for a 4 mg/kg dose. The mean (CV%) AUC was 64.8 (20) μg.day/mL for a 1 mg/kg dose, 180 (20) μg.day/mL for a 2 mg/kg dose and 419 (21) μg.day/mL for a 4 mg/kg dose (Study PDY6656).

Bound aflibercept concentrations were not dose proportional whereas the C_{max} and AUC for total aflibercept were dose proportional.

Pharmacodynamics

Pharmacodynamic data were provided for the systemic effects of aflibercept.

In Study PDY6655 there was an increase in SBP that was maximal at Day 16: the mean increase was 5.54 mmHg for subcutaneous administration and 6.50 mmHg for intravenous administration (Figure 3). There was an increase in DBP that was maximal at Day 16: mean...
increase of 6.32 mmHg for subcutaneous administration and 7.22 mmHg for intravenous administration (Figure 4). For both routes of administration there was an increase in MAP, which was maximal at Day 16 at around 6 mmHg (Figure 5). Plasma renin activity and aldosterone concentrations decreased (Figures 6 and 7) whereas angiotension I had little change. Free VEGF concentrations were decreased within 1 day of administration and appeared to have recovered by Day 29 (Figure 8).

Figure 3. Summary plots of 24-hour mean SBP (mean ± SE, mm Hg). Change from baseline

![Figure 3](image)

Figure 4. Summary plots of 24 hour mean DBP (mean ± SE, mm Hg); change from baseline

![Figure 4](image)
Figure 5. Summary plots of mean arterial blood pressure (mean ± SEM, mm Hg) – Day 1 profile (left panel) and Day 1 to Day 43 profile (right panel); change from baseline

Figure 6. Summary plots of plasma active renin concentrations (mean ± SEM, pg/mL) – Change from baseline
Figure 7. Summary plots of plasma aldosterone concentrations (mean ± SEM, pmol/L) – Change from baseline

![Figure 7](image)

Figure 8. Summary plots of plasma free VEGF concentrations (mean ± SE, pg/mL). Raw data

![Figure 8](image)

In Study PDY6656, SBP, DBP and MAP increased in the active treatment groups. In comparison with placebo, the mean (95% CI) maximum increase in SBP was 5.16 (0.74 to 9.58) mmHg for 1 mg/kg, 4.90 (0.58 to 9.22) mmHg for 2 mg/kg and 10.27 (5.77 to 14.78) mmHg for 4 mg/kg. In comparison with placebo, the mean (95% CI) maximum increase in DBP was 5.31 (2.36 to 8.26) mmHg for 1 mg/kg, 5.13 (2.19 to 8.06) mmHg for 2 mg/kg and 10.67 (7.68 to 13.66) mmHg for 4 mg/kg. In comparison with placebo, the mean (95% CI) maximum increase in MAP was 3.12 (-
0.13 to 6.37) mmHg for 1 mg/kg, 4.41 (1.15 to 7.66) mmHg for 2 mg/kg and 10.67 (7.68 to 13.66) mmHg for 4 mg/kg. A significant increase in SBP was noted for 16 days at the 1 mg/kg and 2 mg/kg dose levels and for 44 days at the 4 mg/kg dose level. There was a decrease in heart rate that reached statistical significance in the 4 mg/kg group. In comparison with placebo, the mean (95% CI) maximum decrease in heart rate was 1.17 (-2.42 to 4.76) beats per minute (bpm) for 1 mg/kg, 3.26 (-0.32 to 6.85) bpm for 2 mg/kg and 4.48 (0.90 to 8.06) bpm for 4 mg/kg.

Plasma rennin activity and aldosterone concentrations were reduced with all three dose levels of aflibercept. There was no significant change in angiotensin I concentrations. There was no consistent change in plasma endothelin concentrations, plasma E-selectin concentrations, plasma cyclic guanosine 3',5'-monophosphate (cGMP) or urinary nitrate excretion. There was no change in proteinuria or microalbuminuria. Plasma free VEGF increased in all three active treatment groups from 2 weeks after treatment.

**Evaluator’s overall conclusions on pharmacodynamics**

Aflibercept at high doses administered intravenously significantly increases blood pressure. However, the level of systemic exposure from intravitreal administration would not be sufficient to cause similar effects on blood pressure.

Intravenous or subcutaneous 2 mg/kg aflibercept increased SBP by a mean of up to 6.5 mmHg and DBP of up to 7.22 mmHg with a maximal effect at Day 16 post administration (Study PDY6655). SBP was increased by 10.27 (5.77 to 14.78) mmHg and DBP by 10.67 (7.68 to 13.66) mmHg by 4 mg/kg aflibercept administered intravenously (Study PDY6656). The increase in blood pressure persisted for up to 44 days at the 4 mg/kg dose level. Plasma renin activity and aldosterone concentrations were decreased.

**Efficacy**

**Introduction**

The sponsor provided data from a development program for aflibercept for the indication of AMD. The efficacy data were provided by 11 studies (see Introduction above).

**Phase I and dose finding studies**

*Study VGFT-OD-0502/14395 Part A*

*Study VGFT-OD-0502/14395 Part A (CLEAR-IT 1)* was a Phase I, open label, dose escalation safety and tolerability study. The study included:

- Males and females ≥50 years of age
- With subfoveal CNV secondary to AMD
- Central retinal/lesion thickness (CR/LT) ≥ 250 μm as measured by OCT
- Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA of 20/40 (73 letters) or worse
- Clear ocular media and clear lens(es) to permit good quality stereoscopic fundus photography
- If history of prior ocular or major systemic surgery, including fine needle biopsy/aspiration, placement of a central venous access device or removal/biopsy of a skin lesion, procedures performed at least 12 weeks prior to Visit 2 (Day 1)
- Normal ECG
• Treated or untreated blood pressure ≤140/90 mmHg or isolated systolic pressure of ≤160 mmHg with diastolic pressure of ≤85 mmHg

The study treatments were VEGF Trap-Eye at dose levels:

1. 0.05 mg,
2. 0.15 mg,
3. 0.50 mg,
4. 1 mg,
5. 2 mg and
6. 4 mg.

There was sequential enrolment and dose escalation. The treatments were administered as single doses by intravitreous injection. This was followed by an open-label extension phase of aflibercept 4 mg by intravitreous injection on an as required basis.

The efficacy outcome measures were:

• CR/LT as determined by OCT; total lesion size,
• CNV size, and
• Classic CNV size by fluorescein angiography and best corrected visual acuity (BCVA).

The safety outcome measures were:

• AEs,
• Laboratory tests,
• Ophthalmic investigations, and
• Antibodies to VEGF-trap.
• PK assessments were also performed.

The study enrolled 21 subjects: three subjects were treated with 0.05 mg, three with 0.15 mg, three with 0.50 mg, six with 1 mg, three with 2 mg, and three with 4 mg. Nine subjects continued into the open-label study. All subjects were included in the analysis. There were 13 (61.9%) females, eight (38.1%) males and the age range was 62 to 85 years. The dose groups were similar in baseline CR/LT and visual acuity.

The greatest effect was in the 2 mg to 4.0 mg dose grouping. At Day 57, the mean (SD) percentage change in CR/LT was -2.0 (20.9) in the 0.05 mg to 0.5 mg grouping, -21.1 (25.9) in the 1.0 mg group and -33.8 (23.0) in the 2.0 mg to 4.0 mg grouping, p=0.0074 (Table 5). Change from baseline in total macular volume was greatest in the 4 mg dose group but macular volume was greatest in this group at baseline and result could represent regression to the mean (Table 6). Change in visual acuity was greatest in the 2.0 mg to 4.0 mg dose grouping (Table 7). The mean (SD) change from baseline at Day 57 was 1.6 (5.0) in the 0.05 mg to 0.5 mg group; -0.2 (14.39) in the 1.0 mg group; and 15.0 (16.84) in the 2.0 mg and 4.0 mg group; but this difference did not reach statistical significance, p=0.1057. There was no significant change from baseline, or between treatment groups, in fluorescein angiography.
Table 5. Percentage change in CR/LT from Baseline (LOCF)

<table>
<thead>
<tr>
<th>Day/Pooled Group</th>
<th>N</th>
<th>Mean % Change</th>
<th>Standard Deviation</th>
<th>Median % Change</th>
<th>Range of % Changes</th>
<th>P Value (1-Sample t-Test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (0.05 to 0.5 mg)</td>
<td>8</td>
<td>-1.4</td>
<td>18.4</td>
<td>2.5</td>
<td>-26 to 28</td>
<td></td>
</tr>
<tr>
<td>B (1.0 mg)</td>
<td>6</td>
<td>-27.9</td>
<td>19.3</td>
<td>-25.4</td>
<td>-57 to -5</td>
<td></td>
</tr>
<tr>
<td>C (2.0 and 4.0 mg)</td>
<td>6</td>
<td>-33.8</td>
<td>22.2</td>
<td>-23.2</td>
<td>-68 to -16</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>-19.1</td>
<td>24.0</td>
<td>-18.4</td>
<td>-68 to 28</td>
<td>0.0021</td>
</tr>
<tr>
<td>Day 43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (0.05 to 0.5 mg)</td>
<td>8</td>
<td>-3.2</td>
<td>23.5</td>
<td>-13.8</td>
<td>-24 to 39</td>
<td></td>
</tr>
<tr>
<td>B (1.0 mg)</td>
<td>6</td>
<td>-24.5</td>
<td>27.6</td>
<td>-25.8</td>
<td>-57 to 17</td>
<td></td>
</tr>
<tr>
<td>C (2.0 and 4.0 mg)</td>
<td>6</td>
<td>-26.4</td>
<td>33.4</td>
<td>-27.9</td>
<td>-66 to 21</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>-16.5</td>
<td>28.7</td>
<td>-14.5</td>
<td>-66 to 39</td>
<td>0.0185</td>
</tr>
<tr>
<td>Day 57</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (0.05 to 0.5 mg)</td>
<td>8</td>
<td>-2.0</td>
<td>20.9</td>
<td>0.1</td>
<td>-28 to 39</td>
<td></td>
</tr>
<tr>
<td>B (1.0 mg)</td>
<td>6</td>
<td>-21.2</td>
<td>25.9</td>
<td>-26.8</td>
<td>-47 to 19</td>
<td></td>
</tr>
<tr>
<td>C (2.0 and 4.0 mg)</td>
<td>6</td>
<td>-33.8</td>
<td>23.0</td>
<td>-26.4</td>
<td>-69 to -10</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>-17.3</td>
<td>25.8</td>
<td>-14.8</td>
<td>-69 to 39</td>
<td>0.0074</td>
</tr>
</tbody>
</table>

Note: The larger the percentage decrease from baseline, the more favorable the effect on retinal thickness.

*Baseline CR/LT was not determined for 2 patients in the 0.05 mg cohort. The screening value was used as the baseline value for 1 of the 2 patients. For the other patient, no screening value was available.
### Table 6. Summary of Total Macular Volume (mm³) by OCT (Full Analysis Set) Study Part A

<table>
<thead>
<tr>
<th>VEGF Dose Regimen</th>
<th>0.05mg (N=3)</th>
<th>0.15mg (N=3)</th>
<th>0.50mg (N=3)</th>
<th>1.00mg (N=6)</th>
<th>2.00mg (N=3)</th>
<th>4.00mg (N=3)</th>
<th>Total (N=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>17</td>
</tr>
<tr>
<td>Mean</td>
<td>9.7</td>
<td>6.9</td>
<td>7.4</td>
<td>9.0</td>
<td>7.4</td>
<td>10.3</td>
<td>8.6</td>
</tr>
<tr>
<td>SD</td>
<td>0.64</td>
<td>0.76</td>
<td>2.16</td>
<td>0.92</td>
<td>3.95</td>
<td>2.26</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>9.7</td>
<td>6.9</td>
<td>7.4</td>
<td>8.1</td>
<td>7.5</td>
<td>9.4</td>
<td>7.6</td>
</tr>
<tr>
<td>Min,Max</td>
<td>10,10</td>
<td>6,7</td>
<td>7,8</td>
<td>7,12</td>
<td>6,8</td>
<td>7,15</td>
<td>6,15</td>
</tr>
<tr>
<td><strong>Value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td>Mean</td>
<td>9.6</td>
<td>6.7</td>
<td>6.7</td>
<td>8.1</td>
<td>6.7</td>
<td>7.2</td>
<td>7.6</td>
</tr>
<tr>
<td>SD</td>
<td>0.84</td>
<td>0.30</td>
<td>0.47</td>
<td>1.44</td>
<td>0.27</td>
<td>1.34</td>
<td>1.36</td>
</tr>
<tr>
<td>Median</td>
<td>9.6</td>
<td>6.7</td>
<td>6.9</td>
<td>7.5</td>
<td>6.7</td>
<td>6.6</td>
<td>6.9</td>
</tr>
<tr>
<td>Min,Max</td>
<td>9,10</td>
<td>6,7</td>
<td>6,7</td>
<td>6,10</td>
<td>6,7</td>
<td>6,9</td>
<td>6,10</td>
</tr>
<tr>
<td><strong>Change from Baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>17</td>
</tr>
<tr>
<td>Mean</td>
<td>-0.9</td>
<td>-0.2</td>
<td>-0.7</td>
<td>-1.0</td>
<td>-0.7</td>
<td>-3.1</td>
<td>-1.2</td>
</tr>
<tr>
<td>SD</td>
<td>0.23</td>
<td>1.39</td>
<td>2.00</td>
<td>0.66</td>
<td>4.58</td>
<td>2.28</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>-0.9</td>
<td>-0.2</td>
<td>-0.7</td>
<td>-0.7</td>
<td>-0.8</td>
<td>-0.7</td>
<td>-0.7</td>
</tr>
<tr>
<td>Min,Max</td>
<td>-1,-1</td>
<td>-0,-0</td>
<td>-2,0</td>
<td>-4,2</td>
<td>-1,0</td>
<td>-8,-0</td>
<td>-8,2</td>
</tr>
<tr>
<td>1 sample t-test p-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change ANCOVA Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.5084</td>
</tr>
<tr>
<td>p-values</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Change in Visual Acuity from Baseline (LOCF).

<table>
<thead>
<tr>
<th>Day/Pooled Group</th>
<th>N</th>
<th>Mean Change</th>
<th>Standard Deviation</th>
<th>Median Change</th>
<th>Range of Changes</th>
<th>P Value (1-Sample t-Test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 29 A (0.05 to 0.5 mg)</td>
<td>9</td>
<td>1.1</td>
<td>3.02</td>
<td>2.0</td>
<td>-5 to 4</td>
<td></td>
</tr>
<tr>
<td>Day 29 B (1.0 mg)</td>
<td>6</td>
<td>-0.7</td>
<td>10.39</td>
<td>0.5</td>
<td>-20 to 10</td>
<td></td>
</tr>
<tr>
<td>Day 29 C (2.0 and 4.0 mg)</td>
<td>6</td>
<td>14.3</td>
<td>15.15</td>
<td>11.0</td>
<td>0 to 35</td>
<td></td>
</tr>
<tr>
<td>Day 29 Total</td>
<td>21</td>
<td>4.4</td>
<td>11.41</td>
<td>2.0</td>
<td>-20 to 35</td>
<td>0.0937</td>
</tr>
<tr>
<td>Day 43 A (0.05 to 0.5 mg)</td>
<td>9</td>
<td>0.6</td>
<td>5.43</td>
<td>0.0</td>
<td>-11 to 6</td>
<td></td>
</tr>
<tr>
<td>Day 43 B (1.0 mg)</td>
<td>6</td>
<td>1.2</td>
<td>11.02</td>
<td>4.0</td>
<td>-20 to 10</td>
<td></td>
</tr>
<tr>
<td>Day 43 C (2.0 and 4.0 mg)</td>
<td>6</td>
<td>13.5</td>
<td>15.73</td>
<td>12.5</td>
<td>-3 to 31</td>
<td></td>
</tr>
<tr>
<td>Day 43 Total</td>
<td>21</td>
<td>4.4</td>
<td>11.78</td>
<td>1.0</td>
<td>-20 to 31</td>
<td>0.1002</td>
</tr>
<tr>
<td>Day 57 A (0.05 to 0.5 mg)</td>
<td>9</td>
<td>1.6</td>
<td>5.00</td>
<td>2.0</td>
<td>-8 to 10</td>
<td></td>
</tr>
<tr>
<td>Day 57 B (1.0 mg)</td>
<td>6</td>
<td>-0.2</td>
<td>14.39</td>
<td>4.0</td>
<td>-29 to 11</td>
<td></td>
</tr>
<tr>
<td>Day 57 C (2.0 and 4.0 mg)</td>
<td>6</td>
<td>15.0</td>
<td>16.84</td>
<td>15.5</td>
<td>-7 to 35</td>
<td></td>
</tr>
<tr>
<td>Day 57 Total</td>
<td>21</td>
<td>4.9</td>
<td>13.27</td>
<td>4.0</td>
<td>-29 to 35</td>
<td>0.1057</td>
</tr>
</tbody>
</table>

Study VGFT-OD-0502/14395 Part C

Study VGFT-OD-0502/14395 Part C (CLEAR-IT 1) was a randomised double masked Phase I study of safety and tolerability. The inclusion criteria were similar to Study VGFT-OD-0502/14395 Part A with the variations of:

- Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 letters to 24 letters)
- Subretinal hemorrhage making up ≤ 50% of total lesion size and sparing the fovea
- Total lesion size ≤12 disk area (including blood, scars, atrophy and neovascularization) as assessed by fluorescein angiography (FA)

The study treatments were:
1. 1. VEGF Trap-Eye 0.15 mg
2. 2. VEGF Trap-Eye 4 mg

The treatments were administered as a single dose of 100 μL volume by intravitreal injection. During the open label phase the dose was 4 mg on a as needed (pro re nata; PRN) basis for up to 12 months.

The efficacy outcome measures were:

- CR/LT as determined by OCT;
- Total lesion size; CNV size,
- Classic CNV size by FA; and
- BCVA.

The safety outcome measures were:

- AEs,
- Clinical laboratory tests,
- Ophthalmic examinations of both the study eye and the fellow eye, and
- Antibodies to VEGF Trap-Eye.
The study included 28 subjects: 14 were treated with 0.15 mg; and 14 were treated with 4 mg. There were 15 (53.6%) males, 13 (46.4%) females and the age range was 55 to 89 years. Twenty two subjects entered the open label extension. The treatment groups were similar in demographic characteristics. The treatment groups were similar in baseline CR/LT and visual acuity.

Improvement in CR/LT from baseline was greatest at Day 29 and there was significantly greater improvement in the 4.0 mg group: mean % change (SD) was -13.3 (20.55) for the 0.15 mg dose and -34.2 (17.08) for the 4.0 mg dose, p<0.0001 (Table 8). There was a significant decrease in total macular volume (TMV) at Day 43 that was greater in the 4.0 mg group: mean (SD) change from baseline -0.8 (1.21) for the 0.15 mg dose and -1.0 (0.86) for the 4.0 mg, p=0.0295. There was greater improvement in visual acuity in the 4.0 mg group at Day 43: mean (SD) 0.7 (6.93) for 0.15 mg and 8.9 (12.28) for 4.0 mg, p=0.0237. There was no significant change in FA.

Table 8. Percentage Change in CR/LT from Baseline (LOCF)

<table>
<thead>
<tr>
<th>Day/Group</th>
<th>N</th>
<th>Mean % Change</th>
<th>Standard Deviation</th>
<th>Median % Change</th>
<th>Range of % Changes</th>
<th>P Value (1-Sample t-Test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.15 mg</td>
<td>14</td>
<td>-13.3</td>
<td>20.55</td>
<td>-7.3</td>
<td>-57 to 13</td>
<td></td>
</tr>
<tr>
<td>4.0 mg</td>
<td>14</td>
<td>-34.2</td>
<td>17.08</td>
<td>-37.4</td>
<td>-57 to 0</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>28</td>
<td>-23.8</td>
<td>21.39</td>
<td>-25.5</td>
<td>-57 to 13</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Day 43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.15 mg</td>
<td>14</td>
<td>-5.9</td>
<td>19.96</td>
<td>-1.4</td>
<td>-53 to 23</td>
<td></td>
</tr>
<tr>
<td>4.0 mg</td>
<td>14</td>
<td>-23.8</td>
<td>22.31</td>
<td>-28.1</td>
<td>-53 to 28</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>28</td>
<td>-14.8</td>
<td>22.68</td>
<td>-9.1</td>
<td>-53 to 28</td>
<td>0.0018</td>
</tr>
<tr>
<td>Day 57</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.15 mg</td>
<td>14</td>
<td>-11.3</td>
<td>22.09</td>
<td>-6.6</td>
<td>-57 to 35</td>
<td></td>
</tr>
<tr>
<td>4.0 mg</td>
<td>14</td>
<td>-25.2</td>
<td>25.89</td>
<td>-35.5</td>
<td>-55 to 19</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>28</td>
<td>-18.3</td>
<td>24.65</td>
<td>-18.9</td>
<td>-57 to 35</td>
<td>0.0005</td>
</tr>
</tbody>
</table>

Note: The larger the percentage decrease from baseline, the more favorable the effect on retinal thickness.

Study VGFT-OD-0603/14396

Study VGFT-OD-0603/14396 (CLEAR-IT 1b) was a double-masked, three arm (two randomised, one open-label) parallel group cohort study of the safety and tolerability of IVT-1 and IVT-2 formulations. The study included adults at least 50 years of age; male or female; with a diagnosis of AMD due to active primary or recurrent subfoveal choroidal neovascularization (CNV); with BCVA in the range of 20/40 to 20/400 (corresponding to a letters-read score of 73 to 20 when using the ETDRS visual acuity charts) in the study eye. One eye was designated as the study eye, the other as the fellow (untreated) eye.

The study treatments were VEGF Trap-Eye 4 mg single injections from Day 1 to Week 12:

1. 4 mg in 100 μL q4w IVT-1 formulation
2. 4 mg in 100 μL q4w IVT-2 formulation
3. 4 mg in 50 μL q4w open label cohort (IVT-2)

After Week 12 the subjects could enter an open label follow-on phase with treatments of 4 mg of the same formulation used in the primary analysis phase PRN for up to 12 months. All the treatments were administered by intravitreal injection.

The efficacy outcome measures were:
- Change from baseline in BCVA as measured by ETDRS letter score
- Patients who gain at least 15 letters of vision from baseline
- Change in CNV area from baseline
• Change from baseline in CRT as measured by OCT
• Patients showing complete resolution of FA leakage
• Change from baseline in total lesion area and area of fluorescein leakage as assessed by FA

The safety outcome measures were:
• Ophthalmic examination (including IOP),
• Laboratory tests,
• Treatment emergent adverse events (TEAEs) and
• Anti-VEGF Trap antibodies.

No sample size calculations were performed and no hypothesis tests were undertaken.

The study included 20 subjects: six randomised to IVT-1, six randomised IVT-2; and eight treated with open label IVT-2. Two subjects withdrew from the 12 week primary analysis phase, one withdrew after the first dose and the second died 47 days following the last dose. Seventeen subjects entered the open label phase. There were 16 (80%) females, four (20%) males and the age range was 63 to 87 years. The treatment groups were similar in demographic characteristics. Apart from greater mean retinal thickness in the IVT-2 randomised group, the treatment groups were similar in baseline disease characteristics.

Hypothesis tests were not performed on the efficacy outcome measures. There was a similar change in central retinal thickness for the two formulations: mean (SD) change from baseline to Week 12: -188.8 (123.52) for IVT-1 and -288.6 (148.97) for IVT-2. The mean (SD) change in visual acuity to Week 12 was 4.7 (5.24) for IVT-1 and 9.6 (18.61) for IVT-2. There were no apparent differences between the groups in FA.

**Study VGFT-OD-0512/14805(CLEAR-IT DME 1)**

This was an open label safety and tolerability study in five subjects with diabetic macular oedema (DME). The study included: males and non-pregnant, non-lactating females, age ≥18 years with DME; best corrected ETDRS visual acuity score of ≥ 24 letters (20/320 or better) and ≤ 73 letters (20/40 or worse); on clinical examination, definite retinal thickening due to DME involving the center of the macula; retinal thickness at the center point ≥ 250 microns.

The treatment was VEGF Trap-Eye, 4 mg as a single intravitreal injection of 100 μL volume. The efficacy outcome measures were:
• ERT and total macular volume as determined by OCT;
• Best-corrected ETDRS visual acuity; and
• Area of vascular leak on FA.

The Safety outcome measures were:
• AEs,
• Clinical laboratory tests,
• Ophthalmic examinations, and
• Antibodies to VEGF Trap.

The PK measure was plasma concentration of VEGF Trap.

The study included five subjects, all received treatment, one withdrew from the active observation phase and another subject withdrew from long-term follow-up. There were three (60%) females, two (40%) males and the age range was 56 to 75 years.
The study protocol did not intend any hypothesis testing on efficacy measures. On Day 43 the median (range) % change from baseline in ERL was -37.5 (-100 to -15.9) %, and the median (range) % change from baseline in TMV was -12.36 (-24.36 to -1.6) %. At Day 29 the median (range) change in visual acuity was 9 (-1 to 10) letters. There was no consistent pattern of change in FA.

**Study VGFT-OD-0305**

In Study VGFT-OD-0305 hypothesis tests were not reported on the efficacy outcome measures. The greatest improvement in visual acuity appeared to be in the VEGF Trap 3.0 mg/kg intravenous group at Day 29: 11.0 letters. The 0.3 mg/kg and 1.0 mg/kg groups appeared to be similar to placebo. The greatest decrease in ERT was also in the 3.0 mg/kg group at Day 29: -153.7 μm. The greatest improvement in macular volume was also in the 3.0 mg/kg group at Day 29: -1.75 mm³. There were no changes in FA.

**Study VGFT-OD-0306**

Study VGFT-OD-0306 was an open label, long term safety and tolerability extension study of intravenous VEGF Trap in subjects with neovascular AMD who had been included in Study VEGF-OD-0305. The study treatments were VEGF Trap at the same dose level the subjects had been treated with in Study VEGF-OD-0305: either 0.3 mg/kg or 1 mg/kg, by intravenous administration every 2 weeks. Placebo patients from Study VGFT-OD-0305 were assigned to VEGF Trap at the dose level at which they were enrolled in Study VGFT-OD-0305. The efficacy outcome measures were:

- Visual acuity (ETDRS),
- Retinal thickness (OCT) and
- Funduscopic examination,
- Fundus photography, and
- FA.

The safety outcome measures were:

- AEs,
- Clinical laboratory tests, and
- Ophthalmic exam.

Treatment duration was for up to 106 days. There were seven subjects: four subjects treated with 0.3 mg/kg, 3 subjects treated with 1 mg/kg. There were five females, two males and the age range was 68 to 84 years. Six of the seven subjects had a slight reduction in ERT in the study eye and six of seven subjects had slight reductions in macular volume in the study eye.

**Phase II Studies of Treatment Regimens**

*Study VGFT-OD-0508/14394 (CLEAR-IT AMD-2)* was a multicentre, double blind, randomised, parallel group, efficacy and safety study. The study compared five dosing regimens for aflibercept.

The inclusion criteria included:

- Males and non-pregnant, non-lactating females ≥50 years of age
- Subfoveal CNV secondary to AMD
- Central retinal (including lesion) thickness ≥300 μm as measured by OCT
- ETDRS BCVA of 73 letters to 34 letters
• For previously treated patients with minimally classic or occult lesions, a loss of ≥5 ETDRS letters (or ≥1 Snellen line) in BCVA over the 6 months prior to the start of the study
• Lesion greatest linear diameter (GLD) ≤5400 μm (including blood, scars, atrophy and neovascularisation) as assessed by FA
• Subretinal haemorrhage making up ≤50% of total lesion size and sparing the fovea
• Area of scar ≤25% of total lesion
• Sufficiently clear ocular media, including the lens, to allow photography of the retina
• Treated or untreated blood pressure ≤150/90 mmHg or isolated systolic pressure of ≤160 mmHg with diastolic pressure of ≤85 mmHg

The fellow eye inclusion criteria included:

• Subfoveal CNV secondary to AMD
• Clear ocular media and clear lens(es) to permit good quality stereoscopic fundus photography
• BCVA 20/40 (73 letters) or worse

The dosing regimens were:
1. Aflibercept 0.5 mg every 4 weeks
2. Aflibercept 0.5 mg every 12 weeks
3. Aflibercept 2 mg every 4 weeks
4. Aflibercept 2 mg every 12 weeks
5. Aflibercept 4 mg every 12 weeks

The treatments were administered by intravitreal injection, in an injection volume of 100 μL.

The primary efficacy outcome measure was retinal thickness determined by OCT at Week 12. The secondary efficacy outcome measures were:

• BCVA determined by ETDRS
• Fundus photography and FA
• Vision related quality of life

Hypothesis tests were performed using analysis of covariance (ANCOVA). A sample size calculation was not performed.

The safety outcome measures were:

• IOP,
• Ophthalmic examinations,
• Physical examination,
• ECG,
• AEs and
• Clinical laboratory tests.

Plasma concentrations of aflibercept were measured in order to estimate PK parameters.

A total of 159 subjects were enrolled and 157 of these received treatment: 32 in the 0.5 mg every 4 weeks (q4w) group, 32 in the 0.5 mg every 12 weeks (q12w), 31 in the 2 mg q4w, 31 in the 2 mg q12w and 31 in the 4 mg q12w. A total of 153 subjects completed to Week 12.
were 98 (62.4%) females, 59 (37.6%) males and the age range was 53 to 94 years. The treatment groups were mismatched in gender but similar in other baseline demographic variables.

At Week 12 the greatest reduction in CRT was in the 2 mg q4w group: mean (SD) change -169.2 (138.46) μm; followed by the 0.5 mg q12h group: -153.5 (113.3) μm and the 4 mg q12h group: -139.8 (228.59) μm (Table 9). However, at all other time points over the 52 weeks the 4 mg q12w group had the greatest reduction in central retinal thickness. The greatest improvement in visual acuity through to Week 52 was in the 2 mg q4w group. The greatest improvement in vision related quality of life through to Week 52 was in the 4 mg q12w group. The greatest decrease in total lesion size by FA was in the 2 mg q4w group at Week 52, followed by the 4 mg q12w group.

Table 9. Mean Change from Baseline in Central Retinal/Lesion Thickness through Week 52* by Treatment Group (Full Analysis Set)

<table>
<thead>
<tr>
<th>Week 1</th>
<th>0.5mg q4</th>
<th>0.5mg q12</th>
<th>2mg q4</th>
<th>2mg q12</th>
<th>4mg q12</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>31</td>
<td>32</td>
<td>31</td>
<td>31</td>
<td>28</td>
<td>153</td>
</tr>
<tr>
<td>Mean change (μm)</td>
<td>-89.3</td>
<td>-107.7</td>
<td>-96.1</td>
<td>-69.5</td>
<td>-157.6</td>
<td>-103.0</td>
</tr>
<tr>
<td>SD (μm)</td>
<td>100.74</td>
<td>85.22</td>
<td>102.02</td>
<td>94.47</td>
<td>160.41</td>
<td>112.70</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week 12</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>32</td>
<td>32</td>
<td>31</td>
<td>31</td>
<td>31</td>
<td>157</td>
</tr>
<tr>
<td>Mean change (μm)</td>
<td>-153.5</td>
<td>-75.6</td>
<td>-169.2</td>
<td>-56.3</td>
<td>-139.8</td>
<td>-118.8</td>
</tr>
<tr>
<td>SD (μm)</td>
<td>113.30</td>
<td>110.64</td>
<td>138.46</td>
<td>133.05</td>
<td>228.59</td>
<td>155.31</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week 16</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>32</td>
<td>32</td>
<td>31</td>
<td>31</td>
<td>31</td>
<td>157</td>
</tr>
<tr>
<td>Mean change (μm)</td>
<td>-163.3</td>
<td>-139.6</td>
<td>-182.7</td>
<td>-107.4</td>
<td>-208.6</td>
<td>-160.2</td>
</tr>
<tr>
<td>SD (μm)</td>
<td>108.13</td>
<td>126.41</td>
<td>146.75</td>
<td>112.22</td>
<td>202.07</td>
<td>145.34</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Week 52</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>32</td>
<td>32</td>
<td>31</td>
<td>31</td>
<td>31</td>
<td>157</td>
</tr>
<tr>
<td>Mean change (μm)</td>
<td>-125.0</td>
<td>-108.5</td>
<td>-143.0</td>
<td>-111.6</td>
<td>-161.4</td>
<td>-129.7</td>
</tr>
<tr>
<td>SD (μm)</td>
<td>117.54</td>
<td>106.56</td>
<td>156.15</td>
<td>135.80</td>
<td>215.68</td>
<td>150.27</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Table 9. Mean Change from Baseline in Central Retinal/Lesion Thickness through Week 52* by Treatment Group (Full Analysis Set)

Note: The larger the decrease from baseline, the more favorable the effect on retinal thickness
* Missing values were imputed by LOCF
** P-value based on 1-Sample t-Test

Pivotal efficacy studies

Study VGFT-OD-0605/14393

Methods

This was a multicentre, double masked, randomised, active controlled, parallel group, non-inferiority efficacy and safety study. The submission included the report of the first 52 weeks of the study (total intended duration of 2 years). The study was conducted in the US and Canada.

The inclusion criteria included:

- Men and women ≥50 years of age
- Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtapfoveal lesions that affected the fovea as evidenced by FA in the study eye
• CNV must be at least 50% of total lesion size.
• ETDRS BCVA of: 20/40 to 20/320 (letter score of 73 to 25) in the study eye.
• The exclusion criteria included:
  • Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins
  • Prior treatment with anti-VEGF agents in the study eye (prior, but not concurrent, treatment with anti-VEGF therapy in the fellow eye was allowed)
  • Total lesion size >12 disc areas (DAs) (30.5 mm², including blood, scars and neovascularisation) as assessed by FA in the study eye
  • Subretinal hemorrhage that was either 50% or more of the total lesion area, or if the blood was under the fovea and was one or more DAs in size in the study eye
  • Scar or fibrosis, making up >50% of total lesion in the study eye
  • Scar, fibrosis, or atrophy involving the center of the fovea
  • Presence of retinal pigment epithelium (RPE) tears or rips involving the macula in the study eye
  • History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye
  • Presence of other causes of CNV, including pathologic myopia (spherical equivalent of 8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis syndrome, angiod streaks, choroidal rupture, or multifocal choroiditis in the study eye
  • History or clinical evidence of diabetic retinopathy, diabetic macular edema (DME) or any other vascular disease affecting the retina, other than AMD, in either eye
  • Prior vitrectomy in the study eye
  • History of retinal detachment or treatment or surgery for retinal detachment in the study eye
  • Any history of macular hole of Stage 2 and above in the study eye
  • Any intraocular or periocular surgery within 3 months of Day 1 on the study eye
  • Prior trabeculectomy or other filtration surgery in the study eye.
  • Uncontrolled glaucoma (defined as IOP ≥25 mmHg despite treatment with anti-glaucoma medication) in the study eye
  • Active intraocular inflammation in either eye
  • Active ocular or periocular infection in either eye
  • Any ocular or periocular infection within the last 2 weeks prior to screening in either eye
  • Any history of uveitis in either eye
  • Active scleritis or episcleritis in either eye
  • Presence or history of scleromalacia in either eye
  • Aphakia or pseudophakia with absence of posterior capsule in the study eye
  • Previous therapeutic radiation in the region of the study eye
  • History of corneal transplant or corneal dystrophy in the study eye
• Significant media opacities, including cataract, in the study eye which might interfere with VA, assessment of safety, or fundus photography (FP)

• Any concurrent intraocular condition in the study eye (such as cataract) that, in the opinion of the investigator, could have required either medical or surgical intervention during the 96 week study period.

• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might have affected interpretation of the results of the study or rendered the subject at high risk for treatment complications.

• The use of long acting steroids, either systemically or intraocularly, in the 6 months prior to Day 1.

• Females who were pregnant, breastfeeding or of childbearing potential, unwilling to practice adequate contraception throughout the study.

The study treatments were:

1. Aflibercept 2 mg q4w
2. Aflibercept 0.5 mg q4w
3. Aflibercept 2 mg every 8 weeks (q8w)
4. Ranibizumab 0.5 mg q4w

Subjects were randomised in balanced groups by Interactive Voice Response System (IVRS). Treatments were performed by an unmasked investigator but efficacy and safety evaluations were performed by a masked investigator. Blinding of subjects was maintained in the q8w group through “sham” injections (performed without a needle, active drug or ocular penetration). Treatments were administered by intravitreal injections. In each subject one eye was treated and the other not treated (fellow eye). The allocation of the treated eye was not by randomisation.

The primary efficacy outcome measure was the proportion of subjects who maintained vision at Week 52. Maintenance of vision was defined as a loss of fewer than 15 letters in ETDRS letter score compared to baseline. The secondary efficacy outcome measures were:

• Change from baseline in BCVA as measured by ETDRS letter score at Week 52
• Proportion of subjects who gained at least 15 letters of vision from baseline to Week 52
• Change in total NEI VFQ-25 score from baseline to Week 52
• Change in CNV area from baseline to Week 52

Additional efficacy outcome measures were:

• Change from baseline in BCVA at Week 12
• Change from baseline in CRT at Week 52
• Proportion of subjects who lost 15 or more letters of vision ("moderate" vision loss) at Week 52
• Proportion of subjects who gained 30 or more letters of vision at Week 52
• Proportion of subjects who lost 30 or more letters of vision ("severe" vision loss) at Week 52
• Change from baseline in scores for National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) subscales (near activities, distance activities, vision dependency) at Week 52
• Change from baseline in total lesion area as assessed by FA at Week 52
• Proportion of subjects with VA of 20/40 or better at Week 52
• Proportion of subjects with VA of 20/200 or worse at Week 52
• Proportion of subjects who gained ≥0 letter of vision at Week 52
• Proportion of subjects who gained ≥10 letters of vision at Week 52
• Change from baseline in classic CNV area at Week 52
• Proportion of subjects showing complete resolution of FA leakage at Week 52
• Change from baseline in area of fluorescein leakage as assessed by FA at Week 52

The safety outcome measures were
• AEs,
• Vital signs,
• IOP,
• Clinical laboratory tests and
• Anti-aflibercept antibodies.

The schedule of study visits up to Week 52 was presented in the report.

Statistical Issues

The study was designed as a non-inferiority study with the condition for non-inferiority being that the 95% CI for the difference in the proportion of subjects who maintained vision at Week 52 compared to baseline (ranibizumab – aflibercept) was entirely below 10%. Multiplicity for the primary analysis was controlled using a conditional sequence of tests for non-inferiority:

1. aflibercept 2 mg q4w versus ranibizumab
2. aflibercept 0.5 mg q4w versus ranibizumab
3. aflibercept 2 mg q8w versus ranibizumab

The sample size calculation assumed that 90% of subjects treated with 0.5 mg ranibizumab would maintain vision and that 90% of subjects treated with aflibercept would also maintain vision, defined the non-inferiority margin at 10% and determined that in order to achieve a power of 90% at an α of 0.05, then 191 subjects per group would be required. Assuming a dropout rate of approximately 30%, enrollment of 300 subjects per group would be necessary.

Results

A total of 2063 subjects were screened and of these, 1217 subjects were randomised: 304 were treated with aflibercept 2 mg q4w, 304 with 0.5 mg q4w, 303 with 2 mg q8w, and 306 with ranibizumab 0.5 mg q4w. A total of 103 (8.5%) subjects discontinued prematurely, 18 (1.5%) due to AE, and 13 (1.1%) subjects died. There were 711 (58.8%) females, 499 (41.2%) males, with an age range of 49 to 99 years: 86 (7.1%) aged <65 years, 255 (21.1%) ≥65 to <75 years and 869 (71.8%) ≥75 years. The treatment groups were similar in demographic characteristics. The treatment groups were similar in baseline disease severity, prior medical history and concomitant medication.

The primary efficacy outcome was similar for all four treatment groups and non-inferiority was demonstrated for all three aflibercept dosing regimens compared with ranibizumab. For the per-protocol group, the difference (95% CI) in proportion of subjects that maintained vision at Week 52 (ranibizumab – aflibercept) was −0.7 (−4.4 to 3.1) for 2 mg q4w, −1.5 (−5.1 to 2.1) for 0.5 mg q4w and −0.7 (−4.5 to 3.1) for 2 mg q8w. Non-inferiority was also demonstrated in the
full analysis group and in sensitivity analyses (Table 10). The proportion maintaining vision at Week 52 in the full analysis group was: 289 (95.1%) for aflibercept 2 mg q4w, 286 (95.0%) for 0.5 mg q4w, 284 (94.4%) for 2 mg q8w and 285 (93.8%) for ranibizumab. There was no significant difference between the treatment groups in the secondary efficacy outcome measures but the results were supportive of non-inferiority. The mean change from baseline in CNV area was -4.6 (5.47) for aflibercept 2 mg q4w, -3.5 (5.27) for 0.5 mg q4w, -3.4 (6.02) for 2 mg q8w and -4.2 (5.59) for ranibizumab.

Table 10. Sensitivity Analyses of the Proportion of Subjects who Maintained Vision at Week 52 (Full Analysis Set).

<table>
<thead>
<tr>
<th></th>
<th>Ranibizumab</th>
<th>VEGF Trap-Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5Q4 (N = 304)</td>
<td>2Q4 (N = 304)</td>
</tr>
<tr>
<td>Last observation carried forward</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>285 (93.4%)</td>
<td>289 (95.1%)</td>
</tr>
<tr>
<td>Difference (%) (95.1% CI)</td>
<td>-1.3 (-5.0, 2.4)</td>
<td>-1.3 (-4.9, 2.4)</td>
</tr>
<tr>
<td>Observed Values*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>259/273 (94.9%)</td>
<td>271/285 (95.1%)</td>
</tr>
<tr>
<td>Difference (%) (95.1% CI)</td>
<td>-0.2 (-3.9, 3.4)</td>
<td>-1.7 (-5.1, 1.7)</td>
</tr>
<tr>
<td>Worst observation carried forward</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>284 (93.4%)</td>
<td>289 (95.1%)</td>
</tr>
<tr>
<td>Difference (%) (95.1% CI)</td>
<td>-1.6 (-5.4, 2.1)</td>
<td>-1.6 (-5.3, 2.1)</td>
</tr>
<tr>
<td>All drop-outs counted as non-responders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>267 (87.8%)</td>
<td>279 (91.8%)</td>
</tr>
<tr>
<td>Difference (%) (95.1% CI)</td>
<td>-3.9 (-8.8, 0.9)</td>
<td>-0.9 (-6.4, 3.3)</td>
</tr>
<tr>
<td>All treatment failures counted as non-responders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>280 (92.1%)</td>
<td>287 (94.4%)</td>
</tr>
<tr>
<td>Difference (%) (95.1% CI)</td>
<td>-2.3 (-6.3, 1.7)</td>
<td>-0.3 (-4.5, 3.9)</td>
</tr>
</tbody>
</table>

Note: Maintenance of vision was defined as a loss of < 15 letters in the ETDRS letter score
Differences in ranibizumab minus VEGF Trap-Eye. CI was calculated using a normal approximation.
*Observed values are presented by visit in Post-text Table 14.2.1/18

There was no significant difference between the groups in:

- Change from baseline in BCVA at Week 12
- Proportion of subjects who lost 15 or more letters of vision (“moderate” vision loss) at Week 52
- Proportion of subjects who gained 30 or more letters of vision at Week 52
- Proportion of subjects who lost 30 or more letters of vision (“severe” vision loss) at Week 52
- Proportion of subjects who gained ≥ 0 letter of vision at Week 52
- Proportion of subjects who gained 10 or more letters of vision at Week 52
- Proportion of subjects with VA of 20/40 or better at Week 52
- Proportion of subjects with VA of 20/200 or worse at Week 52
• Change from baseline in total lesion area as assessed by FA at Week 52
• Change from baseline in CRT at Week 52
• Change from baseline in scores for NEI VFQ-25 subscales (near activities, distance activities, vision dependency) at Week 52
• Change from baseline in classic CNV area at Week 52
• Change from baseline in area of fluorescein leakage as assessed by FA at Week 52.

However, the proportion of subjects showing complete resolution of FA leakage at Week 52 was significantly lower in the aflibercept 2 mg q8w group than in the ranibizumab: 159 (52.8%) subjects compared with 193 (63.5%); difference (95% CI) -10.7 (-18.5 to -2.8) %, p=0.0084.

Study 311523

Methods

Study 311523 (VIEW 2) was a multicentre, double masked, randomised, active controlled, parallel group, non-inferiority efficacy and safety study. The study was almost identical in design to Study VGFT-OD-0605/14393 (VIEW 1). The submission contained the report of the first 52 weeks of the study. The study was conducted at 186 centres in 26 countries.

The inclusion criteria, exclusion criteria and study treatments were identical to Study VGFT-OD-0605/14393 (VIEW 1).

The efficacy outcome measures were the same, except for the additional outcome measure: change in scores of the EQ-5D questionnaire from screening at Week 52.

Statistical Issues

The sample size determination was the same as for Study VGFT-OD-0605/14393 (VIEW 1) except for the additional requirement to recruit a planned target population to be enrolled in Japan of 140 subjects with a minimum of 120 subjects, based on regional regulatory requirements.

Results

A total of 2031 subjects were screened and 1240 subjects were randomised: 313 to aflibercept 2 mg q4w, 311 to 0.5 mg q4w, 313 to 2 mg q8w and 303 to ranibizumab 0.5 mg q4w. At least one dose of study medication was received by 1204 subjects. A total of 125 (10.1%) subjects discontinued prematurely: 25 (2.0%) due to AE, and nine (0.7%) died. There were 667 (55.5%) females and 535 (44.5%) males, 185 (15.5%) subjects were aged <65 years, 385 (32.0%) ≥65 to <75 years and 731 (71.8%) ≥75 years. The age range was 50 to 93 years. The treatment groups were similar in demographic characteristics. The treatment groups were similar in baseline disease characteristics, past medical history and concomitant medication.

The primary efficacy outcome was similar for all four treatment groups and non-inferiority was demonstrated for all three aflibercept dosing regimens compared with ranibizumab. For the per-protocol group, the difference (95% CI) in proportion of subjects that maintained vision at Week 52 (ranibizumab – aflibercept) was -1.2 (-4.86 to 2.46) for 2 mg q4w, -1.84 (-5.40 to 1.71) for 0.5 mg q4w and -1.13 (-4.81 to 2.55) for 2 mg q8w. Non-inferiority was also demonstrated in the full analysis group and in sensitivity analyses (Table 11). The proportion maintaining vision at Week 52 in the full analysis group was: 292 (94.5%) for aflibercept 2 mg q4w, 282 (95.27%) for 0.5 mg q4w, 292 (95.42%) for 2 mg q8w and 276 (94.85%) for ranibizumab. There was no significant difference between the treatment groups in the secondary efficacy outcome measures but the results were supportive of non-inferiority.
Table 11. Sensitivity analysis of the proportion of subjects who maintained vision at Week 52 (full analysis set)

<table>
<thead>
<tr>
<th>Last observation carried forward</th>
<th>Ranibizumab 0.5Q4</th>
<th>VEGF Trap-Eye 0.5Q4</th>
<th>2Q4</th>
<th>2Q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>276 / 291 (94.85)</td>
<td>292 / 309 (94.50)</td>
<td>282 / 296 (95.27)</td>
<td>292 / 306 (95.42)</td>
</tr>
<tr>
<td>Difference (%) (95% CI)</td>
<td>0.35 (-3.26 to 3.94)</td>
<td>-0.42 (-3.93 to 3.08)</td>
<td>-0.56 (-4.03 to 2.88)</td>
<td></td>
</tr>
<tr>
<td>Observed cases</td>
<td>257 / 272 (94.49)</td>
<td>281 / 278 (94.57)</td>
<td>267 / 268 (95.90)</td>
<td>285 / 278 (95.32)</td>
</tr>
<tr>
<td>Difference (%) (95% CI)</td>
<td>-0.08 (-3.80 to 3.73)</td>
<td>-1.41 (-6.02 to 2.20)</td>
<td>-0.84 (-4.62 to 2.84)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Worst observation carried forward</th>
<th>Ranibizumab 0.5Q4</th>
<th>VEGF Trap-Eye 0.5Q4</th>
<th>2Q4</th>
<th>2Q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>274 / 291 (94.16)</td>
<td>290 / 309 (93.85)</td>
<td>282 / 296 (95.27)</td>
<td>292 / 306 (95.42)</td>
</tr>
<tr>
<td>Difference (%) (95% CI)</td>
<td>0.31 (-3.49; 4.11)</td>
<td>-1.11 (-4.73; 2.51)</td>
<td>-1.27 (-4.84; 2.30)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>All drop-outs counted as non-responders</th>
<th>Ranibizumab 0.5Q4</th>
<th>VEGF Trap-Eye 0.5Q4</th>
<th>2Q4</th>
<th>2Q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>260 / 291 (93.95)</td>
<td>266 / 309 (86.08)</td>
<td>262 / 296 (88.51)</td>
<td>271 / 306 (88.56)</td>
</tr>
<tr>
<td>Difference (%) (95% CI)</td>
<td>3.26 (-1.98; 8.50)</td>
<td>0.83 (-4.24; 5.91)</td>
<td>0.78 (-4.24; 5.81)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>All treatment failures counted as non-responders</th>
<th>Ranibizumab 0.5Q4</th>
<th>VEGF Trap-Eye 0.5Q4</th>
<th>2Q4</th>
<th>2Q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects who maintained vision at Week 52 (%)</td>
<td>272 / 291 (93.47)</td>
<td>287 / 309 (92.88)</td>
<td>278 / 296 (93.92)</td>
<td>288 / 306 (94.12)</td>
</tr>
<tr>
<td>Difference (%) (95% CI)</td>
<td>0.59 (-3.44; 4.63)</td>
<td>-0.45 (-4.38; 3.48)</td>
<td>-0.65 (-4.52; 3.23)</td>
<td></td>
</tr>
</tbody>
</table>

Note: Maintenance of vision was defined as a loss of < 15 letters in the ETDRS letter score. Difference is ranibizumab minus VEGF Trap-Eye; C.I. = confidence interval was calculated using a normal approximation.

The results for the additional efficacy outcome measures were:

- With respect to change from baseline in BCVA at Week 12, there was a significant improvement in the ranibizumab group compared to aflibercept 2 mg q4w: LS mean difference (95% CI) -1.61 (-3.19 to -0.04) p=0.045.

There was no significant difference between the groups in:

- Proportion of subjects who lost 15 or more letters of vision ("moderate" vision loss) at Week 52
- Proportion of subjects who gained 30 or more letters of vision at Week 52
- Proportion of subjects who lost 30 or more letters of vision ("severe" vision loss) at Week 52
- Proportion of subjects who gained ≥ 1 letter of vision at Week 52
- Proportion of subjects who gained 10 or more letters of vision at Week 52
- Proportion of subjects with VA of 20/40 or better at Week 52

However, the proportion of subjects with VA of 20/200 or worse at Week 52 was greater in the aflibercept 2 mg q4w group than in the ranibizumab group: difference (95% CI) 6.05 (1.25 to 10.86) p=0.014.
There was no significant between group differences in:

- Change from baseline in total lesion area as assessed by FA at Week 52
- Change from baseline in classic CNV area at Week 52

However, the proportion of subjects showing complete resolution of FA leakage at Week 52 was significantly greater in the aflibercept 2 mg q4w group than in the ranibizumab group: 210 (67.96%) subjects compared with 162 (55.67%); difference (95% CI) 13.24 (5.60 to 20.89)%, p=0.0009. There was no difference between the groups in change from baseline in area of fluorescein leakage as assessed by FA at Week 52. There was a decrease in CRT in the aflibercept 2 mg q4w group compared to ranibizumab: LS mean difference (95% CI) -10.60 (-21.1 to -0.09) p=0.047.

For the change from baseline in scores for NEI VFQ-25 distance activities ranibizumab was superior to aflibercept 2 mg q4w and 2 mg q8w; and for vision dependency ranibizumab was superior to aflibercept 2 mg q4w at Week 52. There was no significant difference in the EQ-5D.

**Supportive efficacy data**

**Study VGFT-OD-0702/14262**

*Study VGFT-OD-0702/14262* was a single masked, randomised study conducted to compare long-term safety and tolerability of aflibercept in pre-filled syringes and vials. Subjects were eligible if they had neovascular AMD and completed dosing in *Study VGFT-OD-0502, Study VGFT-OD--0508,* or *Study VGFT-OD--0603.* The study treatments were aflibercept 2 mg PRN either as pre-filled syringe or as vials by intravitreal injection. The minimum time between treatments was 4 weeks. The aflibercept concentration was 40 mg/mL, hence the injection volume was 50 µL.

The efficacy outcome measures were:

- Change from baseline in ETDRS letters read
- Proportion of subjects who maintain vision (loss of <15 letters) from baseline
- Proportion of subjects with an increase of at least 15 letters from the baseline
- Frequency of treatment

The safety outcome measures were:

- AEs,
- Laboratory tests and
- IOP.

The study enrolled 157 subjects and of these, 149 were randomised to treatment: 99 to pre-filled syringe and 50 to vial. A total of 132 subjects received at least one treatment. A total of 129 (82.2%) subjects completed the study: four (2.5%) withdrew because of AE and seven (4.5%) patients died. There were 93 (62.4%) females, 56 (37.6%) males and the age range was 55 to 93 years. The vial and pre-filled syringe groups were similar in demographic characteristics.

The median time to first re-injection was 112 days. Visual acuity was reduced from baseline but it is not clear whether the rate of decline was influenced by aflibercept (Figure 9). Vision was maintained to Week 136 by 132 (84.1%) subjects. Visual acuity decreased at the same rate in the vial and pre-filled syringe groups (Figure 10).
Figure 9. Mean Change in Visual Acuity (LOCF) from Baseline of This Study to the Cut-Off Date by Visit (All Enrolled Set).

![Graph](image1.png)

Figure 10. Mean Change in Visual Acuity (LOCF) from Baseline of This Study to the Cut-Off Date by Visit (All Randomized Set).

![Graph](image2.png)

**Study VGFT-OD-0706/13336 (DAVINCI)**

*Study VGFT-OD-0706/13336 (DAVINCI)* was a double masked, randomised, parallel group, active controlled clinical trial of the efficacy and safety of aflibercept in subjects with DME. The study included subjects with clinically significant DME and central involvement defined as OCT central retinal thickness ≥250 μm; aged ≥18 years with Type 1 or 2 Diabetes Mellitus (DM); with ETDRS BCVA 20/40 to 20/320 (letter score of 73 to 24) in the study eye; and willing to use adequate contraception.
The study treatments were:

1. Aflibercept 0.5 mg q4w
2. Aflibercept 2 mg q4w
3. Aflibercept 2 mg q8w
4. Aflibercept 2 mg PRN
5. Laser photocoagulation

Aflibercept was administered by intravitreal injection. The study duration was 52 weeks.

The primary efficacy outcome measure was the change in BCVA from baseline to Week 24. The secondary efficacy outcome measures were:

- The proportion of patients who gained at least 15 ETDRS letters in BCVA from baseline to Week 24
- Change from baseline in central retinal thickness at Week 24 as assessed by OCT
- The number of focal laser treatments through Week 24

The exploratory efficacy outcome measure was the change in central retinal sensitivity as measured by microperimetry.

The safety outcome measures were:

- AEs,
- Clinical laboratory tests,
- ECGs,
- Vital signs, and
- Ophthalmic examinations.

Hypothesis tests were performed using ANCOVA. The study was designed as a superiority study. The sample size calculation assumed a difference between laser and aflibercept in BCVA at 24 weeks to be 8 letters, with a SD of 10 for each group. In order to provide 84% power at an α of 0.0125 (to correct for four comparisons) 40 subjects would be required in each study group.

A total of 221 subjects were randomised and 219 of these received treatment: 44 with 0.5 mg aflibercept q4w, 44 with 2 mg q4w, 42 with 2 mg q8w, 45 with 2 mg PRN and 44 with laser photocoagulation. A total of 200 (90.5%) subjects completed the study; one discontinued due to AE and three patients died. There were 129 (58.9%) males, 90 (41.1%) females and the age range was 29 to 87 years. The treatment groups were similar in demographic characteristics.

All four aflibercept treatment groups were superior to laser treatment by the primary efficacy outcome measure. The mean change (SD) from baseline in BCVA was 8.6 (14.64) letters for aflibercept 0.5 mg q4w, 11.4 (8.67) for 2 mg q4w, 8.5 (7.50) for 2 mg q8w, 10.3 (7.52) for 2 mg PRN and 2.5 (16.14) for laser photocoagulation. There was no significant difference between the groups in the proportion of patients who gained at least 15 ETDRS letters in BCVA from baseline to Week 24. There was a greater decrease in CRT in the aflibercept groups than in the laser group: mean (SD) change from baseline -144.6 (110.65) µm for aflibercept 0.5 mg q4w, -194.5 (143.04) µm for 2 mg q4w, -127.3 (141.78) µm for 2 mg q8w, -153.3 (132.17) µm for 2 mg PRN, and -67.9 (135.17) µm for laser. In the laser group, most subjects had the maximum allowance of two treatments over the study period.
Evaluator’s Overall Conclusions on Clinical Efficacy

The primary efficacy measures used in the drug development program were clinically important and had been adequately validated. The efficacy outcome measures were refined during Phase I development. BCVA became the tool used to determine the primary efficacy outcome measures in the pivotal studies. The secondary efficacy measures (CRT and macular volume) assessed pathology and disease severity. Fluorescein angiography was not useful to demonstrate differences between treatments.

In the initial dose finding studies, the greatest effect was in the 2 mg to 4 mg dose grouping (Study VGFT-OD-0502/14395 Part A). Effect increased with increasing dose up to 4 mg. Peak effect appeared to be at Day 29 (Study VGFT-OD-0502/14395 Part C). Different formulations, volumes and concentrations of aflibercept were evaluated in Study VGFT-OD-0603/14396 (CLEAR-IT 1b), which enabled a 50 μL volume to be used in further studies.

There were some Phase I data of aflibercept administered intravenously. Study VGFT-OD-0305 indicated a dose of 3 mg/kg aflibercept by intravenous injection was effective but that a dose of 1 mg/kg was not. Study VGFT-OD-0306 indicated that intravenous treatment with aflibercept would not be as effective long-term as intravitreal.

The Phase II study (Study VGFT-OD-0508/14394 [CLEAR-IT AMD-2]) did not clearly indicate the most appropriate dosing regimen. In the Phase II study the greatest reduction in CRT at Week 12 was with a 2 mg q4w dosing regimen but at all other time points over 52 weeks the greatest reduction in CRT was with 4 mg q12w. The greatest improvement in BCVA through to Week 52 was with 2 mg q4w. However the greatest improvement in vision related quality of life was with 4 mg q12w.

In the pivotal efficacy studies (Study VGFT-OD-0605/14393 [VIEW 1] and Study 311523 [VIEW 2]) the non-inferiority margin of 10% was appropriate as this would represent a clinically significant difference in treatment effect. The choice of comparator was appropriate. Ranibizumab is currently approved in Australia for the treatment of neovascular (wet) age-related macular degeneration and the dosing regimen used in the studies was consistent with the manufacturer’s recommendations. The population studied was appropriate and representative of the patient population likely to require treatment. However, it is not clear whether blinding of the sham injections was maintained and the selection/allocation of study and fellow eyes was not randomised.

In the pivotal efficacy studies non-inferiority was demonstrated for all three aflibercept dosing regimens. In Study VGFT-OD-0605/14393 (VIEW 1), for the per-protocol group, the difference (95% CI) in proportion of subjects that maintained vision at Week 52 (ranibizumab – aflibercept) was −0.7 (−4.4 to 3.1) for 2 mg q4w, −1.5 (−5.1 to 2.1) for 0.5 mg q4w and −0.7 (−4.5 to 3.1) for 2 mg q8w. In Study 311523 (VIEW 2), for the per-protocol group the difference (95% CI) in proportion of subjects that maintained vision at Week 52 (ranibizumab – aflibercept) was −1.2 (−4.86 to 2.46) for 2 mg q4w, −1.84 (−5.40 to 1.71) for 0.5 mg q4w and −1.13 (−4.81 to 2.55) for 2 mg q8w. The secondary efficacy outcome measures in both studies were supportive of the primary analysis.

In some of the additional efficacy outcome measures there were some differences between treatments in favour of the comparator:

- In Study VGFT-OD-0605/14393 (VIEW 1) the proportion of subjects showing complete resolution of FA leakage at Week 52 was significantly lower in the aflibercept 2 mg q8w group compared to the ranibizumab group: 159 (52.8%) subjects compared with 193 (63.5%); difference (95% CI) -10.7 ( -18.5 to -2.8%), p=0.0084

- In Study 311523 (VIEW 2), for the change from baseline in BCVA at Week 12 there was a significant improvement in the ranibizumab group compared to aflibercept 2 mg q4w: LS mean difference (95% CI) -1.61 (-3.19 to -0.04) p=0.045.
• In Study 311523 (VIEW 2) the proportion of subjects with VA of 20/200 or worse at Week 52 was greater in the aflibercept 2 mg q4w group than in the ranibizumab group: difference (95% CI) 6.05 (1.25 to 10.86) p=0.014.

• In Study 311523 (VIEW 2), for the change from baseline in scores for NEI VFQ-25 distance activities ranibizumab was superior to aflibercept 2 mg q4w and 2 mg q8w; and for vision dependency ranibizumab was superior to aflibercept 2 mg q4w at Week 52.

However, there were also some additional efficacy outcome measures that were in favour of aflibercept:

• In Study 311523 (VIEW 2) the proportion of subjects showing complete resolution of FA leakage at Week 52 was significantly greater in the aflibercept 2 mg q4w group compared to the ranibizumab group: 210 (67.96%) subjects compared with 162 (55.67%); difference (95% CI) 13.24 (5.60 to 20.89) %, p=0.0009.

• In Study 311523 (VIEW 2) there was a decrease in CRT in the aflibercept 2 mg q4w group compared to the ranibizumab group: LS mean difference (95% CI) -10.60 (-21.1 to -0.09) p=0.047.

The long term follow-on study, Study VGFT-OD-0702/14262, did not contribute useful efficacy data because it was not possible to determine whether the rate of decline in visual function was modified by aflibercept. There were also some data for subjects with DME, a different indication to that sought in the present application, (Study VGFT-OD-0512/14805 [CLEAR-IT DME 1] and Study VGFT-OD-0706/13336 (DAVINCI)). There were insufficient data to conclude efficacy. Study VGFT-OD-0706/13336 (DAVINCI) was supportive of efficacy but was conducted for a different indication than that applied for in the present application.

Safety

Introduction

Safety data were provided for the pharmacokinetic, pharmacodynamic and efficacy studies. In addition there was one study evaluable only for safety and limited safety data from three ongoing studies. The study evaluable only for safety was:

• Study VGFT-OD-0502/14395 Part B (CLEAR-IT 1)

The three ongoing studies (discussed below) were:

1. Study VGFT-OD-0910/14832
2. Study VGFT-OD-0819/14232 (COPERNICUS)
3. Study 14130 (GALILEO)

Study VGFT-OD-0502/14395 Part B (CLEAR-IT 1) was a randomised, double masked, active control Phase I study of safety, tolerability and initial bioeffect in subjects with neovascular AMD. The study was terminated after two of the planned 30 subjects were recruited. One subject was treated with VEGF Trap-eye, and the other with pegaptanib. The study treatments were:

4. VEGF Trap-Eye, 2 mg, one single injection followed by a sham injection 6 weeks later
5. Pegaptanib sodium, 0.3 mg, two injections 6 weeks apart

There was a double masked phase of 57 days duration followed by an open label phase of up to 12 months where VEGF Trap-Eye, 4 mg was administered on a PRN basis. Treatments were administered by intravitreal injection. Efficacy outcome measures were not reported.
The safety outcome measures were:

- AEs
- Laboratory measures and
- Anti-VEGF Trap antibodies.

**Patient exposure**

*Study VGFT-OD-0502/14395 Part A (CLEAR-IT 1)*, a total of 21 subjects were exposed to doses of aflibercept ranging from 0.05 mg to 4.0 mg. Twelve subjects received a single dose and nine subjects received additional doses of 4.0 mg in the open label phase, up to 10 doses.

*Study VGFT-OD-0502/14395 Part B (CLEAR-IT 1)*, one subject was treated with VEGF Trap-Eye 2 mg on one occasion and 4 mg on five occasions. The other subject was treated with VEGF Trap-Eye 4 mg on two occasions.

*Study VGFT-OD-0502/14395 Part C (CLEAR-IT 1)*, 28 subjects were exposed to VEGF Trap-Eye for a range of 0.15 mg to 60.15 mg and the total number of injections ranged from 1 to 16.

*Study VGFT-OD-0603/14396 (CLEAR-IT 1b)*, twenty subjects were exposed to 4 mg VEGF-Trap for one to twelve doses.

*Study VGFT-OD-0512/14805 (CLEAR-IT DME 1)*, five subjects with DME were treated with a single intravitreal administration of VEGF Trap-Eye 4 mg in 100μL volume.

*Study VGFT-OD-0305*, exposure to intravenous VEGF Trap was: seven subjects exposed to 0.3 mg/kg for two to four doses; seven exposed to 1.0 mg/kg for one to four doses and five exposed to 3.0 mg/kg for one to two doses.

*Study VGFT-OD-0306*, four subjects received one to eight doses of 0.3 mg/kg and three subjects received one to three doses of 1 mg/kg.

*Study VGFT-OD-0307*, six subjects received four doses of VEGF Trap 0.3 mg/kg intravenously.

*Study PDY6655*, 40 subjects were exposed to a single injection of 2.0 mg/kg aflibercept subcutaneously and of these, 38 were also exposed to 2.0 mg/kg intravenously.

*Study PDY6656*, 36 subjects were exposed to a single dose of intravenous aflibercept: twelve were treated with 1 mg/kg, twelve with 2 mg/kg and twelve with 4 mg/kg.

*Study VGFT-OD-0508/14394 (CLEAR-IT AMD-2)*, 32 subjects were exposed to 0.5 mg q4w for one to 13 doses; 32 subjects to 0.5 mg q12w for one to seven doses; 31 subjects to 2 mg q12w for three to eight doses; 31 subjects to 2 mg q12h for one to eight doses; and 31 subjects to 4 mg q12h for one to nine doses.

*Study VGFT-OD-0605/14393 (VIEW 1)*, 304 subjects were treated with aflibercept 2 mg q4w for a median of 13 treatments, 304 subjects with 0.5 mg q4w for a median of 13 treatments and 303 subjects with 2 mg q8w for a median of 8 treatments.

*Study 311523 (VIEW 2)*, 309 subjects were exposed to aflibercept 2 mg q4w, 297 subjects to 0.5 mg q4w, 307 subjects to 2 mg q8w and 291 subjects to ranibizumab. Thirteen injections (including, where allocated, sham injections) were received by 237 (76.7%) subjects in the aflibercept 2 mg q4w group, 238 (80.1%) in the 0.5 mg q4w group, 287 (93.5%) in the 2 mg q8w group and 280 (96.2%) in the ranibizumab group. Thirteen injections would correspond with 52 weeks exposure for each treatment.

*Study VGFT-OD-0702/14262*, 132 subjects were exposed to aflibercept 2 mg by intravitreal injection; 112 subjects were exposed for more than 24 weeks.
**Study VGFT-OD-0706/13336 (DAVINCI)**, to Week 20, 44 subjects were exposed to 0.5 mg aflibercept by intravitreal injection, with 33 subjects exposed to six injections, and 131 subjects were exposed to 2 mg with 42 subjects exposed to six injections.

**Adverse events**

*Study VGFT-OD-0502/14395 Part A*, ocular TEAEs were reported in the treated eye by 18 (85.7%) subjects and in the fellow eye by 14 (66.7%). There was an excess of pain and reduced visual acuity in the treated eye. During the open label extension six (66.7%) subjects reported TEAEs: three (33.3%) reported increased intraocular pressure, two (22.2%) eye pain and two (22.2%) vitreous detachment. There was a mean (SD) increase in intraocular pressure of 4.3 (3.89) mmHg 30 minutes postdose.

*Study VGFT-OD-0502/14395 Part B*, during the double blind phase the subject treated with VEGF Trap-Eye had conjunctival hyperaemia, retinal haemorrhage and increased IOP (increase of 17 mmHg post dose). The subject treated with pegaptinib had conjunctival hyperaemia. During the open label phase one subject had episodes of refractive disorder, and one subject had vitreous floaters.

*Study VGFT-OD-0502/14395 Part C*, ten (71.4%) subjects in each treatment group reported TEAEs that were associated with the study eye. Four (28.6%) subjects in each group reported TEAEs associated with the fellow eye. The excess of TEAEs in the study eye was attributable to more subjects with conjunctival haemorrhage, refractive disorder and decreased visual acuity. Seventeen (77.3%) subjects had study eye TEAEs during the open-label extension. The most frequent study eye TEAEs were conjunctival hemorrhage in four (18.2%) subjects, increased IOP in four (18.2%) subjects, eye pain in three (13.6%) subjects, reduced VA in three (13.6%) subjects and vitreous floaters in three (13.6%) subjects.

*Study VGFT-OD-0603*, 15 (75%) subjects reported non-ocular TEAEs. The most commonly reported TEAE was nasopharyngitis in four (20%) subjects. Ocular TEAEs were reported in 19 (95%) subjects in the treated eye and nine (45%) in the fellow eye. There was an excess of subjects with conjunctival haemorrhage, eye irritation and eye pain in the treated eye compared with the fellow eye (Tables 12 and 13). There was no apparent difference between the treatment groups or the 50 µL and 100 µL injection sizes in IOP (Table 14).
Table 12. Number of Patients who Reported Ocular Treatment-emergent Adverse Events in the Study Eye by SOC and PT

<table>
<thead>
<tr>
<th>MedDRA term</th>
<th>Double-masked cohort</th>
<th>Open label cohort</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 mg ITV-1 (100 µL)</td>
<td>4 mg ITV-2 (100 µL)</td>
<td>4 mg ITV-2 (50 µL)</td>
</tr>
<tr>
<td>Any Ocular AE</td>
<td>N=6</td>
<td>N=6</td>
<td>N=8</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjunctival haemorrhage</td>
<td>6(100%)</td>
<td>5(83.3%)</td>
<td>6(100%)</td>
</tr>
<tr>
<td>Eye irritation</td>
<td>3(50%)</td>
<td>3(50%)</td>
<td>2(25%)</td>
</tr>
<tr>
<td>Eye pain</td>
<td>2(33.3%)</td>
<td>3(50%)</td>
<td>3(37.5%)</td>
</tr>
<tr>
<td>Vitreous floaters</td>
<td>1(16.7%)</td>
<td>1(16.7%)</td>
<td>2(25%)</td>
</tr>
<tr>
<td>Vision blurred</td>
<td>2(33.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual acuity reduced</td>
<td>1(16.7%)</td>
<td></td>
<td>1(12.5%)</td>
</tr>
<tr>
<td>Anterior chamber cell</td>
<td></td>
<td>1(16.7%)</td>
<td></td>
</tr>
<tr>
<td>Blepharitis</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataract</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataract subcapsular</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage</td>
<td>1(16.7%)</td>
<td></td>
<td>1(12.5%)</td>
</tr>
<tr>
<td>Eyelids pruritus</td>
<td>1(16.7%)</td>
<td></td>
<td>1(12.5%)</td>
</tr>
<tr>
<td>Macular degeneration</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Photopsia</td>
<td>1(16.7%)</td>
<td></td>
<td>1(12.5%)</td>
</tr>
<tr>
<td>Retinal artery occlusion</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal haemorrhage</td>
<td></td>
<td>1(16.7%)</td>
<td></td>
</tr>
<tr>
<td>Retinal vascular disorder</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual disturbance</td>
<td>1(16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitreous detachment</td>
<td></td>
<td>1(12.5%)</td>
<td></td>
</tr>
<tr>
<td>Injury, poisoning and procedural complication</td>
<td>0(0.0%)</td>
<td>0(0.0%)</td>
<td>3(37.5%)</td>
</tr>
<tr>
<td>Incorrect dose administered</td>
<td></td>
<td></td>
<td>3(37.5%)</td>
</tr>
<tr>
<td>Investigations</td>
<td>2(33.3%)</td>
<td>0(0.0%)</td>
<td>0(0.0%)</td>
</tr>
<tr>
<td>Intraocular pressure increased</td>
<td>2(33.3%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 13. Number of Patients who reported Ocular Treatment-emergent Adverse Events in the Fellow Eye by SOC and PT.

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Double-masked cohort</th>
<th>Open label cohort</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 mg ITV-1 (100 µL)</td>
<td>4 mg ITV-2 (100 µL)</td>
<td>4 mg ITV-2 (50 µL)</td>
</tr>
<tr>
<td></td>
<td>N=6</td>
<td>N=6</td>
<td>N=8</td>
</tr>
<tr>
<td>Any Ocular AE:</td>
<td>4 (66.7%)</td>
<td>2 (33.3%)</td>
<td>3 (37.5%)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>4 (66.7%)</td>
<td>2 (33.3%)</td>
<td>3 (37.5%)</td>
</tr>
<tr>
<td>Macular degeneration</td>
<td>1 (16.7%)</td>
<td>1 (16.7%)</td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>Macular oedema</td>
<td>1 (16.7%)</td>
<td>1 (16.7%)</td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>Blepharitis</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjunctival haemorrhage</td>
<td>1 (16.7%)</td>
<td></td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>Detachment of retinal pigment epithelium</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal artery embolism</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal exudates</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal oedema</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision blurred</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitreous detachment</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitreous floaters</td>
<td>1 (16.7%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 14. Baseline Values and Change from Baseline in Pre-dose IOP (mmHg) to Weeks 1, 4, 8, and 12.

<table>
<thead>
<tr>
<th>Study Week</th>
<th>Statistic</th>
<th>Double-masked cohort</th>
<th>Open label cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>4 mg ITV-1 (100 µL)</td>
<td>4 mg ITV-2 (100 µL)</td>
</tr>
<tr>
<td>Baseline</td>
<td>n</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>15 (2.83)</td>
<td>13.7 (2.94)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>15</td>
<td>13.5</td>
</tr>
<tr>
<td></td>
<td>(min:max)</td>
<td>(11:18)</td>
<td>(11:19)</td>
</tr>
<tr>
<td>Week 1</td>
<td>n</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>-1.9 (1.9)</td>
<td>-0.8 (2.71)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>-1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>(min:max)</td>
<td>(-4:1)</td>
<td>(-6:2)</td>
</tr>
<tr>
<td>Week 4</td>
<td>n</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>-3.2 (3.82)</td>
<td>-1.3 (3.81)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>-4</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>(min:max)</td>
<td>(-8:3)</td>
<td>(-7:3)</td>
</tr>
<tr>
<td>Week 8</td>
<td>n</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>-3.3 (2.67)</td>
<td>-3.4 (6.11)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>-3.5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>(min:max)</td>
<td>(-6:1)</td>
<td>(-13:1)</td>
</tr>
<tr>
<td>Week 12</td>
<td>n</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>-2.5 (4.09)</td>
<td>-2.2 (4.15)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>-3.5</td>
<td>-2</td>
</tr>
<tr>
<td></td>
<td>(min:max)</td>
<td>(-8:4)</td>
<td>(-9:2)</td>
</tr>
</tbody>
</table>

Study VGFT-OD-0512, four subjects reported TEAEs affecting the study eye: conjunctival haemorrhage in three subjects. Four subjects reported systemic TEAEs: infection in two subjects.

Study VGFT-OD-0305, non-ocular TEAEs were reported in all subjects in the VEGF trap groups and 4 (66.7%) subjects in the placebo (Table 15). The most commonly reported TEAEs were: headache, hypertension, and proteinuria. VEGF Trap was associated with an increase in mean diastolic blood pressure. There did not appear to be an excess of ocular AEs in the VEGF Trap treatment groups.
Table 15. Most Common Non-Ocular AEs

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>n (%)</th>
<th>Pooled Placebo (6)</th>
<th>Dose of VEGF Trap 0.3 mg/kg (7)</th>
<th>1.0 mg/kg (7)</th>
<th>3.0 mg/kg (5)</th>
<th>Active Groups Combined (19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>0 (0)</td>
<td>1 (14.3)</td>
<td>3 (42.9)</td>
<td>4 (60.0)</td>
<td>8 (42.1)</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (42.9)</td>
<td>6 (31.6)</td>
<td>5 (26.3)</td>
<td></td>
</tr>
<tr>
<td>Proteinuria</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (28.6)</td>
<td>3 (60.0)</td>
<td>5 (26.3)</td>
<td></td>
</tr>
<tr>
<td>Hoarseness</td>
<td>1 (16.7)</td>
<td>0 (0)</td>
<td>2 (28.6)</td>
<td>3 (60.0)</td>
<td>5 (26.3)</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1 (16.7)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
<td>2 (20.0)</td>
<td>4 (21.1)</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>1 (16.7)</td>
<td>1 (14.3)</td>
<td>2 (28.6)</td>
<td>0 (0)</td>
<td>3 (15.8)</td>
<td></td>
</tr>
<tr>
<td>Aggravation of Arthritis Pain</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (60.0)</td>
<td>3 (15.8)</td>
<td></td>
</tr>
</tbody>
</table>

**Study VGFT-OD-0306,** a total of 29 non-ocular TEAEs were reported in seven subjects. The most commonly reported TEAE was dysphonia in two subjects. A total of five ocular TEAEs were reported in two subjects. The most commonly reported ocular TEAE was reduced visual acuity in both subjects.

**Study VGFT-OD-0307,** all subjects (six VEGF Trap and three placebo) reported at least one TEAE. The most commonly reported TEAEs were: hypoglycemia (3), arthralgia (2), back pain (2) and proteinuria (2). There were no dose limiting toxicities.

**Study PDY6655,** 132 TEAEs were reported in 36 (94.7%) subjects after intravenous administration and 159 in 34 (85.0%) after subcutaneous. Twelve injection site reactions were reported with intravenous and six with subcutaneous (Table 16). The most commonly reported TEAEs were headache, acneform dermatitis and gastroenteritis (Table 16). No prolonged QTc interval >450 ms and QTc interval increases from baseline (>60 ms) were reported irrespective of the route of administration.

**Study PDY6656,** a total of 30 TEAEs were reported in ten (83.3%) subjects in the 1 mg/kg group, 44 in eleven (91.7%) in the 2 mg/kg group, 48 in eleven (91.7%) in the 4 mg/kg group and 23 in ten (83.3%) in the placebo group. The incidence of headache appeared to be dose related and the incidence of dysphonia was increased in the aflibercept groups.

**Study VGFT-OD-0508,** systemic TEAEs were reported in 27 (84.45) subjects in the 0.5 mg q4w group, 25 (78.1%) in the 0.5 mg q12w group, 28 (90.3%) in the 2 mg q4w group, 24 (77.4%) in the 2 mg q12w group and 25 (80.6%) in the 4 mg q12w group. The commonest TEAEs were infections and there did not appear to be any dose related TEAEs. Ocular TEAEs in the study eye were reported in 29 (90.6%) subjects in the 0.5 mg q4w group, 26 (81.3%) in the 0.5 mg q12w group, 26 (83.9%) in the 2 mg q4w group, 25 (80.6%) in the 2 mg q12h group and 28 (90.3%) in the 4 mg q12h group. The commonest TEAE in the study eye was conjunctival haemorrhage which did not appear to be related to either dose or frequency of administration (Table 17). There was no clinically significant change in mean blood pressure values. There was a mean (SD) increase in IOP of 3.2 (5.05) mmHg the day after intravitreal injection that did not increase

---

12 QT interval: a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle. A prolonged QT interval is a risk factor for ventricular tachyarrhythmias and sudden death. The QT interval is dependent on the heart rate (the faster the heart rate, the shorter the QT interval). To correct for changes in heart rate and thereby improve the detection of patients at increased risk of ventricular arrhythmia, a heart rate-corrected QT interval QTc is often calculated.
following subsequent treatments. Seven subjects had treatment emergent clinically significant ECG abnormalities but none appeared to be treatment related.

### Table 16. Summary of treatment-emergent adverse events. Safety population

<table>
<thead>
<tr>
<th>Primary System Organ Class</th>
<th>Preferred term</th>
<th>I.V. (N=38)</th>
<th>S.C. (N=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any class</td>
<td></td>
<td>36 (94.7%)</td>
<td>34 (85.0%)</td>
</tr>
<tr>
<td>Infectious and infestations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td></td>
<td>1 (2.6%)</td>
<td>2 (5.0%)</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td></td>
<td>10 (26.3%)</td>
<td>10 (25.0%)</td>
</tr>
<tr>
<td>Hordeolum</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td>1 (2.6%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td></td>
<td>3 (7.9%)</td>
<td>2 (5.0%)</td>
</tr>
<tr>
<td>Oral herpes</td>
<td></td>
<td>3 (7.9%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td></td>
<td>1 (2.6%)</td>
<td>2 (5.0%)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Sore throat</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td></td>
<td>0 (0%)</td>
<td>2 (5.0%)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Allergy to arthropod bite</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td>17 (44.7%)</td>
<td>18 (45.0%)</td>
</tr>
<tr>
<td>Headache</td>
<td></td>
<td>16 (42.1%)</td>
<td>17 (42.5%)</td>
</tr>
<tr>
<td>Paraesthesia</td>
<td></td>
<td>1 (2.6%)</td>
<td>2 (5.0%)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Vertigo</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Palpitations</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td>10 (26.3%)</td>
<td>7 (17.5%)</td>
</tr>
<tr>
<td>Dysphonia</td>
<td></td>
<td>4 (10.5%)</td>
<td>5 (12.5%)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td></td>
<td>4 (10.5%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
<td></td>
<td>1 (2.6%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Rhinitis allergic</td>
<td></td>
<td>2 (5.3%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td>10 (26.3%)</td>
<td>15 (37.5%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
<td>2 (5.3%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Aplachous stomatitis</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
<td>1 (2.6%)</td>
<td>3 (7.5%)</td>
</tr>
<tr>
<td>Dental caries</td>
<td></td>
<td>1 (2.6%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td></td>
<td>1 (2.6%)</td>
<td>4 (10.0%)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td></td>
<td>3 (7.9%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Flatulence</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Glossitis</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
<td>3 (7.9%)</td>
<td>6 (15.0%)</td>
</tr>
<tr>
<td>Periodontitis</td>
<td></td>
<td>0 (0%)</td>
<td>1 (2.5%)</td>
</tr>
<tr>
<td>Stomatitis</td>
<td></td>
<td>1 (2.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td></td>
<td>2 (5.3%)</td>
<td>1 (2.5%)</td>
</tr>
</tbody>
</table>
Table 17. Number of Patients (%) with Ocular TEAEs in the Study Eye by Preferred Term as Reported by ≥2% of Patients

<table>
<thead>
<tr>
<th>MedDRA v10.0 Preferred Term</th>
<th>0.5mg q4</th>
<th>0.5mg q12</th>
<th>2mg q4</th>
<th>2mg q12</th>
<th>4mg q12</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=32</td>
<td>N=32</td>
<td>N=31</td>
<td>N=31</td>
<td>N=31</td>
<td>N=157</td>
<td></td>
</tr>
<tr>
<td>Any Ocular TEAE in the Study Eye</td>
<td>26(81.3)</td>
<td>26(83.9)</td>
<td>25(80.6)</td>
<td>28(90.3)</td>
<td>134(85.4)</td>
<td></td>
</tr>
<tr>
<td>Conjunctival Haemorrhage</td>
<td>12(37.5)</td>
<td>9(29.0)</td>
<td>15(48.4)</td>
<td>13(41.9)</td>
<td>60(38.2)</td>
<td></td>
</tr>
<tr>
<td>Intraocular Pressure Increased</td>
<td>4(12.5)</td>
<td>6(19.4)</td>
<td>3(9.7)</td>
<td>7(22.6)</td>
<td>30(19.1)</td>
<td></td>
</tr>
<tr>
<td>Refraction Disorder</td>
<td>7(21.9)</td>
<td>5(16.1)</td>
<td>3(9.7)</td>
<td>7(22.6)</td>
<td>26(16.6)</td>
<td></td>
</tr>
<tr>
<td>Retinal Haemorrhage</td>
<td>6(18.8)</td>
<td>2(6.5)</td>
<td>6(19.4)</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td></td>
</tr>
<tr>
<td>Visual Acuity Reduced</td>
<td>5(15.6)</td>
<td>6(18.8)</td>
<td>5(16.1)</td>
<td>3(9.7)</td>
<td>23(14.6)</td>
<td></td>
</tr>
<tr>
<td>Vitreous Detachment</td>
<td>2(6.3)</td>
<td>3(9.7)</td>
<td>5(16.1)</td>
<td>4(12.9)</td>
<td>18(11.5)</td>
<td></td>
</tr>
<tr>
<td>Eye Pain</td>
<td>5(15.6)</td>
<td>4(12.9)</td>
<td>1(3.2)</td>
<td>4(12.9)</td>
<td>16(10.2)</td>
<td></td>
</tr>
<tr>
<td>Vitreous Floaters</td>
<td>3(9.4)</td>
<td>2(6.5)</td>
<td>4(12.9)</td>
<td>2(6.5)</td>
<td>14(8.9)</td>
<td></td>
</tr>
<tr>
<td>Detachment Of Retinal Pigment Epithelium</td>
<td>1(3.1)</td>
<td>2(6.3)</td>
<td>4(12.9)</td>
<td>1(3.2)</td>
<td>12(7.6)</td>
<td></td>
</tr>
<tr>
<td>Blepharitis</td>
<td>3(9.4)</td>
<td>0</td>
<td>3(9.7)</td>
<td>3(9.7)</td>
<td>10(6.4)</td>
<td></td>
</tr>
<tr>
<td>Retinal Oedema</td>
<td>2(6.3)</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td>10(6.4)</td>
<td></td>
</tr>
<tr>
<td>Cataract</td>
<td>1(3.1)</td>
<td>2(6.3)</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td>8(5.1)</td>
<td></td>
</tr>
<tr>
<td>Subretinal Fibrosis</td>
<td>1(3.1)</td>
<td>1(3.2)</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td>8(5.1)</td>
<td></td>
</tr>
<tr>
<td>Visual Disturbance</td>
<td>2(6.3)</td>
<td>1(3.1)</td>
<td>2(6.5)</td>
<td>3(9.7)</td>
<td>8(5.1)</td>
<td></td>
</tr>
<tr>
<td>Cataract Nuclear</td>
<td>0</td>
<td>4(12.9)</td>
<td>0</td>
<td>0</td>
<td>7(4.5)</td>
<td></td>
</tr>
<tr>
<td>Dry Eye</td>
<td>3(9.4)</td>
<td>0</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td>7(4.5)</td>
<td></td>
</tr>
<tr>
<td>Eye Irritation</td>
<td>5(15.6)</td>
<td>1(3.2)</td>
<td>0</td>
<td>1(3.2)</td>
<td>7(4.5)</td>
<td></td>
</tr>
<tr>
<td>Retinal Pigment</td>
<td>0</td>
<td>2(6.3)</td>
<td>1(3.2)</td>
<td>3(9.7)</td>
<td>7(4.5)</td>
<td></td>
</tr>
<tr>
<td>Epitheliopathy</td>
<td>1(3.1)</td>
<td>1(3.2)</td>
<td>1(3.2)</td>
<td>2(6.5)</td>
<td>6(3.8)</td>
<td></td>
</tr>
<tr>
<td>Cataract Subcapsular</td>
<td>1(3.1)</td>
<td>1(3.2)</td>
<td>1(3.2)</td>
<td>2(6.5)</td>
<td>6(3.8)</td>
<td></td>
</tr>
<tr>
<td>Photopsia</td>
<td>1(3.1)</td>
<td>0</td>
<td>2(6.5)</td>
<td>3(9.7)</td>
<td>6(3.8)</td>
<td></td>
</tr>
<tr>
<td>Lacerination Increased</td>
<td>1(3.1)</td>
<td>1(3.2)</td>
<td>0</td>
<td>2(6.5)</td>
<td>5(3.2)</td>
<td></td>
</tr>
<tr>
<td>Punctate Keratitis</td>
<td>0</td>
<td>1(3.2)</td>
<td>2(6.5)</td>
<td>2(6.5)</td>
<td>5(3.2)</td>
<td></td>
</tr>
<tr>
<td>Eye Inflammation</td>
<td>2(6.3)</td>
<td>0</td>
<td>1(3.2)</td>
<td>1(3.2)</td>
<td>4(2.5)</td>
<td></td>
</tr>
<tr>
<td>Foreign Body Sensation In</td>
<td>0</td>
<td>1(3.2)</td>
<td>0</td>
<td>0</td>
<td>4(2.5)</td>
<td></td>
</tr>
<tr>
<td>Eyes</td>
<td>3(9.4)</td>
<td>0</td>
<td>1(3.2)</td>
<td>0</td>
<td>4(2.5)</td>
<td></td>
</tr>
<tr>
<td>Maculopathy</td>
<td>1(3.1)</td>
<td>0</td>
<td>2(6.5)</td>
<td>1(3.2)</td>
<td>4(2.5)</td>
<td></td>
</tr>
</tbody>
</table>

Study VGFT-OD-0605/14393 (VIEW 1), non-ocular TEAEs were reported in 220 (72.4%) subjects in the aflibercept 2 mg q4w group, 231 (76.0%) in the 0.5 mg q4w group, 223 (73.6%) in the 2 mg q8w group and 234 (77.0%) in the ranibizumab group. Infections were the most common TEAEs and the pattern of TEAEs was similar for all four treatment groups. Ocular TEAEs in the study eye were reported in 228 (75.0%) subjects in the aflibercept 2 mg q4w group, 226 (74.3%) in the 0.5 mg q4w group, 238 (78.5%) in the 2 mg q8w group and 246 (80.9%) in the ranibizumab group. Conjunctival haemorrhage was the most common TEAE in the study eye and the patterns were similar for the treatment groups. Pre-injection IOP decreased from baseline by approximately 0.2 mmHg in the aflibercept groups but remained at baseline levels in the ranibizumab. Ocular TEAEs in the fellow eye were reported in 151 (49.7%) subjects in the aflibercept 2 mg q4w group, 151 (49.7%) in the 0.5 mg q4w group, 143 (47.2%) in the 2 mg q8w group and 150 (49.3%) in the ranibizumab group. The commonest injection related TEAE was conjunctival haemorrhage, occurring in 105 (34.5%) subjects in the 2 mg q4w group, 117 (38.5%) in the 0.5 mg q4w group, 127 (41.9%) in the 2 mg q8w group and 140 (46.1%) in the ranibizumab group. Hypertension was reported in 21 (6.9%) subjects in the aflibercept 2 mg q4w group, 21 (6.9%) in the 0.5 mg q4w group, 20 (6.6%) in the 2 mg q8w group and 25 (8.2%) in the ranibizumab group. Arterial thromboembolic events were reported in two (0.7%).
subjects in the aflibercept 2 mg q4w group, seven (2.3%) in the 0.5 mg q4w group, six (2.0%) in
the 2 mg q8w group and five (1.6%) in the ranibizumab group.

**Study 311523 (VIEW 2),** TEAEs were reported in 277 (89.6%) subjects in the aflibercept 2 mg
q4w group, 262 (88.2%) in the 0.5 mg q4w group, 277 (90.2%) in the 2 mg q8w group and 250
(85.9%) in the ranibizumab group. Ocular TEAEs in the study eye were reported in 191 (61.8%)
subjects in the aflibercept 2 mg q4w group, 182 (61.3%) in the 0.5 mg q4w group, 198 (64.5%)
in the 2 mg q8w group and 187 (64.3%) in the ranibizumab group. The commonest ocular
TEAEs in the study eye were reduced visual acuity and conjunctival haemorrhage (Table 18).
Ocular TEAEs in the fellow eye were reported in 110 (35.6%) subjects in the aflibercept 2 mg
q4w group, 118 (39.7%) in the 0.5 mg q4w group, 123 (40.1%) in the 2 mg q8w group and 124
(42.6%) in the ranibizumab group. Non-ocular TEAEs were reported in 231 (74.8%) subjects in
the aflibercept 2 mg q4w group, 206 (69.4%) in the 0.5 mg q4w group, 213 (69.4%) in the 2 mg
q8w group and 181 (62.2%) in the ranibizumab group. The commonest non-ocular TEAEs were
nasopharyngitis (6.4%) and influenza (4.3%). Arterial thromboembolic events were reported in
eight (2.6%) subjects in the aflibercept 2 mg q4w group, eight (2.7%) in the 0.5 mg q4w group,
eight (2.6%) in the 2 mg q8w group and six (2.1%) in the ranibizumab group. Hypertension was
reported in 31 (10.0%) subjects in the aflibercept 2 mg q4w group, 22 (7.4%) in the 0.5 mg q4w
group, 28 (9.1%) in the 2 mg q8w group and 29 (10.0%) in the ranibizumab group. Pre-
injection mean IOP increased slightly in the ranibizumab group and decreased slightly in the
aflibercept groups (Table 18). There were no clinically significant changes in mean vital sign or
ECG parameters.

**Table 18. Ocular TEAEs in the study eye occurring in ≥5.0% of the subjects in any treatment group
(Safety analysis set).**

<table>
<thead>
<tr>
<th>MedDRA preferred term</th>
<th>Ranibizumab</th>
<th>VEGF Trap-Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5Q4 (N = 291)</td>
<td>2Q4 (N = 309)</td>
</tr>
<tr>
<td>Visual acuity reduced</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Conjunctival haemorrhage</td>
<td>187 (64.3)</td>
<td>191 (63.8)</td>
</tr>
<tr>
<td>Retinal haemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macular degeneration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraocular pressure increased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detachment of retinal pigment epithelium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitreous detachment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataract</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocular hyperaemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal degeneration</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**StudyVGF-OD-0702/14262, TEAEs were reported by 154 (98.1%) subjects. There was a lower
rate of AEs in subjects treated with the pre-filled syringes: 93 (93.9%) subjects compared with
50 (100%) subjects in the vial group (Table 19). Ocular AEs were reported in 134 (85.4%)
subjects. The most commonly reported ocular AEs were: cataract in 23 (14.6%) subjects,
conjunctival haemorrhage in 23 (14.6%) subjects, ‘visual acuity reduced’ in 23 (14.6%) subjects
and retinal haemorrhage in 20 (12.7%) subjects. Ocular AEs were more common in the vial
group than in the pre-filled syringe (Table 20). Non-ocular AEs were reported in 148 (94.3%)
subjects and the pattern of AEs is as would be expected for the age group. The most common
injection related AEs were: conjunctival hemorrhage in 20 (13%) subjects, eye pain in eight
(5%) subjects and injection site pain in seven (5%) subjects. One subject had an increase in IOP
≥10 mmHg.
Table 19. Overall Adverse Event Profile (All Randomized Set)

<table>
<thead>
<tr>
<th>Subjects with Events</th>
<th>Vial (N=50)</th>
<th></th>
<th>PFS (N=99)</th>
<th></th>
<th>Total (N=149)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td></td>
<td>Randomization</td>
<td></td>
<td>Randomization</td>
<td></td>
<td>Randomization</td>
<td></td>
</tr>
<tr>
<td>No. of Subjects with Events, n (%)</td>
<td>41 (82.0)</td>
<td>50 (100)</td>
<td>82 (82.8)</td>
<td>93 (93.9)</td>
<td>123 (82.6)</td>
<td>143 (96.0)</td>
</tr>
<tr>
<td>Ocular AEs</td>
<td>29 (58.0)</td>
<td>42 (84.0)</td>
<td>63 (63.6)</td>
<td>71 (71.7)</td>
<td>92 (61.7)</td>
<td>113 (75.8)</td>
</tr>
<tr>
<td></td>
<td>23 (46.0)</td>
<td>38 (76.0)</td>
<td>55 (55.6)</td>
<td>58 (58.6)</td>
<td>78 (52.3)</td>
<td>96 (64.4)</td>
</tr>
<tr>
<td>Non-Ocular AEs</td>
<td>20 (40.0)</td>
<td>35 (70.0)</td>
<td>43 (43.4)</td>
<td>50 (50.5)</td>
<td>63 (42.3)</td>
<td>85 (57.0)</td>
</tr>
<tr>
<td>Drug-Related AEs</td>
<td>33 (66.0)</td>
<td>44 (88.0)</td>
<td>65 (65.7)</td>
<td>87 (87.9)</td>
<td>98 (65.8)</td>
<td>131 (87.9)</td>
</tr>
<tr>
<td></td>
<td>1 (2.0)</td>
<td>0</td>
<td>1 (1.0)</td>
<td>1 (1.0)</td>
<td>2 (1.3)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Maximum Intensity of Ocular AEs</td>
<td>23 (46.0)</td>
<td>39 (78.0)</td>
<td>56 (56.6)</td>
<td>65 (65.7)</td>
<td>79 (53.0)</td>
<td>104 (69.8)</td>
</tr>
<tr>
<td>Mild</td>
<td>1 (2.0)</td>
<td>0</td>
<td>1 (1.0)</td>
<td>0</td>
<td>2 (1.3)</td>
<td>0</td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (2.0)</td>
<td>3 (6.0)</td>
<td>3 (3.0)</td>
<td>5 (5.1)</td>
<td>4 (2.7)</td>
<td>8 (5.4)</td>
</tr>
<tr>
<td>Severe</td>
<td>1 (2.0)</td>
<td>2 (4.0)</td>
<td>2 (2.0)</td>
<td>4 (4.0)</td>
<td>3 (2.0)</td>
<td>6 (4.0)</td>
</tr>
<tr>
<td>Maximum Intensity of Non-Ocular AEs</td>
<td>22 (44.0)</td>
<td>39 (78.0)</td>
<td>55 (55.6)</td>
<td>77 (77.8)</td>
<td>77 (51.7)</td>
<td>116 (77.9)</td>
</tr>
<tr>
<td>Mild</td>
<td>19 (38.0)</td>
<td>17 (34.0)</td>
<td>32 (32.3)</td>
<td>55 (55.6)</td>
<td>51 (34.2)</td>
<td>72 (48.3)</td>
</tr>
<tr>
<td>Moderate</td>
<td>5 (10.0)</td>
<td>12 (24.0)</td>
<td>6 (6.1)</td>
<td>16 (16.2)</td>
<td>11 (7.4)</td>
<td>28 (18.8)</td>
</tr>
<tr>
<td>Severe</td>
<td>9 (18.0)</td>
<td>16 (32.0)</td>
<td>13 (13.1)</td>
<td>33 (33.3)</td>
<td>22 (14.8)</td>
<td>40 (27.9)</td>
</tr>
<tr>
<td>Injection-related SAEs</td>
<td>1 (2.0)</td>
<td>0</td>
<td>1 (1.0)</td>
<td>0</td>
<td>1 (0.7)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>AEs Leading to Withdrawal from Study</td>
<td>0</td>
<td>2 (4.0)</td>
<td>0</td>
<td>1 (1.0)</td>
<td>0</td>
<td>3 (2.0)</td>
</tr>
<tr>
<td>Discontinuation of Study Drug due to AEs</td>
<td>0</td>
<td>1 (2.0)</td>
<td>0</td>
<td>2 (2.0)</td>
<td>0</td>
<td>3 (2.0)</td>
</tr>
<tr>
<td>Death due to AE</td>
<td>0</td>
<td>2 (4.0)</td>
<td>0</td>
<td>3 (3.0)</td>
<td>0</td>
<td>5 (3.4)</td>
</tr>
</tbody>
</table>
Table 20. Post-Randomization Ocular TEAEs Reported by >3 Subjects in Either Group, Study Eye (All Randomized Set)

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Vial (N=50)</th>
<th>PFS (N=99)</th>
<th>Total (N=149)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Subjects with Events, n (%)</td>
<td>38 (76.0)</td>
<td>58 (58.6)</td>
<td>96 (64.4)</td>
</tr>
<tr>
<td>Retinal haemorrhage</td>
<td>8 (16.0)</td>
<td>8 (8.1)</td>
<td>16 (10.7)</td>
</tr>
<tr>
<td>Cataract</td>
<td>7 (14.0)</td>
<td>9 (9.1)</td>
<td>16 (10.7)</td>
</tr>
<tr>
<td>VA reduced</td>
<td>8 (16.0)</td>
<td>7 (7.1)</td>
<td>15 (10.1)</td>
</tr>
<tr>
<td>Conjunctival haemorrhage</td>
<td>6 (12.0)</td>
<td>8 (8.1)</td>
<td>14 (9.4)</td>
</tr>
<tr>
<td>Vitreous floaters</td>
<td>2 (4.0)</td>
<td>7 (7.1)</td>
<td>9 (6.0)</td>
</tr>
<tr>
<td>Blepharitis</td>
<td>5 (10.0)</td>
<td>2 (2.0)</td>
<td>7 (4.7)</td>
</tr>
<tr>
<td>Macular degeneration</td>
<td>3 (6.0)</td>
<td>4 (4.0)</td>
<td>6 (4.0)</td>
</tr>
<tr>
<td>Retinal detachment</td>
<td>0</td>
<td>6 (6.1)</td>
<td>6 (4.0)</td>
</tr>
<tr>
<td>Vitreous detachment</td>
<td>5 (10.0)</td>
<td>1 (1.0)</td>
<td>6 (4.0)</td>
</tr>
<tr>
<td>Eye pain</td>
<td>1 (2.0)</td>
<td>3 (3.0)</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td>Eye pruritus</td>
<td>0</td>
<td>4 (4.0)</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>0</td>
<td>4 (4.0)</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td>IOP increased</td>
<td>0</td>
<td>4 (4.0)</td>
<td>4 (2.7)</td>
</tr>
</tbody>
</table>

Study VGFT-OD-0706/13336 (DAVINCI), ocular TEAEs in the study eye were reported in 26 (59.1%) subjects with aflibercept 0.5 mg q4w, 20 (45.5%) subjects with 2 mg q4w, 23 (54.8%) subjects with 2 mg q8w, 19 (42.2%) subjects with 2 mg PRN and 21 (47.7%) subjects with laser. The pattern of TEAEs in the study was similar for all five treatment groups. Ocular procedure related TEAEs were reported in 16 (36.4%) subjects with aflibercept 0.5 mg q4w, eleven (25.0%) subjects with 2 mg q4w, 17 (40.5%) subjects with 2 mg q8w, 19 (42.2%) subjects with 2 mg PRN and 14 (31.1%) subjects with laser. Ocular TEAEs in the fellow eye were reported in 14 (31.8%) subjects with aflibercept 0.5 mg q4w, seven (15.9%) subjects with 2 mg q4w, 13 (31.0%) subjects with 2 mg q8w, 13 (28.9%) subjects with 2 mg PRN and eight (18.2%) subjects with laser. Conjunctival haemorrhage, eye pain and ocular hyperaemia were more common in the treated eye than the fellow eye. Non-ocular TEAEs were reported in 14 (31.8%) subjects with aflibercept 0.5 mg q4w, 32 (72.7%) subjects with 2 mg q4w, 24 (54.5%) subjects with 2 mg q8w, 26 (61.9%) subjects with 2 mg PRN and 27 (60.0%) subjects with laser. The pattern of non-ocular TEAEs was similar for the five treatment groups. TEAEs of interest occurred to a greater extent in the aflibercept groups: 27 (15.4%) subjects overall compared with three (6.8%) subjects in the laser group (Table 21). Two subjects in the aflibercept 2 mg q4w group had an increase in IOP of ≥10 mmHg from baseline at Week 24.
Table 21. Treatment-Emergent Adverse Events of Interest (SAF).

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Laser (N=44) n (%)</th>
<th>0.5 q4 (N=44) n (%)</th>
<th>2.0 q4 (N=44) n (%)</th>
<th>2.0 q8 (N=42) n (%)</th>
<th>2.0 PRN (N=45) n (%)</th>
<th>All VEGF Trap-Eye (N=175) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total No. of Events, n</td>
<td>3</td>
<td>13</td>
<td>10</td>
<td>3</td>
<td>7</td>
<td>33</td>
</tr>
<tr>
<td>Total No. of Patients, n (%)</td>
<td>3 (6.8)</td>
<td>11 (25.0)</td>
<td>8 (18.2)</td>
<td>2 (4.8)</td>
<td>6 (13.3)</td>
<td>27 (15.4)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3 (6.8)</td>
<td>2 (4.5)</td>
<td>4 (9.1)</td>
<td>1 (2.4)</td>
<td>3 (6.7)</td>
<td>10 (5.7)</td>
</tr>
<tr>
<td>Blood pressure increased</td>
<td>0</td>
<td>2 (4.5)</td>
<td>2 (4.5)</td>
<td>1 (2.4)</td>
<td>1 (2.2)</td>
<td>6 (3.4)</td>
</tr>
<tr>
<td>Anterior chamber cell</td>
<td>0</td>
<td>3 (6.8)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3 (1.7)</td>
</tr>
<tr>
<td>Iritis</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>1 (2.2)</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Endophthalmitis</td>
<td>0</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>1 (2.2)</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Cerebrovascular accident</td>
<td>0</td>
<td>1 (2.3)</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Hypertensive emergency</td>
<td>0</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Anterior chamber flare</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Vittis</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (2.2)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Silent myocardial infarction</td>
<td>0</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>0</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.6)</td>
</tr>
</tbody>
</table>

* Events are presented in decreasing order of frequency in the All VEGF Trap-Eye column.

Serious adverse events and deaths

*Study VGFT-OD-0502/14395 Part A*, no serious adverse events (SAEs) occurred during the treatment phase but SAEs were reported for three subjects during the extended follow-up phase. One subject in the 1.0 mg cohort had atrial fibrillation, bradycardia, acute renal failure and pneumonia. One subject in the 2.0 mg cohort had cerebral infarction, angina pectoris, and esophageal dyskinesia and this patient subsequently withdrew from the study because of medical issues. One subject in the 4.0 mg cohort had prostate cancer. A further two subjects had SAEs during the open-label extension: breast cancer and retinal detachment.

*Study VGFT-OD-0502/14395 Part C*, there were no ocular SAEs. For the entire study, eight (28.6%) subjects reported systemic SAEs: squamous cell carcinoma of the skin in two patients; colon cancer, congestive cardiac failure in two patients, lobar pneumonia; fall/contusion/facial bones fracture; and hydronephrosis/urinary retention.

*Study VGFT-OD-0603*, a total of 19 SAEs were reported in eight subjects. None of the SAEs appeared to be related to treatment.

*Study VGFT-OD-0603*, one subject in the IVT-1 cohort died 47 days after the last dose of study drug due to cardiac arrest.

*Study VGFT-OD-0512*, two subjects reported SAEs: one with coronary artery disease and one with streptococcal cellulites/ acute renal failure/ anemia/ peripheral ischemia/ osteomyelitis.

*Study VGFT-OD-0305*, SAEs were reported in three subjects: one placebo, one given 0.3 mg/kg and one given 3.0 mg/kg. The event in the 3.0 mg/kg subject was malignant hypertension, which was considered to be a dose-limiting toxicity. A second subject with proteinuria was also considered to have a dose limiting toxicity. Two subjects experienced serious ocular adverse events: both retinal haemorrhage.

*Study VGFT-OD-0306*, one subject reported a SAEs: fall/ left hip fracture.

*Study VGFT-OD-0508*, SAEs were reported in eleven (34.4%) subjects in the 0.5 mg q4w group, five (15.6%) subjects in the 0.5 mg q12w group, ten (32.3%) subjects in the 2 mg
q4w group, seven (22.6%) subjects in the 2 mg q12w group and two (6.5%) subjects in the 4 mg q12w group. One subject in the 0.5 mg q4w group developed suspected culture-negative endophthalmitis that was reported as an SAE of uveitis after receiving the fifth injection of study treatment.

Study VGFT-OD-0508, there were two deaths: one in the 2 mg q4w group (pancreatic carcinoma) and one in the 4 mg q12w group (pulmonary hypertension).

Study VGFT-OD-0605/14393 (VIEW 1), SAEs were reported in 49 (16.1%) subjects in the aflibercept 2 mg q4w group, 58 (19.1%) subjects in the 0.5 mg q4w group, 58 (19.1%) subjects in the 2 mg q8w group and 71 (23.4%) subjects in the ranibizumab group. Ocular SAEs in the study eye were reported in seven (2.3%) subjects in the aflibercept 2 mg q4w group, six (2.0%) subjects in the 0.5 mg q4w group, three (1.0%) subjects in the 2 mg q8w group and ten (3.3%) subjects in the ranibizumab group. Ocular SAEs in the fellow eye were reported in no subjects in the aflibercept 2 mg q4w group, three (1.0%) subjects in the 0.5 mg q4w group, two (0.7%) subjects in the 2 mg q8w group and three (1.0%) subjects in the ranibizumab group. Non-ocular SAEs were reported in 49 (16.1%) subjects in the aflibercept 2 mg q4w group, 58 (19.1%) subjects in the 0.5 mg q4w group, 58 (19.1%) subjects in the 2 mg q8w group and 71 (23.4%) subjects in the ranibizumab group. The pattern of non-ocular SAEs was similar for the four study groups and as expected given the age range of the subjects.

Study VGFT-OD-0605/14393 (VIEW 1), death was reported in one (0.3%) subject in the aflibercept 2 mg q4w group, one (0.3%) subject in the 0.5 mg q4w group, seven (2.3%) subjects in the 2 mg q8w group and five (1.6%) subjects in the ranibizumab group.

Study 311523 (VIEW 2), treatment emergent SAEs were reported in 49 (15.9%) subjects in the aflibercept 2 mg q4w group, 41 (13.8%) subjects in the 0.5 mg q4w group, 48 (15.6%) subjects in the 2 mg q8w group and 35 (12.0%) subjects in the ranibizumab group. Ocular treatment emergent SAEs in the study eye occurred in six (1.9%) subjects in the aflibercept 2 mg q4w group, five (1.7%) subjects in the 0.5 mg q4w group, nine (2.9%) subjects in the 2 mg q8w group and nine (3.1%) subjects in the ranibizumab group. Ocular treatment emergent SAEs in the fellow eye occurred in nine (2.9%) subjects in the aflibercept 2 mg q4w group, two (0.7%) subjects in the 0.5 mg q4w group, three (1.0%) subjects in the 2 mg q8w group and three (1.0%) subjects in the ranibizumab group. Non-ocular treatment emergent SAEs occurred in 36 (11.7%) subjects in the aflibercept 2 mg q4w group, 37 (12.5%) subjects in the 0.5 mg q4w group, 38 (12.4%) subjects in the 2 mg q8w group and 26 (8.9%) subjects in the ranibizumab group (Table 22).
Table 22. Non-ocular treatment-emergent SAEs occurring in at least 2 subjects in any treatment group (safety analysis set)

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Ranibizumab</th>
<th>VEGF Trap-Eye</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5Q4 (N = 291) n (%)</td>
<td>2Q4 (N = 309) n (%)</td>
<td>0.5Q4 (N = 297) n (%)</td>
</tr>
<tr>
<td>Any non-ocular serious TEAE</td>
<td>26 (8.9)</td>
<td>38 (11.7)</td>
<td>37 (12.5)</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>5 (1.7)</td>
<td>8 (2.6)</td>
<td>7 (2.4)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>2 (0.7)</td>
<td>0 (0.0)</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>Acute coronary syndrome</td>
<td>0 (0.0)</td>
<td>2 (0.6)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>2 (0.7)</td>
<td>1 (0.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</td>
<td>3 (1.0)</td>
<td>3 (1.0)</td>
<td>9 (3.0)</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>1 (0.3)</td>
<td>0 (0.0)</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>Basal cell carcinoma</td>
<td>1 (0.3)</td>
<td>0 (0.0)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>0 (0.0)</td>
<td>4 (1.3)</td>
<td>6 (2.0)</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>2 (0.7)</td>
<td>1 (0.3)</td>
<td>7 (2.4)</td>
</tr>
<tr>
<td>Upper limb fracture</td>
<td>2 (0.7)</td>
<td>0 (0.0)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Fall</td>
<td>2 (0.7)</td>
<td>0 (0.0)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Neurological system disorders</td>
<td>2 (0.7)</td>
<td>8 (2.6)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Cerebrovascular accident</td>
<td>1 (0.3)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Transient ischaemic attack</td>
<td>0 (0.0)</td>
<td>2 (0.6)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>6 (2.1)</td>
<td>4 (1.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>0 (0.0)</td>
<td>2 (0.6)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>1 (0.3)</td>
<td>4 (1.3)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>3 (1.0)</td>
<td>4 (1.3)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>2 (0.7)</td>
<td>2 (0.6)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>2 (0.7)</td>
<td>3 (1.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Skin and subcutaneous</td>
<td>2 (0.7)</td>
<td>1 (0.3)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Tissue disorders</td>
<td>0 (0.0)</td>
<td>2 (0.6)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>0 (0.0)</td>
<td>1 (0.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>0 (0.0)</td>
<td>2 (0.6)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Investigations</td>
<td>0 (0.0)</td>
<td>1 (0.3)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Surgical and medical procedures</td>
<td>2 (0.7)</td>
<td>0 (0.0)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>2 (0.7)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

Note: System organ classes (SOCs) as well as preferred terms within each SOC are sorted in descending order by frequency in the VEGF Trap-Eye combined group.

Study 311523 (VIEW 2), there were nine deaths in total: three (1.0%) subjects in the aflibercept 2 mg q4w group, two (0.7%) subjects in the 0.5 mg q4w group, two (0.7%) subjects in the 2 mg q8w group and two (0.7%) subjects in the ranibizumab group.

Study VGFT-OD-0702/14262, SAEs were reported in 64 (40.8%) subjects. Ocular SAEs were reported in eight (5.1%) subjects. Non-ocular SAEs were reported in 59 (37.6%) subjects. Procedure related SAEs were reported in two (1.3%) subjects.

Study VGFT-OD-0702/14262, eight (5.1%) subjects died but none of the deaths appeared to be related to study treatment.

Study VGFT-OD-0706/13336 (DAVINCI), SAEs were reported in seven (15.9%) subjects in the aflibercept 0.5 mg q4w group, nine (20.9%) subjects in the 2 mg q4w group, eight (19.0%) subjects in the 2 mg q8w group, three (6.7%) subjects in the 2 mg PRN group and six (13.6%) subjects in the laser group. There were more infections reported as SAEs in the aflibercept groups: nine (5.1%) subjects compared with none in the laser group. Ocular SAEs in the study eye were reported in one (2.3%) subject with aflibercept 0.5 mg...
q4w, one (2.3%) subject with 2 mg q4w, one (2.4%) subject with 2 mg q8w, one (2.2%) subject with 2 mg PRN and three (6.8%) subjects with laser. Ocular SAEs in the fellow eye were reported in one (2.4%) subject with 2 mg q8w. Non-ocular SAEs were reported in six (13.6%) subjects with aflibercept 0.5 mg q4w, eight (18.2%) subjects with 2 mg q4w, six (14.3%) subjects with 2 mg q8w, two (4.4%) subjects with 2 mg PRN and three (6.8%) subjects with laser.

*Study VGFT-OD-0706/13336 (DAVINCI)*, death was reported in one (2.3%) patient with aflibercept 0.5 mg q4w (multi-organ failure), one (2.3%) patient with 2 mg q4w (sudden unexplained), and one (2.4%) patient with 2 mg q8w (convulsions).

There were no SAEs reported in *Study VGFT-OD-0502/14395 Part B*, *Study VGFT-OD-0307*, *Study PDY6655* or *Study PDY6656*.

There were no deaths reported in *Study VGFT-OD-0502/14395 Part A, Part B and Part C*; or in *Study VGFT-OD-0512*, *Study VGFT-OD-0305*, *Study VGFT-OD-0306*, *Study VGFT-OD-0307*, *Study PDY6655* and *Study PDY6656*.

**Laboratory findings**

*Study VGFT-OD-0502/14395 Part A*, there was one clinically significant abnormality in a laboratory test: elevated creatinine kinase to 923 U/L.

*Studies VGFT-OD-0502/14395 Part B and Part C*, there were no clinically significant laboratory abnormalities.

*Study VGFT-OD-0603*, one subject was reported with a urinary tract infection (UTI) and one with hypokalaemia. Both abnormalities resolved.

*Study VGFT-OD-0512*, laboratory test abnormalities were consistent with the subjects’ history of diabetes.

*Study VGFT-OD-0305*, proteinuria was reported in 5 patients: 2 in the 1.0 mg/kg group and 3 in the 3.0 mg/kg group. Haematuria was reported in one subject in the VEGF Trap 1.0 mg/kg group.

*Study VGFT-OD-0306*, proteinuria was reported in six (85.7%) subjects.

*Study VGFT-OD-0307*, one subject had proteinuria related to treatment

*Study PDY6655*, one subject had elevated alanine aminotransferase (ALT) (155.8 IU/L) and one had elevated aspartate aminotransferase (AST) (98 IU/L).

*Study PDY6656*, one subject in the 4 mg/kg group had an elevation of AST to 101 IU/L on Day 43 that had normalised by the end of study. One subject in the placebo group and one subject in the 2 mg/kg group had decreases in neutrophil count that had normalised by the end of study.

*Study VGFT-OD-0508*, there were few clinically significant laboratory tests abnormalities and these did not appear to be dose or frequency related. The majority of plasma samples assayed for free aflibercept concentrations were below the lower limit of quantification (LLOQ).

*Study VGFT-OD-0605/14393 (VIEW 1)*, the pattern of abnormal test results was similar for all three treatment groups and compatible with the age range of the study subjects. Shift in urine protein creatinine ratio from normal at baseline to high at Week 52 was reported for 30 (16.9%) subjects in the aflibercept 2 mg q4w group, 34 (21.1%) subjects in the 0.5 mg q4w group, 26 (15.3%) subjects in the 2 mg q8w group and 35 (19.7%) subjects in the ranibizumab group.

*Study 311523 (VIEW 2)*, the pattern of significant abnormalities in laboratory tests was similar for all four treatment groups.
Study VGFT-OD-0702/14262, there were no clinically significant laboratory test abnormalities.

Study VGFT-OD-0706/13336 (DAVINCI), abnormalities in laboratory tests were uncommon and did not indicate any association with study treatment. Six (3.4%) subjects in the aflibercept groups developed proteinuria compared with none in the laser group.

Safety in special populations

Older persons were well represented in the study population. There were no data provided from the paediatric population or during pregnancy.

Immunological events

Study VGFT-OD-0502/14395 Part A, one subject developed anti-aflibercept antibodies (concentration <1.2 mg/L).

Study VGFT-OD-0605/14393 (VIEW 1), a positive anti-drug antibody assay was reported in 13 (4.3%) subjects in the aflibercept 2 mg q4w group, eleven (3.6%) subjects in the 0.5 mg q4w group, six subjects in the 2 mg q8w group and 15 (4.9%) subjects in the ranibizumab group. One subject in the aflibercept 2 mg q4w group exhibited neutralising activity. The presence of anti-drug antibody did not appear to influence efficacy (Table 23).

Table 23. Supportive Analysis of the Proportion of Subjects with Maintained Vision at Week 52 by Anti-VEGF Trap Antibodies Status, LOCF (Per Protocol Set)

<table>
<thead>
<tr>
<th>Sub Group</th>
<th>Treatment Group</th>
<th>Subjects who Maintained Vision at week 52 (%)</th>
<th>Difference [1] % (95.1 % C.I.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>POSITIVE</td>
<td>VTE 2Q4 (N = 13)</td>
<td>11 (84.6%)</td>
<td>8.7 (-14.7, 32.1)</td>
</tr>
<tr>
<td></td>
<td>R 0.5Q4 (N = 15)</td>
<td>14 (93.3%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VTE 0.5Q4 (N = 11)</td>
<td>10 (90.9%)</td>
<td>2.4 (-18.8, 23.7)</td>
</tr>
<tr>
<td></td>
<td>R 0.5Q4 (N = 15)</td>
<td>14 (93.3%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VTE 2Q6 (N = 6)</td>
<td>6 (100%)</td>
<td>-6.7 (-19.3, 6)</td>
</tr>
<tr>
<td></td>
<td>R 0.5Q4 (N = 15)</td>
<td>14 (93.3%)</td>
<td></td>
</tr>
<tr>
<td>NEGATIVE</td>
<td>VTE 2Q4 (N = 272)</td>
<td>260 (95.6%)</td>
<td>-1.1 (-4.9, 2.6)</td>
</tr>
<tr>
<td></td>
<td>R 0.5Q4 (N = 253)</td>
<td>239 (94.5%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VTE 0.5Q4 (N = 259)</td>
<td>249 (96.1%)</td>
<td>-1.7 (-5.4, 2)</td>
</tr>
<tr>
<td></td>
<td>R 0.5Q4 (N = 253)</td>
<td>239 (94.5%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VTE 2Q8 (N = 259)</td>
<td>246 (95.0%)</td>
<td>-0.5 (-4.4, 3.4)</td>
</tr>
<tr>
<td></td>
<td>R 0.5Q4 (N = 253)</td>
<td>239 (94.3%)</td>
<td></td>
</tr>
</tbody>
</table>

Study 311523 (VIEW 2), systemic reactions related to immunogenicity were reported in two (0.6%) subjects in the aflibercept 2 mg q4w group, four (1.3%) subjects in the 0.5 mg q4w group, five (1.6%) subjects in the 2 mg q8w group and seven (2.4%) subjects in the ranibizumab group. There were no anaphylactic reactions reported in the aflibercept groups whereas one anaphylactic reaction was reported in the in the ranibizumab group. Anti-drug antibodies were detected in 16 (5.4%) subjects in the aflibercept 2 mg q4w group, 15 (4.9%) subjects in the 0.5 mg q4w group, three (1.0%) subjects in the 2 mg q8w group and eight (2.7%) subjects in the ranibizumab group. No subject was detected with neutralising anti-drug antibodies. Antibody status did not appear to influence efficacy (Table 24).
Table 24. Proportion of subjects with maintained vision at Week 52 by AB positive/negative, LOCF (Full analysis set)

<table>
<thead>
<tr>
<th>AB development flag n</th>
<th>Treatment group</th>
<th>Subjects with maintained vision at week 52(%)</th>
<th>Difference [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>VT1E04(N=385)</td>
<td>270(69.64)</td>
<td>-0.09(-3.79,3.60)</td>
</tr>
<tr>
<td></td>
<td>VT1E08(N=280)</td>
<td>266(94.64)</td>
<td>-0.66(-4.29,7.96)</td>
</tr>
<tr>
<td></td>
<td>VT1E09(N=277)</td>
<td>260(95.31)</td>
<td>-0.72(-4.27,7.83)</td>
</tr>
<tr>
<td></td>
<td>VT1E08(N=303)</td>
<td>288(95.30)</td>
<td>3.33(3.37,3.30,54)</td>
</tr>
<tr>
<td></td>
<td>VT1E08(N=15)</td>
<td>149(92.53)</td>
<td>0.67(-3.90,19.29)</td>
</tr>
<tr>
<td></td>
<td>VT1E08(N=5)</td>
<td>100(100)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VT1E08(N=8)</td>
<td>100(100)</td>
<td></td>
</tr>
</tbody>
</table>

Anti aflibercept antibodies were not detected in Study VGFT-OD-0502/14395 Part B, Study VGFT-OD-0512, Study VGFT-OD-0305, Study VGFT-OD-0306, Study VGFT-OD-0307, Study PDY6655, Study PDY6656, Study VGFT-OD-0508, Study VGFT-OD-0702/14262 or Study VGFT-OD-0706/13336.

Safety related to drug-drug interactions and other interactions

No data with regard to drug-drug interactions were included in the submission.

Discontinuation due to adverse events

Study VGFT-OD-0502/14395 Part A, (as discussed above) one subject in the 2.0 mg cohort had cerebral infarction, angina pectoris and esophageal dyskinesia and subsequently withdrew from the study because of medical issues.

Study VGFT-OD-0502/14395 Part C, one subject withdrew because of a low platelet count that had been present from baseline.

Study VGFT-OD-0305, three subjects discontinued due to AEs (DAE): two in the 3.0 mg/kg group (hypertension and malignant hypertension) and one in the 1 mg/kg group (headache/ hypertension/ proteinuria).

Study VGFT-OD-0306, one subject withdrew because of a TEAE: hypertension.

Study VGFT-OD-0307, two subjects in the placebo group withdrew due to TEAEs.

Study PDY6655, two subjects discontinued due to AEs following subcutaneous administration: delayed allergic dermatitis at the injection site; and multiple trauma caused by car accident.

Study VGFT-OD-0508, DAE occurred for seven subjects overall: one (3.1%) in the 0.5 mg q4w group, three (9.4%) in the 0.5 mg q12w group, none in the 2 mg q4w group, 2 (6.5%) in the 2 mg q12w group and one (3.2%) in the 4 mg q12w group. Two of the DAEs were considered to be treatment related: retinal haemorrhage and retinal oedema.

Study VGFT-OD-0605/14393 (VIEW 1), AEs leading to the discontinuation of study treatment was reported in three (1.0%) subjects in the aflibercept 2 mg q4w group, five (1.6%) subjects in the 0.5 mg q4w group, three (1.0%) subjects in the 2 mg q8w group and five (1.6%) subjects in the ranibizumab group.

Study 311523 (VIEW 2) TEAE leading to discontinuation of study treatment was reported in twelve (3.9%) subjects in the aflibercept 2 mg q4w group, 14 (4.7%) subjects in the 0.5 mg q4w group, ten (3.3%) subjects in the 2 mg q8w group and four (1.4%) subjects in the ranibizumab group.
**Study VGFT-OD-0702/14262**, three (2%) subjects permanently discontinued study treatment: macular degeneration; reduced visual acuity; and metastatic non-small cell lung cancer.

**Study VGFT-OD-0706/13336 (DAVINCI)**, DAE was reported in one (2.3%) subject with aflibercept 0.5 mg q4w (uveitis).

There were no withdrawals due to TEAEs in **Study VGFT-OD-0502/14395 Part B, Study VGFT-OD-0603, Study VGFT-OD-0512 or Study PDY6656**.

**Additional safety data**

**Study VGFT-OD-0910/14832** is an open label, long term safety and tolerability study follow-on to Study VGFT-OD-0605. The study includes subjects with neovascular AMD that have completed Study VGFT-OD-0605. The study is ongoing and a report was not provided with the current submission. Limited data were provided in the sponsor’s Summary of Clinical Safety. The study treatment is aflibercept 2 mg PRN, but at least every 12 weeks, by intravitreal injection with an injection volume of 50 μL. The study is of 18 months duration. A total of 178 subjects had been recruited. Three SAEs were reported in the sponsor’s Summary of Clinical Safety: device dislocation; renal cancer and urinary tract infection.

**Study VGFT-OD-0819/14232 (COPERNICUS)** is a randomised double masked sham controlled study the efficacy and safety of aflibercept in central retinal venous occlusion (CRVO). The study is ongoing. The study includes subjects at least 18 years of age with centre involved macular edema secondary to CRVO with mean central retinal thickness ≥250 μm on OCT. The study treatments were: aflibercept 2 mg q4w by intravitreal injection in comparison with sham injections q4w. Efficacy data were not reported. SAEs reported to date were included in the sponsor’s Summary of Clinical Safety. A total of 189 subjects had been recruited. There were 58 SAEs reported in 29 (15.4%) subjects. The most commonly reported SAEs were: vitreous haemorrhage in four (2.1%) subjects, glaucoma in two (1.1%) subjects, iris neovascularisation in two (1.1%) subjects, pneumonia in two (1.1%) subjects and retinal haemorrhage in two (1.1%) subjects.

**Study 14130 (GALILEO)** is a randomised double masked sham controlled study the efficacy and safety of aflibercept in CRVO. The study is ongoing. The study includes adults ≥ 18 years, with centre-involved macular edema secondary to CRVO for no longer than 9 months with mean central subfield thickness ≥ 250 μm on optical coherence tomography (OCT) and with ETDRS BCVA of 20/40 to 20/320 (73 to 24 letters) in the study eye. The study treatments were: aflibercept 2 mg q4w by intravitreal injection which was compared with sham injections q4w. Efficacy data were not reported. SAEs reported to date were included in the sponsor’s Summary of Clinical Safety. A total of 177 subjects had been recruited. A total of 17 SAEs were reported in 13 (7.6%) subjects. No SAE was reported in more than one subject.

**Post marketing experience**

No postmarketing data were included with the current submission.

**Evaluator’s overall conclusions on clinical safety**

Intravitreal aflibercept is associated with an increased rate of conjunctival haemorrhage, eye pain and reduction in visual acuity. These adverse events appear primarily to be due to the procedure of intravitreal injection rather than the local effects of aflibercept. There was an increase in IOP of around 3.2 mmHg immediately post treatment that did not increase with subsequent treatments. Ocular adverse events did not appear to be influenced by dose or dosing regimen. However, ocular AEs were more common with the
vial presentation than with the pre-filled syringe. A similar rate of ocular AEs was observed with ranibizumab.

Intravenous (high dose) aflibercept is associated with headache, hypertension, proteinuria and dysphonia. Hypertension was a dose limiting adverse event at a dose level of 3mg/kg.

The rates of SAE and death did not indicate any safety issues with aflibercept. The conditions leading to non-ocular SAE and death were as expected for the age group and general health of the population of subjects included in the studies. Ocular SAEs appeared to be related to the procedure of intravitreal injection and not to aflibercept.

The rates of clinical laboratory test abnormalities with intravitreal aflibercept were low and were consistent with the age and general health of the study population. Proteinuria appears to be associated with intravenous high dose aflibercept.

Less than 5% of the treatment population developed anti-aflibercept antibodies. The development of anti-aflibercept antibodies was not associated with loss of efficacy, immunological AEs or increased risk of AE.

There was a low rate of withdrawal from the clinical studies due to AE. This indicates that intravitreal aflibercept is well tolerated.

**List of questions**

During 2010, the TGA began to change the way applications were evaluated. As part of this change, after an initial evaluation, a List of Questions to the sponsor is generated.

**Efficacy**

It is not clear from the clinical studies how the sponsor determined the final dosing recommendations in the product information document. The proposed dosing regimen (2 mg intravitreal injection each month for the first three injections followed by administration every second month) would provide the sponsor with a marketing advantage, that is, a perception that less frequent dosing is required. Hence, it is important that the dosing regimen is supported by data. Can the sponsor provide a justification for the dosing regimen proposed in the Product Information document?

The sponsor provided a response to this question (see Response to the Clinical Evaluation Report).

**Clinical summary and conclusions**

**Clinical aspects**

Eylea (aflibercept) is intended for intravitreal administration and systemic exposure is important from a safety perspective but not from an efficacy perspective. The systemic exposure following intravitreal injection was minimal in comparison with studies of intravenous aflibercept. This would be expected given the differences in total dose: up to 4 mg intravitreal compared with up to 4 mg/kg intravenous.

Following intravitreal injection of 2 mg aflibercept the exposure to free aflibercept, expressed as AUC_{last} was median (range) 0.0221 (0 to 0.474) mg•day/L, and exposure to aflibercept:VEGF complex expressed as median AUC_{last} was (range) 4.67 (2.12 to 6.71) mg•day/L (Study VGFT-OD-0702.PK). Following 4 mg intravitreal injection, for aflibercept: VEGF complex T_{max} was 12 weeks and the mean C_{max} was (SE) 0.236 (0.0302) mg/mL (Study VGFT-OD-0603). Following 4 mg intravitreal injection, the mean
concentrations of aflibercept were 0.0502 and 0.0272 mg/L on Days 3 and 8, respectively (Study VGFT-OD-0512).

Following intravenous administration, $C_{\text{max}}$ for free aflibercept was 50 mg/L for a 3.0 mg/kg dose, around 16 mg/L for a 1.0 mg dose and 5 mg/L for a 0.3 mg/kg dose. The $C_{\text{max}}$ for total aflibercept was 50 mg/L for the 3.0 mg/kg dose, around 15 mg/L for the 1.0 mg dose and 5 mg/L for the 0.3 mg/kg dose (Study VGFT-OD-0305).

Following 2.0 mg/kg aflibercept by intravenous or subcutaneous administration, the mean (CV%) $AUC$ and $C_{\text{max}}$ for free aflibercept were 177 (33) µg.day/mL and 44.4 (36) µg/mL, respectively, for intravenous whereas the $AUC$ and $C_{\text{max}}$ were 84.9 (30) µg.day/mL and 7.76 (39) µg/mL for subcutaneous administration. For bound aflibercept, the mean (CV%) $AUC$ and $C_{\text{max}}$ were 57.7 (19) µg.day/mL and 1.84 (22) µg/mL, respectively, for intravenous administration and 47.3 (27) µg.day/mL and 1.60 (27) µg/mL, respectively, for subcutaneous administration (Study PDY6655).

Following intravenous administration, the mean (CV%) $C_{\text{max}}$ for free aflibercept was 18.2 (18) µg/mL for a 1 mg/kg dose, 39.7 (27) µg/mL for a 2 mg/kg dose and 78.6 (15) µg/mL for a 4 mg/kg dose. The mean (CV%) $AUC$ was 64.8 (20) µg.day/mL for a 1 mg/kg dose, 180 (20) for a 2 mg/kg dose and 419 (21) for a 4 mg/kg dose (Study PDY6656). Bound aflibercept concentrations were not dose proportional but $C_{\text{max}}$ and $AUC$ for total aflibercept were dose proportional.

Aflibercept at high doses administered intravenously significantly increases blood pressure. However, the level of systemic exposure from intravitreal administration would not be sufficient to cause similar effects on blood pressure.

Intravenous or subcutaneous 2 mg/kg aflibercept increased SBP by a mean of up to 6.5 mmHg and DBP of up to 7.22 mmHg with a maximal effect at Day 16 post administration (Study PDY6655). SBP was increased by 10.27 (5.77 to 14.78) mmHg and DBP by 10.67 (7.68 to 13.66) mmHg by 4 mg/kg aflibercept administered intravenously (Study PDY6656). The increase in blood pressure persisted for up to 44 days at the 4 mg/kg dose level. Plasma renin activity and aldosterone concentrations were decreased.

**Benefit risk assessment**

**Benefits**

The primary efficacy measures used in the drug development program were clinically important and had been adequately validated. The efficacy outcome measures were refined during Phase I development. BCVA became the tool used to determine the primary efficacy outcome measures in the pivotal studies. The secondary efficacy measures (CRT and macular volume) assessed pathology and disease severity. Fluorescein angiography was not useful to demonstrate differences between treatments.

In the initial dose finding studies, the greatest effect was in the 2 mg to 4 mg dose grouping (Study VGFT-OD-0502/14395 Part A). Effect increased with increasing dose up to 4 mg. Peak effect appeared to be at Day 29 (Study VGFT-OD-0502/14395 Part C). Different formulations, volumes and concentrations of aflibercept were evaluated in Study VGFT-OD-0603/14396 (CLEAR-IT 1b), which enabled a 50 µL volume to be used in further studies.

There were some Phase I data of aflibercept administered intravenously. Study VGFT-OD-0305 indicated that a dose of 3 mg/kg aflibercept by intravenous injection was effective but that a dose of 1 mg/kg was not. Study VGFT-OD-0306 indicated that intravenous treatment with aflibercept would not be as effective long-term as intravitreal.

The Phase II study (Study VGFT-OD-0508/14394 [CLEAR-IT AMD-2]) did not clearly indicate the most appropriate dosing regimen. In the Phase II study the greatest reduction
in CRT at Week 12 was with a 2 mg q4w dosing regimen but at all other time points over 52 weeks the greatest reduction in CRT was with 4 mg q12w. The greatest improvement in BCVA through to Week 52 was with 2 mg q4w. However, the greatest improvement in vision related quality of life was with 4 mg q12w.

In the pivotal efficacy studies (Study VGFT-OD-0605/14393 [VIEW 1] and Study 311523 [VIEW 2]) the non-inferiority margin of 10% was appropriate as this would represent a clinically significant difference in treatment effect. The choice of comparator was appropriate. Ranibizumab is currently approved in Australia for the treatment of neovascular (wet) age-related macular degeneration and the dosing regimen used in the studies was consistent with the manufacturer's recommendations. The population studied was appropriate and representative of the patient population likely to require treatment. However, it is not clear whether blinding of the sham injections was maintained and the selection/allocation of study and fellow eyes was not randomised.

In the pivotal efficacy studies non-inferiority was demonstrated for all three aflibercept dosing regimens. In Study VGFT-OD-0605/14393 (VIEW 1), for the per-protocol group, the difference (95% CI) in proportion of subjects that maintained vision at Week 52 (ranibizumab – aflibercept) was -0.7 (-4.4 to 3.1) for 2 mg q4w, -1.5 (-5.1 to 2.1) for 0.5 mg q4w and -0.7 (-4.5 to 3.1) for 2 mg q8w. In Study 311523 (VIEW 2), for the per-protocol group, the difference (95% CI) in proportion of subjects that maintained vision at Week 52 (ranibizumab – aflibercept) was -1.2 (-4.86 to 2.46) for 2 mg q4w, -1.84 (-5.40 to 1.71) for 0.5 mg q4w and -1.13 (-4.81 to 2.55) for 2 mg q8w. The secondary efficacy outcome measures in both studies were supportive of the primary analysis.

In some of the additional efficacy outcome measures there were some differences between treatments in favour of the comparator:

**Study VGFT-OD-0605/14393 (VIEW 1),** the proportion of subjects showing complete resolution of FA leakage at Week 52 was significantly lower in the aflibercept 2 mg q8w group than in the ranibizumab group: 159 (52.8%) subjects compared with 193 (63.5%); difference (95% CI) -10.7 (-18.5 to -2.8) %, p=0.0084

**Study 311523 (VIEW 2),** for the change from baseline in BCVA at Week 12 there was a significant improvement in the ranibizumab group compared to the aflibercept 2 mg q4w group: LS mean difference (95% CI) -1.61 (-3.19 to -0.04) p=0.045.

**Study 311523 (VIEW 2),** the proportion of subjects with VA of 20/200 or worse at Week 52 was greater in the aflibercept 2 mg q4w group than in the ranibizumab group: difference (95% CI) 6.05 (1.25 to 10.86) p=0.014.

**Study 311523 (VIEW 2),** for the change from baseline in scores for NEI VFQ-25 distance activities ranibizumab was superior to aflibercept 2 mg q4w and 2 mg q8w; and for vision dependency ranibizumab was superior to aflibercept 2 mg q4w at Week 52. However, there were also some additional efficacy outcome measures that were in favour of aflibercept:

**Study 311523 (VIEW 2),** the proportion of subjects showing complete resolution of FA leakage at Week 52 was significantly greater in the aflibercept 2 mg q4w group than in the ranibizumab group: 210 (67.96%) subjects compared with 162 (55.67%); difference (95% CI) 13.24 (5.60 to 20.89) %, p=0.0009.

**Study 311523 (VIEW 2),** there was a decrease in CRT in the aflibercept 2 mg q4w group compared to the ranibizumab group: LS mean difference (95% CI) -10.60 (-21.1 to -0.09) p=0.047.

The long term follow-on study, **Study VGFT-OD-0702/14262,** did not contribute useful efficacy data because it was not possible to determine whether the rate of decline in visual function was modified by aflibercept. There were also some data for subjects with DME, a different indication to that sought in the present application **(Study VGFT-OD-0512/14805)**
There were insufficient data to conclude efficacy. Study VGFT-OD-0706/13336 (DAVINCI) was supportive of efficacy but was conducted for a different indication than that applied for in the present application.

**Risks**

Intravitreal aflibercept is associated with an increased rate of conjunctival haemorrhage, eye pain and reduction in visual acuity. These adverse events appear primarily to be due to the procedure of intravitreal injection rather than the local effects of aflibercept. There was an increase in IOP of around 3.2 mmHg immediately post treatment that did not increase with subsequent treatments. Ocular adverse events did not appear to be influenced by dose or dosing regimen. However, ocular AEs were more common with the vial presentation than with the pre-filled syringe. A similar rate of ocular AEs was observed with ranibizumab.

Intravenous (high dose) aflibercept is associated with headache, hypertension, proteinuria and dysphonia. Hypertension was a dose limiting adverse event at a dose level of 3mg/kg.

The rates of SAE and death did not indicate any safety issues with aflibercept. The conditions leading to non-ocular SAE and death were as expected for the age group and general health of the population of subjects included in the studies. Ocular SAEs appeared to be related to the procedure of intravitreal injection and not to aflibercept.

The rates of clinical laboratory test abnormalities with intravitreal aflibercept were low and were consistent with the age and general health of the study population. Proteinuria appears to be associated with intravenous high dose aflibercept.

Less than 5% of the treatment population developed anti-aflibercept antibodies. The development of anti-aflibercept antibodies was not associated with loss of efficacy, immunological AEs or increased risk of AE.

There was a low rate of withdrawal from the clinical studies due to AE. This indicates that intravitreal aflibercept is well tolerated.

**Balance**

The risk-benefit balance is in favour of intravitreal aflibercept for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).

**Conclusions**

It was recommended that the application for the following indication should be approved:

*Eylea (aflibercept) is indicated for the treatment of neovascular (wet) age-related macular degeneration (wet AMD)*

**Recommended Conditions for Registration**

There are a number of ongoing studies of intravitreal aflibercept being conducted by the sponsor. Registration should be conditional on the provision of timely updates of the safety and efficacy data from these studies and upon the performance of routine pharmacovigilance activities for Eylea (aflibercept).
V. Pharmacovigilance findings

Risk management plan
The sponsor submitted a Risk Management Plan which was reviewed by the TGA’s Office of Product Review (OPR).

Safety specification
The summary Ongoing Safety Concerns as specified by the sponsor is as follows:

- **Important identified drug-related risk**: None
- **Important identified injection-related risks**: Endophthalmitis due to intravitreal injection
- **Important potential drug-related risks**:
  - Arterial thromboembolic events (ATEs)
  - Embryo-fetotoxicity
- **Important potential injection-related risk**: None
- **Important missing information**: Not identified

**OPR reviewer comment**

While 149 subjects completed study VGFT-OD-0702/14262 (long-term extension of the Phase I and II trials, treatment duration 38 months), the safety of IVT aflibercept in the long-term has not been established in a larger population. At this stage, safety has not been studied beyond 52 weeks in Phase III trials. It is therefore recommended that long-term safety be included as Important missing information in the Ongoing Safety Concerns. However, the sponsor has stated in a TGA response dated 24 October 2011 that

> “it would not be appropriate to add ‘absence of long-term safety experience’ as missing information in the Australian Risk Management Plan as we believe the one year safety data submitted in support of product registration provides sufficient information with respect to establishing the safety profile of Eylea. This dataset....... indicate comparable safety profile between Eylea and the current standard of care, Lucentis, in the treatment of wet AMD.”

The sponsor has further elaborated that the following ongoing studies will provide data to support the long-term safety of Eylea:

- a) two year repeated injections studies from pivotal Phase III randomised, double-masked, active controlled Study VGT-OD-0605 (VIEW 1) and Study 311523/91689 (VIEW 2) with data expected in first quarter of 2012,
- b) a 18-month extension phase study for 323 VIEW 1 subjects, Study VGT-OD-0910 and
- c) a three-year randomised and single-masked Study VGT-OD-0702/145262 with 157 subjects and data expected in first quarter of 2012.

Although it is agreed that the ongoing studies should inform of the long-term safety of Eylea beyond one year, the rationale provided by the sponsor on the comparable safety profile between Eylea and Lucentis in the treatment of wet AMD was not adequate to preclude the inclusion of Eylea’s long-term safety as an Important missing information in the Ongoing Safety Concerns, considering the current lack of supporting data for Eylea’s safety beyond one year. Furthermore, it is noted that the Australian Public Assessment Report for Ranibizumab (Lucentis) has identified long-term safety beyond two years as
Important missing information in Ongoing Safety Concerns for Lucentis. With regard to the nonclinical and clinical evaluation reports, the above summary of the Ongoing Safety Concerns is therefore considered acceptable with the inclusion of long-term safety as important missing information.

Pharmacovigilance plan

**Proposed pharmacovigilance activities**

It is proposed that routine pharmacovigilance (PhV) activities will be supported by targeted follow-up of any post-market or study reports suspicious of intraocular infection by using a questionnaire. There will be a cumulative presentation and evaluation of reports of each of the Ongoing Safety Concerns in the Periodic Safety Update Reports (PSURs). Further data on intraocular infection and ATEs will be collected from the ongoing Phase III clinical trial program (for AMG and central retinal vein occlusion - CRVO). The protocols of these studies have not been reviewed as they are ongoing.

**OPR reviewer’s comments in regard to the pharmacovigilance plan and the appropriateness of milestones**

The use of targeted follow-up seems appropriate to monitor the endophthalmitis safety concern, in particular to ensure a standard approach to collecting information. The details collected as part of the follow-up questionnaire have been provided in response to a TGA request for information dated 24 October 2011. The information requested in this questionnaire includes the details of the event, patient’s history and injection procedure, which is appropriate to monitor the risk of endophthalmitis associated with an IVT procedure.

The incidence of stroke and myocardial infarction (MI) in AMD patients has been estimated using the United States Medicare database. The incidence of MI in patients with neovascular AMD has been estimated to be 2.2% annually and 4.09% over 2 years. The incidence of stroke in patients with neovascular AMD has been estimated to be 3.8% annually and 8.15% over 2 years. Therefore, considering the sample sizes of the ongoing clinical trials, in particular VIEW 1, VIEW 2 and VGFT-OD-0910/14832, it is possible that these studies will be able to detect an increase in the rate of ATEs over the background rate.

---


14 Routine pharmacovigilance practices involve the following activities:

- All suspected adverse reactions that are reported to the personnel of the company are collected and collated in an accessible manner;
- Reporting to regulatory authorities;
- Continuous monitoring of the safety profiles of approved products including signal detection and updating of labeling;
- Submission of PSURs;
- Meeting other local regulatory agency requirements.

Risk minimisation activities

Routine risk minimisation\textsuperscript{16} is planned.

\textbf{OPR reviewer comment}

In regard to the proposed routine risk minimisation activities, the draft product information (and package insert) and consumer medicine information (CMI) are considered satisfactory. The sponsor has indicated in their response to request for information dated 24 October 2011 that additional risk minimisation activities such as physician and consumer education are not required as the proposed Australian PI covers instructions for the handling and administration of Eylea to mitigate the risks of intravitreal injection related adverse events, along with information on monitoring side effects and the CMI adequately covers potential side effects. Additional reasons provided by the sponsor include:

a) IVT injection is not a new procedure practiced by ophthalmologists in Australia as IVT administration of Lucentis has been approved for treatment of wet AMD in Australia since 2007 with a relatively low rate of IVT-related adverse events, that is, endophthalmitis reported,

b) there is a 5 year training program and an annual continuing professional development program provided to practising ophthalmologists in Australia by the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) that cover aspects of clinical and surgical ophthalmology including intraocular injections for macular degeneration

c) RANZCO-issued practical guidelines for performing IVT therapy (August 2006)

d) RANZCO-issued information for patients on IVT procedure, potential side effects and post-IVT injection care instructions and when to seek medical attention, and

e) availability of patient education and support programs offered by the Macular Degeneration Foundation in Australia.

This was considered satisfactory, however, no information is provided in the proposed Australian PI on the recommended duration of treatment, indication for ceasing treatment or ongoing monitoring of response to treatment.

\section*{Summary of Recommendations}

The OPR provides these recommendations in the context that the submitted RMP is supportive to the application and the implementation of the Aflibercept Core Safety Risk Management Plan (CSRMP) version 2.1, 21 January 2011 and any subsequent versions, is imposed as a condition of registration.

If this submission is approved, it is recommended to the Delegate that the Sponsor:

- Includes “long-term safety” as Important missing information in the RMP.
- Updates the information provided in the CSRMP version 2.1 as per the nonclinical evaluation report.

Both of these details can be followed up administratively.

As the risk for postmarket off-label use exists based on experience with other anti-VEGF drugs, and this is unlikely to be effectively monitored by routine pharmacovigilance

\textsuperscript{16} Routine risk minimisation activities may be limited to ensuring that suitable warnings are included in the product information or by careful use of labelling and packaging.
activities, it is recommended that if this submission is approved the Delegate considers the following:

- That the sponsor include "off-label use" as Important missing information in the RMP.
- That the sponsor implement additional/targeted pharmacovigilance activities to evaluate off-label use during postmarket period.

VI. Overall conclusion and risk/benefit assessment

The submission was summarised in the following Delegate's overview and recommendations:

Quality

The evaluator of the quality data states that aflibercept is expressed in Chinese Hamster Ovary cells (CHO K1).

Of note in regard to the presentations, the extractable volume of 100 and 90 µL for the vial and syringe presentation, respectively, appeared to be excessive and was considered to pose a risk to patients, given that only 50 µL is required for each injection. The sponsor's reply included a suggestion that 90 µL is defined as the minimum volume that can be extracted from the syringe and that 100 µL is defined as the minimum volume that can be extracted from the vial.

Quality matters have been resolved, a shelf life of 12 months, stored at -2- 8°C, protected from light was considered approvable for both the vial and syringe presentation. A bioavailability study was not conducted, chiefly due to limitations in the assay.

As is common for biological substances, the evaluator requested samples/batch release data on the first five batches to be supplied in Australia, subject to later review. This will become a condition of registration.

Comment: The sponsor should comment on managing the risks associated with not supplying syringes and needles in the vial package and of not supplying an injection needle in the syringe pack.

Of further note, some development of the formulation occurred during the development of Eylea. As stated in the sponsor's Clinical Summary:

"During the development of VEGF Trap-Eye, the drug substance was manufactured using three different processes (IVT P1, P2 and P3). Two formulations of the drug product for IVT administration of VEGF Trap-Eye were developed and used during the clinical program: ITV-1 and ITV-2. The initial formulation ITV-1 was modified to the current ITV-2 formulation during Phase II in order to improve stability. Throughout the entire Phase III program, VEGF Trap-Eye from the same manufacturing process (IVT P3) and in the same formulation (ITV-2) was used. This formulated drug product is the same as the proposed commercial product. Table 25 below provides an overview of processes and formulations used during the whole development program."
Table 25.

<table>
<thead>
<tr>
<th>Development phase</th>
<th>Study</th>
<th>Manufacturing process (drug substance)</th>
<th>Formulation (drug product)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1</td>
<td>VGFT-OD-0502</td>
<td>IVT P1</td>
<td>ITV-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IVT P2</td>
<td>ITV-1</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0603</td>
<td>IVT P2</td>
<td>ITV-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IVT P3</td>
<td>ITV-2</td>
</tr>
<tr>
<td>Phase 2</td>
<td>VGFT-OD-0508</td>
<td>IVT P2</td>
<td>ITV-1</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0702 long-term safety</td>
<td>IVT P2</td>
<td>ITV-1</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0702 PK substudy</td>
<td>IVT P3</td>
<td>ITV-2</td>
</tr>
<tr>
<td>Phase 3</td>
<td>VIEW 1</td>
<td>IVT P3</td>
<td>ITV-2</td>
</tr>
<tr>
<td></td>
<td>VIEW 2</td>
<td>IVT P3</td>
<td>ITV-2</td>
</tr>
</tbody>
</table>

IVT P3 is the commercial process and IVT-2 is the commercial formulation.

**Nonclinical**

The evaluator noted that the studies submitted were adequate in respect of toxicology and pharmacology and that they were compliant with GLP. Several species were studied; aflibercept was immunogenic in the laboratory animal species but less so in cynomolgus monkeys compared to rodents or rabbits. Monkeys were therefore used in the repeat dose toxicity studies (8 months for intravitreal injection, six months for IV injection). Specific genotoxicity and carcinogenicity studies were not submitted.

Aflibercept showed a long elimination half-life after intravitreal injection; 40 to 64 hours in cynomolgus monkeys. Aflibercept is cleared both renally and hepatically.

Animal models of efficacy (murine oxygen-induced retinopathy model; choroidal neovascularisation in the monkey (laser-induced); and normalised retinal vascular permeability in the rat (diabetic model)) supported the therapeutic concept.

The pharmacology studies’ results were consistent with the purported action of aflibercept: "...as a soluble decoy receptor for vascular endothelial growth factor A (VEGF-A) and also placental growth factor 2 (PIGF-2), angiogenic ligands implicated in the pathophysiology of AMD." That is, aflibercept is expected to act as a competitive receptor of VEGF, unlike ranibizumab which is the antigen binding fragment of a humanised monoclonal antibody that binds with high affinity to the VEGF-A isoforms (such as VEGF110, VEGF121 and VEGF165), thereby preventing the binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2.

Secondary pharmacodynamic studies were conducted to exclude binding to thirty-three other human tissues or to other subtypes of VEGF (-C, -D). Aflibercept was noted to have a pressor effect in monkeys, rats and mice. Immunological studies conducted in vitro did not show that aflibercept can mediate complement-dependent cytotoxicity or antibody dependent cell-mediated cytotoxicity.

Toxicokinetic calculations suggest that the exposure multiples achieved in the studies were small relative to the proposed clinical dose. The relative ocular exposure was based on dose adjusted for species differences in vitreous volume; the intravitreal doses used in the pivotal monkey study (0.5, 2 and 4 mg/eye) are 0.3, 1.25 and 2.5 times the proposed human dose (2 mg/eye).
The acute toxicity of aflibercept was considered to be low. Intravitreal administration of aflibercept was followed by an anterior segment/vitreous inflammatory response in monkeys and this inflammatory response peaked at about two days after dosing. In terms of function, no angiographic or electrotoretinographic changes were found in treated monkeys, nor were any ocular abnormalities observed in imaging or microscopic evaluations or with intraocular pressure.

The nasal cavity was identified as the principal site of toxicity in repeat dosing, showing erosions and ulcerations of the epithelium that occurred at exposure margins ≥6 in monkeys (based on mg/kg intravitreal doses; that is, a relative exposure at the NOEL, 1.5). More extensive toxicities were seen after intravenous administration.

In brief, the toxicity studies were not extensive but adequate.

Of interest, reproduction studies suggested that fertility effects were associated with reductions in the ovarian hormones, inhibin B, oestradiol and progesterone.

Registration was supported but some product information document changes were suggested.

**Clinical**

The clinical trial program was compliant with Good Clinical Practice.

**Pharmacokinetics**

Seven studies were submitted. Unless otherwise stated, they were open-label.

**Study VGFT-OD-0702 PK.** See tabular description below. Efficacy data were collected and suggested greatest treatment effect at 2 mg or 4 mg per eye.

**Study VGFT-OD-0603.** See tabular description below. As noted by the evaluator, C\text{max}\ occurred at 12 weeks. Mean (SE) VEGF Trap: VEGF complex concentrations at Week 12 were 0.236 (0.0302) mg/mL for ITV-1 and 0.215 (0.02) mg/mL for ITV-2.

**Study VGFT-OD-0512** was a safety and tolerability study in five subjects with diabetic macular oedema. Aflibercept 4 mg was given as a single intravitreal injection of 100 μL volume. On Days 3 and 8, the mean concentrations of VEGF Trap were 0.0502 and 0.0272 mg/L, respectively.

**Study VGFT-OD-0305** was a double masked dose escalation study, in patients with neovascular AMD, using IV administration (placebo, 0.3 mg/kg, 1 mg/kg, 3 mg/kg); 3 mg/kg IV was the maximal tolerated dose. C\text{max} for free VEGF trap was 50 mg/L for the 3.0 mg/kg dose, around 16 mg/L for the 1.0 mg dose and 5 mg/L for the 0.3 mg/kg dose; Mean concentration to dose ratio of VEGF Trap: VEGF complex peaked at around 3.5.

**Study VGFT-OD-0307** was a double-masked, placebo-controlled, sequential-group, safety, tolerability and efficacy study of aflibercept in 12 patients with diabetic macular edema. Only the 0.3mg/kg IV dose was studied (n=9) against placebo (n=3). After a 0.3 mg/kg dose, given IV, mean (SD) C\text{max} was 600 (202) ng/mL for free aflibercept, 1522 (659) ng/mL for aflibercept : aflibercept and 1590 (699) ng/mL for total aflibercept.

**Study PDY6655** is of limited pharmacokinetic relevance; it was a single-dose cross-over study in volunteers that compared subcutaneous with IV (infusion) dosing. The doses of 2.0 mg/kg were given 1 to 2 weeks apart and a carry-over effect was seen in Period 2. The volume of distribution of free VEGF Trap following IV administration was been determined to be approximately 6 L. For Period 1, for free aflibercept the mean (CV%) AUC was 177 (33) μg.day/mL and C\text{max} was 44.4 (36) μg/mL for IV administration. The AUC was 84.9 (30) μg.day/mL and the C\text{max} was 7.76 (39) μg/mL for subcutaneous
administration. For Period 1, for bound aflibercept the mean (CV%) AUC was 57.7 (19) μg.day/mL and the C\text{max} was 1.84 (22) μg/mL for IV administration. The AUC was 47.3 (27) μg.day/mL and the C\text{max} was 1.60 (27) μg/mL for subcutaneous administration. The mean (90% CI) ratio for AUC, subcutaneous/IV, was 0.51 (0.46 to 0.56).

This study also assessed safety pharmacology.

Study PDY6656 was a single centre, Phase I, randomised, double blind, placebo-controlled, sequential ascending dose study of IV aflibercept in healthy adult males that used doses of 1 mg/kg, 2 mg/kg and 4 mg/kg. There were three cohorts of 16 subjects; twelve treated with aflibercept and four treated with placebo. Pharmacodynamic endpoints were also reported.

The applicant has summarised these studies' results in the following tables (Tables 26-29).
### Table 26.

**Summary of Mean or Median Free VEGF Trap and Adjusted Bound VEGF Trap Exposure (AUC and C_{max}) Across Studies**

<table>
<thead>
<tr>
<th>Dose (unit)</th>
<th>Study</th>
<th>Route</th>
<th>C_{max} mg/L</th>
<th>C_{max}/Dose l/L</th>
<th>AUC_{C_{max}} day\times mg/L</th>
<th>AUC_{C_{max}}/Dose day/L</th>
<th>C_{max} mg/L</th>
<th>C_{max}/Dose l/L</th>
<th>AUC_{C_{max}} day\times mg/L</th>
<th>AUC_{C_{max}}/Dose day/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3 mg/kg</td>
<td>VGFT-OD-0305-0306 Combined PK Report</td>
<td>IV</td>
<td>4.44 (18.2)</td>
<td>0.233 (24.9)</td>
<td>11.6 (21.9)</td>
<td>0.548 (36.2)</td>
<td>0.602(^5)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>VGFT-OD-0305-0306 Combined PK Report</td>
<td>IV</td>
<td>15.9 (19.8)</td>
<td>0.24 (26.2)</td>
<td>79.3 (28.5)</td>
<td>1.21 (45.6)</td>
<td>1.85(^4)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>3 mg/kg</td>
<td>VGFT-OD-0305-0306 Combined PK Report</td>
<td>IV</td>
<td>58.5 (10.2)</td>
<td>0.218 (20.6)</td>
<td>307 (20.2)</td>
<td>1.16 (34.5)</td>
<td>NA(^3)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>PDY6655 Period 1</td>
<td>IV</td>
<td>44.4 (36)</td>
<td>NA</td>
<td>177 (33)</td>
<td>NA</td>
<td>1.84 (22)</td>
<td>NA</td>
<td>57.7 (19)</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>PDY6655 Period 2</td>
<td>IV</td>
<td>45.3 (31)</td>
<td>NA</td>
<td>181 (32)</td>
<td>NA</td>
<td>2.26 (27)</td>
<td>NA</td>
<td>76.4 (26)</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>PDY6655 Period 1</td>
<td>SC</td>
<td>7.76 (39)</td>
<td>NA</td>
<td>84.9 (30)</td>
<td>NA</td>
<td>1.60 (27)</td>
<td>NA</td>
<td>47.3 (27)</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>PDY6655 Period 2</td>
<td>SC</td>
<td>9.29 (32)</td>
<td>NA</td>
<td>98.4 (32)</td>
<td>NA</td>
<td>2.03 (30)</td>
<td>NA</td>
<td>69.5 (29)</td>
<td>NA</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>PDY6656</td>
<td>IV</td>
<td>18.2 (18)</td>
<td>NA</td>
<td>64.8 (20)</td>
<td>NA</td>
<td>1.21 (12)</td>
<td>NA</td>
<td>35.9 (11)</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>PDY6656</td>
<td>IV</td>
<td>39.7 (27)</td>
<td>NA</td>
<td>180 (20)</td>
<td>NA</td>
<td>2.40 (16)</td>
<td>NA</td>
<td>72.8 (14)</td>
<td>NA</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>PDY6656</td>
<td>IV</td>
<td>78.6 (15)</td>
<td>NA</td>
<td>419 (21)</td>
<td>NA</td>
<td>2.72 (31)</td>
<td>NA</td>
<td>78.3 (21)</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>VGFT-OD-0702 PK</td>
<td>IVT</td>
<td>0.0193 (118)</td>
<td>0.00965</td>
<td>0.153 (156)</td>
<td>0.0765</td>
<td>0.186 (40.3)</td>
<td>0.093</td>
<td>4.43 (42.3)</td>
<td>2.215</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>VGFT-OD-0603 IVT-1 40 mg/mL</td>
<td>IVT</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.331(^1)</td>
<td>0.0828</td>
<td>13.4 (31.4(^4))</td>
<td>3.35</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>VGFT-OD-0603 IVT-2 40 mg/mL</td>
<td>IVT</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.239(^4)</td>
<td>0.0598</td>
<td>11.7 (18(^4))</td>
<td>2.93</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>VGFT-OD-0603 IVT-2 80 mg/mL</td>
<td>IVT</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.320(^5)</td>
<td>0.08</td>
<td>15.8 (37.6(^5))</td>
<td>3.95</td>
</tr>
</tbody>
</table>

\(^1\) Highest reported mean concentration  
\(^2\) Study was terminated early  
\(^3\) C_{\text{peak, last value}}  
\(^4\) AUC_{\text{peak, last value}}  
\(^5\) Dosing regimen q12w.  
\(^6\) Dosing regimen q4w.  

### Table 27.

**Summary of Mean or Median VEGF Trap and Adjusted Bound VEGF Trap Exposure (AUC and C_{max}) Across Studies (Continued)**

<table>
<thead>
<tr>
<th>Dose (unit)</th>
<th>Study</th>
<th>Route</th>
<th>C_{max} mg/L</th>
<th>C_{max}/Dose l/L</th>
<th>AUC_{C_{max}} day\times mg/L</th>
<th>AUC_{C_{max}}/Dose day/L</th>
<th>C_{max} mg/L</th>
<th>C_{max}/Dose l/L</th>
<th>AUC_{C_{max}} day\times mg/L</th>
<th>AUC_{C_{max}}/Dose day/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 mg/kg</td>
<td>VGFT-OD-040502</td>
<td>IVT</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0.15 mg/kg</td>
<td>VGFT-OD-040502</td>
<td>IVT</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>VGFT-OD-040502</td>
<td>IVT</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>VGFT-OD-040502</td>
<td>IVT</td>
<td>0.04</td>
<td>0.04</td>
<td>0.03</td>
<td>0.03</td>
<td>0.04</td>
<td>0.04</td>
<td>1.16(^6)</td>
<td>1.16</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>VGFT-OD-040502</td>
<td>IVT</td>
<td>0.06</td>
<td>0.06</td>
<td>0.30(^6)</td>
<td>0.15</td>
<td>0.15</td>
<td>0.08</td>
<td>6.02(^6)</td>
<td>3.01</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>VGFT-OD-040502</td>
<td>IVT</td>
<td>0.04</td>
<td>0.04</td>
<td>0.41(^6)</td>
<td>0.10</td>
<td>0.20</td>
<td>0.05</td>
<td>7.19(^6)</td>
<td>1.80</td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>VGFT-OD-0508</td>
<td>IVT</td>
<td>0.00085(^6)</td>
<td>0.00017</td>
<td>NA</td>
<td>NA</td>
<td>0.034(^4)</td>
<td>0.008</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>VGFT-OD-0508</td>
<td>IVT</td>
<td>0.0024(^4)</td>
<td>0.0012</td>
<td>NA</td>
<td>NA</td>
<td>0.110(^4)</td>
<td>0.0095</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>4 mg/kg</td>
<td>VGFT-OD-0508</td>
<td>IVT</td>
<td>0.0011(^4)</td>
<td>0.00078</td>
<td>NA</td>
<td>NA</td>
<td>0.0144(^4)</td>
<td>0.0016</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>311523 (VIEW 2)</td>
<td>IVT</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>0.152(^4)</td>
<td>0.006</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>311523 (VIEW 2)</td>
<td>IVT</td>
<td>0.0160(^6)</td>
<td>0.0005</td>
<td>NA</td>
<td>NA</td>
<td>0.025(^6)</td>
<td>0.003</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
Table 28.

<table>
<thead>
<tr>
<th>Study Number</th>
<th>Study Design</th>
<th>Formulation</th>
<th>Treatments Dose, Formulation</th>
<th>Mean Systemic VEGF Trap Levels (Free and Adjusted Bound Drug Levels)</th>
<th>Mean Adjusted Bound VEGF Trap (range of individual results: SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IVT-1</td>
<td></td>
<td>ng/mL</td>
<td>Day</td>
</tr>
<tr>
<td>VGFT-OD-0502</td>
<td>Phase 1, open label, dose escalation study in which six successive cohorts of patients with AMD received a single 100 μL IVT injection of 0.05, 0.15, 0.5, 1, 2, or 4 mg into the study eye; Parts A and C</td>
<td>P1: 3</td>
<td>BLQ (all BLQ)</td>
<td>3</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P1: 3</td>
<td>BLQ (all BLQ)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P1: 3</td>
<td>BLQ (all BLQ)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P2: 6</td>
<td>BLQ (BLQ to 26: SD=12)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P2: 2</td>
<td>BLQ (BLQ to 6: SD=58)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P1: 14</td>
<td>BLQ (BLQ to 16: SD=12)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P2: 9</td>
<td>BLQ (BLQ to 110: SD=32)</td>
</tr>
<tr>
<td>VGFT-OD-0508</td>
<td>Phase 2, double masked, prospective, randomized study in which patients with AMD received a series of 100 μL IVT injections into the study eye at 4- or 12-week intervals over a 12-week period (fixed dosing phase)</td>
<td>ITV-1</td>
<td>0.5 mg q4w ITV-1; 0.5 mg q12w ITV-1; 2 mg q4w ITV-1; 4 mg q4w ITV-1</td>
<td>P2: 32</td>
<td>BLQ (BLQ to 18: SD=3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P2: 29</td>
<td>BLQ (BLQ to 24: SD=8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P2: 27</td>
<td>BLQ (BLQ to 39: SD=7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P2: 29</td>
<td>BLQ (BLQ to 36: SD=10)</td>
</tr>
</tbody>
</table>

Table 29.

<table>
<thead>
<tr>
<th>Study Number</th>
<th>Study Design</th>
<th>Formulation</th>
<th>Treatments Dose, Formulation</th>
<th>Mean Systemic VEGF Trap Levels (Free and Adjusted Bound Drug Levels)</th>
<th>Mean Adjusted Bound VEGF Trap (range of individual results: SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IVT-1</td>
<td></td>
<td>ng/mL</td>
<td>Day</td>
</tr>
<tr>
<td>VGFT-OD-0603</td>
<td>Phase 1 study in patients with AMD comparing ITV-1 and ITV-2 formulations at 4 mg every 4 week for 12 weeks. In the double-masked cohort, patients were administered 100 μL injections of 40 mg/mL VEGF Trap-Eye. In the open-label cohort patients were administered 50 μL injections of 80 mg/mL VEGF Trap-Eye.</td>
<td>4 mg q4w ITV-1 (DM)</td>
<td>4 mg q4w ITV-2 (DM)</td>
<td>4 mg q4w ITV-2 (OL)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P3: 5</td>
<td>BLQ (BLQ to 54: SD=13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P3: 8</td>
<td>BLQ (BLQ to 19: SD=7)</td>
</tr>
<tr>
<td>VGFT-OD-0702</td>
<td>PK sub-study of a Phase II multi-center, open-label, extension study in which patients with AMD received a single 100 μL injection into the study eye</td>
<td>ITV-2^2</td>
<td>2 mg ITV-2^2</td>
<td>P3: 6</td>
<td>15.8 (BLQ to 48: SD=47)</td>
</tr>
</tbody>
</table>

In regard to pharmacokinetics in the intended treatment population, the evaluator concluded, "The systemic exposure following intravitreal injection was minimal in
comparison with studies of intravenous aflibercept. This would be expected given the differences in total dose: up to 4 mg intravitreal compared with up to 4 mg/kg intravenous.”

Pharmacodynamics

Safety pharmacology

Studies PDY6655 and PDY6656 are described above. A pressor effect was seen after IV dosing. The effect was somewhat dose dependent (allowing also for the greater bioavailability of IV versus subcutaneous administration in Study PDY6656). The increase in blood pressure persisted for up to 44 days at the 4 mg/kg dose level. Plasma renin activity and aldosterone concentrations were decreased. The evaluator expressed some doubt that such an effect might be expected in regard to the proposed route of administration and dose.

Dose finding in proposed indication

Intravenous administration

“There were some Phase I data of aflibercept administered IV. Study VGFT-OD-0305 indicated a dose of 3 mg/kg aflibercept by IV injection was effective but that a dose of 1 mg/kg was not. Study VGFT-OD-0306 indicated that IV treatment with aflibercept would not be as effective long-term as intravitreal.”

Intravitreal administration

“The Phase II study (Study VGFT-OD-0508/14394 [CLEAR-IT AMD-2]) did not clearly indicate the most appropriate dosing regimen. In the Phase II study the greatest reduction in CRT at Week 12 was with a 2 mg q4w dosing regimen but at all other time points over 52 weeks the greatest reduction in CRT was with 4 mg q12w. The greatest improvement in BCVA through to Week 52 was with 2 mg q4w. However the greatest improvement in vision related quality of life was with 4 mg q12w.”

Study VGFT-OD-0502/14395 was an open label dose-escalation study in 21 patients with the proposed indication. The study treatments in Part A were aflibercept, given intravitreally at dose levels: 0.05 mg, 0.15 mg, 0.50 mg, 1 mg, 2 mg and 4 mg. Four outcome variables were reported. As noted by the evaluator,

“In the initial dose finding studies, the greatest effect was in the 2 mg to 4 mg dose grouping (Study VGFT-OD-0502/14395 Part A). Effect increased with increasing dose up to 4 mg. Peak effect appeared to be at Day 29 (Study VGFT-OD-0502/14395 Part C).” After Day 57, 9 patients continued in an open label extension to 12 months. The clinical evaluation report discussed the efficacy results at Day 57. The maximal effect was seen with a dose of 2mg or 4mg.

In Part C of the Study, the design was altered to double masked, randomised and the route of administration became intravitreal at doses of 0.15 mg/0.1 mL or 4 mg/0.1 mL. Fourteen patients received each dose and 22 progressed to a 12 month PRN dosing schedule at a dose of 4 mg [reported in the sponsor’s summary as "Up to two injections of 0.15 or 4 mg"]). The patient population had varied indications:

Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 letters to 24 letters)

Subretinal hemorrhage making up ≤ 50% of total lesion size and sparing the fovea
Total lesion size ≤12 disk area (including blood, scars, atrophy and neovascularisation) as assessed by fluorescein angiography (FA).

The higher dose was more effective. The clinical evaluation report discusses the efficacy results at Days 29 and 43.

*Study VGFT-OD-0603/14396 (CLEAR-IT 1b)* was evaluated but it compared two different formulations and was not a dose ranging study and it only enrolled 20 patients with a diagnosis of AMD due to active primary or recurrent subfoveal choroidal neovascularisation. Local adverse events were reported from this study.

*Study VGFT-OD-0508/1494 (CLEAR-IT AMD-2)* is an important study for this submission: it enrolled patients with subfoveal CNV secondary to AMD compared three intravitreal doses at 12 weekly intervals and two doses at four weekly intervals. It had one primary endpoint (retinal thickness determined by optical coherence tomography) and three secondary endpoints (including best corrected visual acuity). One hundred and fifty-seven patients received some treatment: 32 in the 0.5 mg q4w group, 32 in the 0.5 mg q12w group, 31 in the 2 mg q4w group, 31 in the 2 mg q12w group and 31 in the 4 mg q12w group. A total of 153 subjects completed to Week 12.

The dosing regimens were:

1. Aflibercept 0.5/100 μL mg every 4 weeks
2. Aflibercept 0.5/100 μL mg every 12 weeks
3. Aflibercept 2 mg/100 μL every 4 weeks
4. Aflibercept 2 mg/100 μL every 12 weeks
5. Aflibercept 4 mg/100 μL every 12 weeks

The primary outcome results were as reported in Table 10 above. Aflibercept 2 mg/100 μL every 4 weeks and aflibercept 4 mg/100 μL every 12 weeks were associated with the best outcomes in the primary endpoint and a number of secondary endpoints. Aflibercept 2 mg/100 μL every 4 weeks was the regimen that achieved the best result in the primary endpoint at the prespecified 12 week observation. [A sample size calculation was not performed. The study did not formally compare regimens].

The evaluator questioned the rational basis for sponsor’s proposed regimen (see below).

**Phase III efficacy and safety studies**

There were four studies of which *Study VGFT-OD-0605/14393 (VIEW 1)* and *Study 311523 (VIEW 2)* were presented as "pivotal" trials and *Studies VGFT-OD-0702/14262 and VGFT-OD-0706/13336 (DAVINCI)* were considered to be ‘supportive’. In these studies, BCVA was chosen as the primary efficacy outcome measure in the pivotal studies. Various secondary efficacy measures, including morphological endpoints (that is, central retinal thickness (CRT) and macular volume) assessed pathology and disease severity.

**Pivotal studies:**

*VIEW 1 and VIEW 2* were multicentric, double-masked, active-controlled, parallel-group, 2 year studies of aflibercept in the treatment of “wet” AMD. They were designed to assess the efficacy of intravitreally administered aflibercept compared to ranibizumab 0.5mg q4w, using a non-inferiority design, for preventing moderate vision loss in subjects with all subtypes of “wet” AMD. However, only the first 12 months’ data were submitted with this submission. Patient exclusion criteria were extensive. Efficacy and safety evaluations were performed by a masked investigator. The untreated eye received a sham injection.
The primary efficacy endpoint was the proportion of subjects maintaining vision, defined as a loss of fewer than 15 letters in ETDRS letter score compared to baseline at Week 52.

VIEW 1 was conducted in the USA and in Canada. The study treatments were: Aflibercept 2 mg q4w; aflibercept 0.5 mg q4w; aflibercept 2 mg q8w or ranibizumab 0.5 mg q4w. In this study, the condition for non-inferiority was that the 95% CI for the difference in the proportion of subjects who maintained vision at Week 52 compared to baseline (ranibizumab – aflibercept) is entirely below 10%. Of note, multiplicity for the primary analysis was controlled using a conditional sequence of tests for non-inferiority: (1) aflibercept 2 mg q4w versus ranibizumab; (2) aflibercept 0.5 mg q4w versus ranibizumab; and (3) aflibercept 2 mg q8w versus ranibizumab. The study was executed above minimal patient numbers as specified in the power calculations: 1217 subjects were randomised. The treatment groups were well-matched.

The primary endpoint results at Week 52 are shown in Table 30 below.

Table 30. Proportion of Subjects who Maintained* Vision at Week 52 (Per Protocol Set)

<table>
<thead>
<tr>
<th></th>
<th>Ranibizumab</th>
<th>VEGF Trap-Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5Q4 (N = 269)</td>
<td>2Q4 (N = 285)</td>
</tr>
<tr>
<td>Subjects with Maintained Vision at Week 52 [1]</td>
<td>254 (94.4%)</td>
<td>271 (95.1%)</td>
</tr>
<tr>
<td>Difference (%) (95% CI) [2]</td>
<td>-0.7 (-4.3, 3.1)</td>
<td>-1.5 (-5.1, 2.1)</td>
</tr>
</tbody>
</table>

1 LOCF (baseline values were not carried forward)
2 Difference is ranibizumab minus VEGF Trap-Eye; CI was calculated using a normal approximation.

Non-inferiority was thus shown. The testing sequence stopped after the first test. However, the evaluator observed that these secondary endpoints also supported non-inferiority.

VIEW 2 was of similar design to VIEW 1 but had 126 centres in 26 countries. Sample size calculations were as for VIEW 1; 1240 patients were randomised. The treatment groups were well-matched. The primary endpoint results at Week 52 are shown in Table 31 below.

Table 31. Proportion of subjects who maintained vision at Week 52 – LOCF (per protocol set) (VIEW 2)

<table>
<thead>
<tr>
<th></th>
<th>Ranibizumab</th>
<th>VEGF Trap-Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5Q4 (N = 269)</td>
<td>2Q4 (N = 274)</td>
</tr>
<tr>
<td>Subjects who maintained vision at Week 52 (n [%]) [1]</td>
<td>254 (94.42%)</td>
<td>262 (95.62%)</td>
</tr>
<tr>
<td>Difference (%) (95% CI) [2]</td>
<td>-1.20 (-4.86; 2.46)</td>
<td>-1.84 (-5.40; 1.71)</td>
</tr>
</tbody>
</table>

Note: Maintenance of vision was defined as a loss of < 15 letters in the ETDRS letter score.
1 Last observation carried forward (Baseline values were not carried forward)
2 Difference is ranibizumab minus VEGF Trap-Eye; CI = confidence interval was calculated using a normal approximation.
Non-inferiority was thus demonstrated. As with VIEW-1, there were no significant differences between the treatment groups in the secondary efficacy outcome measures but the evaluator opined that these results were supportive of non-inferiority.

**Comment:** It is agreed that the three regimens of aflibercept are non-inferior in respect of the primary endpoint at 12 months, shown from VIEW-1 and in VIEW-2. The numerous secondary endpoints are harder to interpret other than qualitatively as showing small differences. Perhaps the 24 month data may show statistically significant trends in terms of the statistical plan. The Delegate noted that the sponsor pooled the 12 month data from both studies and then claim that non-inferiority has been shown in the secondary endpoints with consistency of response across various subgroups.

**Supportive studies:**

*Study VGFT-OD-0702/14262* was conducted to compare long term safety and tolerability of aflibercept in pre-filled syringes and vials to 12 months. The aflibercept concentration was 40 mg/mL. The injection volume was 50 µL. The patients enrolled came from previous, short-term studies. The study enrolled 157 patients of whom 149 were randomised to treatment: 99 to pre-filled syringe and 50 to vial.

Visual acuity declined on study but the evaluator made no interpretive comment (see Figure 9 above).

*Study VGFT-OD-0706/13336 (DAVINCI)* was a study in diabetic macular oedema and is not relevant to the review of efficacy in the proposed indication. However, the study suggested that intravitreal aflibercept 2 mg q4w was more effective that 0.5 mg given at the same frequency of 4 mg given q8w or PRN.

Overall, the evaluator found:

1. The efficacy studies used validated endpoints.
2. The greatest treatment effect was with the 2 mg to 4 mg doses.
3. Effect increased with increasing dose up to 4 mg.
4. It is unclear whether a 2 mg q4w dosing regimen is therapeutically different from aflibercept 4 mg q12w as the primary endpoint in the Phase II study favoured the former regimen.
5. In the pivotal efficacy studies, non-inferiority was demonstrated for all three aflibercept dosing regimens. Secondary endpoint analyses showed variable trends.

**Safety data**

In addition to the abovementioned studies, safety data also derived from *Study VGFT-OD-0502/14395 Part B (CLEAR-IT 1)* and from three ongoing studies that had some limited reporting of data: *Study VGFT-OD-0910/14832, Study VGFT-OD-0819/14232 (COPERNICUS) and Study 14130 (GALILEO).*

From the applicant’s tabulation, the safety experience is limited by duration of exposure/follow-up as described in Table 32 below.
Table 32. Data pools for Safety Evaluation

<table>
<thead>
<tr>
<th>Studies</th>
<th>Database</th>
<th>Pool 1 Primary safety</th>
<th>Pool 2 Supportive safety</th>
<th>Pool 3 Exposure only</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>View 1 up to 1 year</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td></td>
<td>View 2 up to 1 year</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0502 from Week 12 up to 1 year (flexible dose regimen employed)</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0508 from Week 12 up to 1 year (flexible dose regimen employed)</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0603 up to 1 year</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0702 cut-off date: June 28, 2010 (pre-filled syringe versus, via) up to 36 months</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>DME</td>
<td>VGFT-OD-0512 up to 6 weeks</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td></td>
<td>VGFT-OD-0706 up to 6 months</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
</tbody>
</table>

Number of subjects treated with VEGF Trap-Eye (Safety Analysis Set) 1848 230 2230

* For exposure analysis (Pool 3) single dose parts are included

Common adverse events in the pivotal studies are tabulated below (Table 33; from sponsor).

Table 33.

<table>
<thead>
<tr>
<th>Most common ADRs (≥ 1 %) in Phase-3 wet AMD studies</th>
<th>VEGF Trap_Eye (n= 1824)</th>
<th>Ranibizumab (n= 595)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctival hemorrhage</td>
<td>24.7%</td>
<td>28.1%</td>
</tr>
<tr>
<td>Eye pain</td>
<td>8.7%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Cataract</td>
<td>6.8%</td>
<td>6.6%</td>
</tr>
<tr>
<td>Vitreous detachment</td>
<td>6.0%</td>
<td>5.5%</td>
</tr>
<tr>
<td>Vitreous floaters</td>
<td>5.9%</td>
<td>7.4%</td>
</tr>
<tr>
<td>Intraocular pressure increased</td>
<td>5.2%</td>
<td>6.9%</td>
</tr>
<tr>
<td>Conjunctival hyperemia*</td>
<td>4.4%</td>
<td>7.9%</td>
</tr>
<tr>
<td>Corneal erosion*</td>
<td>3.7%</td>
<td>4.9%</td>
</tr>
<tr>
<td>Detachment of the retinal pigment epithelium</td>
<td>3.3%</td>
<td>3.4%</td>
</tr>
<tr>
<td>Injection site pain</td>
<td>3.0%</td>
<td>3.4%</td>
</tr>
<tr>
<td>Foreign body sensation in eyes</td>
<td>3.0%</td>
<td>3.7%</td>
</tr>
<tr>
<td>Lacrimation increased</td>
<td>2.8%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Vision blurred</td>
<td>2.3%</td>
<td>1.8%</td>
</tr>
<tr>
<td>Retinal pigment epithelium tear</td>
<td>1.6%</td>
<td>1.2%</td>
</tr>
<tr>
<td>Injection site hemorrhage</td>
<td>1.5%</td>
<td>1.7%</td>
</tr>
<tr>
<td>Eyelid edema</td>
<td>1.4%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Corneal edema</td>
<td>1.0%</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

* MedRA labeling group terms

Source: Module 2.7.4, Table 51

The rate of patients discontinuing due to the adverse events in the studies were 2.2% (aflibercept) and 1.1% (ranibizumab).

Shown below is the applicant’s tabulation of serious adverse events from the pooled safety and efficacy studies (Table 34).
Table 34. Severe Non-Ocular Treatment-emergent AEs, Pool 1 (by SOC and PT) (Safety Analysis set).

<table>
<thead>
<tr>
<th>Primary SOC</th>
<th>Preferred term</th>
<th>R 0.5 mg Q4</th>
<th>VTE 1.0 mg Q4</th>
<th>VTE 0.5 mg Q4</th>
<th>VTE 1.0 mg Q8</th>
<th>VTE total N=1824</th>
<th>TOTAL N=2416</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects with at least 1 non-ocular severe TEAE</td>
<td>50 (8.4%)</td>
<td>40 (6.5%)</td>
<td>59 (9.8%)</td>
<td>55 (9.0%)</td>
<td>154 (8.4%)</td>
<td>204 (8.4%)</td>
<td></td>
</tr>
</tbody>
</table>

**Blood system and lymphatic disorders**

- Anemia: 0 (0.2%)
- Hemorrhagic anemia: 0 (0.2%)
- Thrombocytopenia: 0 (0.2%)

**Cardiac disorders**

- Cardiac disorders: 11 (1.8%)
  - Acute myocardial infarction: 1 (0.2%)
  - Angina pectoris: 0 (0.2%)
  - Aortic valve stenosis: 0 (0.2%)

**Atrial fibrillation**

- 0 (0.3%)

**Bradyarrhythmia**

- 0 (0.2%)

**Cardiac arrest**

- 0 (0.2%)

**Cardiac failure**

- 0 (0.2%)

**Cardiac failure congestive**

- 1 (0.2%)

**Coronary artery disease**

- 0 (0.2%)

**Coronary artery occlusion**

- 0 (0.2%)

**Mural valve incompetence**

- 0 (0.2%)

**Myocardial infarction**

- 3 (0.7%)

**Pericarditis**

- 0 (0.2%)

**Pulmonary embolus**

- 0 (0.2%)

**Pulmonary vein stenosis**

- 0 (0.2%)

**Sinus tachycardia**

- 1 (0.2%)

**Tachycardia**

- 0 (0.2%)

**Ventricular tachycardia**

- 0 (0.2%)

**Ear and labyrinth disorders**

- 0 (0.2%)

**Deafness unilateral**

- 0 (0.2%)

**Gastrointestinal disorders**

- 0 (1.0%)

**Abdominal pain upper**

- 0 (0.2%)

**Colitis**

- 0 (0.2%)

**Constipation**

- 2 (0.3%)

**Diarrhea**

- 1 (0.2%)

**Duodenal ulcer hemorrhage**

- 0 (0.2%)

**Gastric ulcer**

- 0 (0.2%)

**Gastroparesis**

- 0 (0.2%)

**Gastroesophageal reflux disease**

- 1 (0.2%)

**Hemorrhagic erosive gastritis**

- 0 (0.2%)

**Hiccups**

- 0 (0.2%)

**Intestinal obstruction**

- 1 (0.2%)

**Pancreatic cancer**

- 0 (0.2%)

**Tongue edema**

- 0 (0.2%)

**Uncontrolled hemorrhage**

- 0 (0.2%)

**Liver disorders**

- 0 (0.2%)

**General disorders and administration site conditions**

- 4 (0.7%)

**Asthma**

- 0 (0.2%)

**Cough**

- 0 (0.2%)

**Chest pain**

- 0 (0.2%)

**Death**

- 0 (0.2%)

**Fainting**

- 0 (0.2%)

**Non-cardiac chest pain**

- 0 (0.2%)

**Pain**

- 0 (0.2%)

**Hepatobiliary disorders**

- 0 (0.2%)

**Cholelithiasis**

- 0 (0.2%)

**Cholelithiasis**

- 0 (0.2%)

**Hepatic cirrhosis**

- 0 (0.2%)

**Immune system disorders**

- 0 (0.2%)

**Drug hypersensitivity**

- 0 (0.2%)

**Infections and infestations**

- 0 (0.2%)

**Bacterial infection**

- 0 (0.2%)

**Cellulitis**

- 0 (0.2%)

Adverse effects of aflibercept were:

- Local, such as conjunctival hemorrhage, eye pain and reduction in visual acuity that might be associated with the injection and the vehicle; an increase in intraocular pressure of around 3.2 mmHg immediately posttreatment that did not increase with subsequent treatments [the duration of this increased intraocular pressure is not clear and the sponsor was asked to discuss the available data to substantiate the proportion that needed treatment and the time course of the increased intraocular pressure];
• Systemic adverse events after IV injection of aflibercept included headache, hypertension, proteinuria and dysphonia. Intravitreally administered aflibercept was associated with antibody formation to aflibercept in about 4% of patients in the studies;

• Serious adverse events were qualitatively similar to those expected in the population studied.

Recommendations of the clinical evaluator

An important question that the evaluator asked was,

“IT IS NOT CLEAR FROM THE CLINICAL STUDIES HOW THE SPONSOR DETERMINED THE FINAL DOSING RECOMMENDATIONS IN THE PRODUCT INFORMATION DOCUMENT. THE PROPOSED DOSING REGIMEN (2 mg INTRAVITREAL INJECTION EACH MONTH FOR THE FIRST THREE INJECTIONS FOLLOWED BY ADMINISTRATION EVERY SECOND MONTH) WOULD PROVIDE THE SPONSOR WITH A MARKETING ADVANTAGE, THAT IS, A PERCEPTION THAT LESS FREQUENT DOSING IS REQUIRED. HENCE, IT IS IMPORTANT THAT THE DOSING REGIMEN IS SUPPORTED BY DATA. CAN THE SPONSOR PROVIDE A JUSTIFICATION FOR THE DOSING REGIMEN PROPOSED IN THE PRODUCT INFORMATION DOCUMENT?”

Response to the clinical evaluation report

A response has been received to the clinical evaluation report. In brief, the introduction concisely states the sponsor’s position:

“The proposed dosing regimen is supported by the data presented from the Phase II study VGFT-OD-0508 and the two pivotal Phase III studies VIEW 1 and VIEW 2 and reflects the treatment advantage of a less frequent dosing scheme over a monthly dosing while efficacy as assessed by the primary endpoint is uncompromised. This is possible by the pharmacology of the product that showed the same efficacy with 2 mg q8 weeks dosing (after three initial loading doses at the start of treatment) as with 2 mg q4 weeks dosing consistently in both pivotal studies. The efficacy of either regimen of VEGF Trap Eye was compared to monthly dosing of the reference product ranibizumab and was found non-inferior in the primary endpoint and can be considered clinically equivalent. Generally, as there are additional risks and burdens associated with a q4 regimen compared with a q8 regimen, the q8 regimen was judged to have a better benefit/risk profile. Therewith, dosing of VEGF Trap-Eye every two months (after three initial loading doses at start of treatment) is justified as it constitutes a good benefit/risk ratio supporting marketing authorisation. The dosing every two months allows also for reducing the number of frequent visits and reduces the general potentially serious risks associated with frequent intravitreal injections without compromising efficacy.”

That is, safety concerns are used to support less frequent dosing. However, the Phase II study had small numbers in each treatment arm and could not be used to make robust conclusions; it is possible to make alternative interpretation, as shown below (Figure 11).
Figure 11. Integrated Analysis of the pooled data from the pivotal studies-Mean change in BCVA (FAS, LOCF).

The figure shows a trend to better results for 4 weekly injections and not 8 weekly. The response does not cite study data that show a higher rate of local adverse events attributable to more frequent injections, so this suggestion by the sponsor is taken to be “in principle”.

Comments

The use of OCT as a primary endpoint was probably useful as an objective tool research but best corrected visual acuity might be more clinically practical. VIEW-1 and VIEW-2 used an appropriate primary endpoint.

The dosing regimen of ranibizumab that was used in the two pivotal studies was acceptable, indeed a little high in terms of drug exposure.

An emerging safety issue with ranibizumab has been the correct dose selection and choosing the right dose (for example, is 0.5 mg too much?) and establishing the longest dosing interval that is compatible with an optimal treatment effect. This matter has not yet been resolved but the current product information document of Lucentis includes the following information:

“Treatment of Wet AMD

The recommended dose of Lucentis is 0.5 mg (0.05 mL) or 0.3 mg (0.03 mL) given as a single intravitreal injection.

Lucentis is given monthly. The interval between two doses should not be shorter than 1 month. Although less effective, treatment might be reduced to one injection every 3 months after the first three injections (e.g. if monthly injections are not feasible) but, compared to continued monthly doses, dosing every 3 months may lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average, over the following nine months. Patients should be evaluated regularly.

Post-Registration Study in DME population

An analysis of 24-month data from two Phase III studies in DME, RIDE and RISE, is available. Both studies are randomised, sham-controlled studies of monthly intravitreal ranibizumab injections (0.5 mg or 0.3 mg) for a total of 36 months in patients with clinically significant macular oedema with centre involvement secondary to diabetes mellitus (Type 1 or Type 2).
The patients are treated using a fixed dosing regimen which requires monthly injections as opposed to the approved individualised dosing regimen (see Dosage and Administration). A total of 500 patients were exposed to ranibizumab treatment in the pooled studies (250 patients in each pooled ranibizumab 0.3mg and 0.5mg arm as well as the sham arm).

The pooled safety analysis showed a numerically higher, but not statistically significant, number of deaths and cerebrovascular events in the 0.5 mg group as compared to the 0.3 mg or sham groups. The stroke rate at 2 years was 3.2% (8/250) with 0.5 mg ranibizumab, 1.2% (3/250) with 0.3 mg ranibizumab, and 1.6% (4/250) with sham. Fatalities in the first 2 years occurred in 4.4% (11/250) of patients treated with 0.5mg ranibizumab, in 2.8% (7/250) of patients treated with 0.3 mg ranibizumab and in 1.2% (3/250) of control patients.

Risk management plan

In regard to the status of Eylea abroad, the evaluator has noted:

“Eylea was approved by the US FDA on 18 November 2011 for the same indication as those proposed for in Australia. A postmarketing pharmacovigilance requirement has been imposed by the FDA for a clinical trial to be conducted to assess the risk of unexpected serious adverse events for Eylea, specifically for corneal endothelial cell decompensation.”

“Endophthalmitis is identified as an important injection-related safety concern while arterial thromboembolic events (ATEs) and embryo-fetal toxicity are identified as potential drug related safety concerns. It is proposed that routine pharmacovigilance (PhV) is supplemented by targeted follow-up of reports of suspicious of intraocular injection. Data from the ongoing clinical trial programme will provide additional monitoring and characterization of the safety profile of aflibercept. Routine risk minimisation is proposed for the ongoing safety concerns.”

Safety data in patients are limited by numbers and duration (52 weeks in Phase III trials). Ongoing safety concerns in the safety specification of the Risk Management Plan include at this time a lack of available long-term data; ongoing studies are noted but the sponsor’s claim of comparable safety with Lucentis has not been established in terms of duration of experience. Further data will accrue from clinical trials that are in progress.

The evaluator has noted the potential for overdose from both presentations but not, for example, the potential risk of multipatient use by combining the residual amount in several vials. Other concerns include use in unapproved indications; the lack of clarity in the draft product information document about experience in long term use; and an open question about the prophylactic use of antibiotic eye drops to reduce the risk of endophthalmitis.

The latest version of the risk management has not been fully accepted by the evaluator. The applicant was asked to address this in the pre Advisory Committee on Prescription Medicines (ACPM) response.

Risk-benefit analysis

Delegate considerations

Comments on this application

The application is supported by an adequate data package in respect of quality and nonclinical matters.

The nonclinical studies, particularly those conducted in cynomolgus monkeys, are informative in regard to local toxicity.
The use of Lucentis as an active comparator in the clinical studies is ethically necessary. Lucentis was given at a high dose and adequate frequency, so ensuring that Eylea was not advantaged in the comparison. Combined use of these agents is unlikely to be of benefit and there are no data on the use of aflibercept in patients who fail to respond to ranibizumab.

Theoretically, the use of aflibercept in combination with a second agent such as anecortave or a corticosteroid would be of value in some potential indications but there are no such studies.

The risk management activities that are planned were considered reasonable.

The PI document should make it clear that there are no evaluated data beyond 12 months and that the optimal dosing schedule has not been defined.

The ACPM was asked to comment on these matters.

**Proposed actions**

The application by Bayer Australia Limited to register Eylea solution for intravitreal injection, containing aflibercept (solution) at 2 mg aflibercept per 50 µL, for the treatment of neovascular (wet) age-related macular degeneration (AMD) should be approved.

Bayer Australia Limited should submit for evaluation the completed pivotal studies. It was noted that this application was based on 12 month, not 24 month data.

Submitted for ACPM’s advice.

**Response from sponsor**

The TGA Evaluators (for quality, nonclinical, clinical, risk management plan [RMP] aspects) and the Delegate have all recommended that Eylea should be approved for the treatment of wet AMD. Overall, the sponsor is in agreement with the TGA Evaluators and Delegate that the efficacy of Eylea has been conclusively demonstrated in two pivotal Phase III clinical studies (VIEW 1 + VIEW 2) and the overall safety profile is favourable such that Eylea is registrable based on these data. The benefit-risk assessment is positive for Eylea and, furthermore, the dosing regimen of every 2 months, after 3 initial loading doses at the start of treatment provides additional potential benefit over current therapies in patients with wet AMD. However, in this response, the sponsor wishes to provide further comments and clarifications to the Delegate’s Overview.

The Delegate commented that the product information should make it clear that there are no evaluated data beyond 12 months and that the optimal dosing schedule has not been defined.

The sponsor contended that the clinical trial section of the PI already clearly states that the efficacy outcomes presented in support of Eylea and the proposed dosing schedule are based on the primary analyses conducted at 12 months. Therefore, the sponsor does not believe that any further clarification is needed in the PI regarding this point.

The VIEW 1 and VIEW 2 studies have now reached their full course and the results at 96 weeks continued to support the positive benefit-risk assessment made based on the primary analyses at Week 52.

The sponsor believes that the optimal dosing schedule of 2 mg Eylea every 8 weeks (2q8) following 3 initial monthly doses is fully supported by the efficacy and safety results from the pivotal Phase-3 studies, VIEW 1 and VIEW 2, and the integrated analysis of the data from these studies. The pivotal studies show that a 2q8 dosing regimen provides equivalent efficacy, especially in regard to the most clinically important outcome, visual acuity, as a monthly dosing regimen of the currently approved treatment for wet AMD. The requirement for less frequent dosing with Eylea from an efficacy perspective is clearly
supported by the clinical data submitted. In addition, review of the data from the 2q8 group did not reveal clinically relevant changes in the efficacy variables between injections. These findings support the conclusion that there is no need for monitoring patients more frequently than every 2 months as no decreases in efficacy that would prompt retreatment were seen between active injections spaced 2 months apart.

In regard to patient safety, because of the safety issues inherent with the application of intravitreal injections (that is, each injection carries the risk for an adverse event), it is in the best interest of the patient to maintain visual acuity and quality of life with the minimal number of injections as possible (and thereby minimum opportunity for an adverse event) without compromising efficacy.

Finally, a reduction in the number of clinic visits without the need for monitoring between visits and no concern for deterioration of visual acuity, also alleviates much of the burden to patients and caregivers and frees up provider resources. The current gold standard treatment for exudative AMD involves monthly injections of Lucentis. However, this regimen places considerable treatment burden and costs on patients and workload for clinicians. Therefore, many ophthalmologists have implemented a treatment regimen that requires fewer injections than the Lucentis approved label by using either the “as needed” (that is, PRN) or “inject & extend” approach. These major barriers to treatment will be met with the introduction of Eylea, which will offer a new, fixed-dosing regimen of bimonthly injections (after 3 initial loading doses at the start of treatment).

In conclusion, fewer doses of Eylea are needed to achieve the same efficacy as monthly dosing with Lucentis and indeed, the data do not support that more frequent dosing with Eylea or more frequent monitoring of patients results in a better clinical outcome than dosing (and monitoring) every 8 weeks. It is self-evident that, given equivalent clinical efficacy, a regimen with fewer intravitreal injections and fewer monitoring visits to the clinic is preferable to one with more intravitreal injections and more visits. Therefore, based on positive considerations of efficacy, safety, and impact on patient and caregiver, the sponsor recommends the optimal dosing regimen of initiating treatment with 2 mg intravitreal injection each month for 3 consecutive months followed by administration of 2 mg every 2 months.

The Delegate commented that safety concerns are used to support less frequent dosing but the Phase II Study VGFT-OD-0508 had small numbers in each treatment arm and could not be used to make robust conclusions and that it is possible to make alternative interpretation.

The sponsor based the recommended dosing regimen, 2 mg every 8 weeks after 3 initial monthly doses, primarily on the efficacy results of the pivotal Phase III studies, which showed no clinically relevant difference in the efficacy achieved with dosing every 4 weeks versus dosing every 8 weeks. In other words, more frequent injections do not result in greater efficacy. There is a low, but defined, per-injection incidence of complications associated with the intravitreal injection procedure. Based on logical considerations that fewer injections, each of which carries risk for an adverse event, expose the patient to fewer opportunities for an adverse event, the sponsor believes that Eylea may impart a clinically relevant decrease in the risk of serious complications associated with intravitreal injections without compromising benefit to the patient.

With reference to the figure representing integrated analysis of pooled data from the pivotal studies for mean change in BCVA, the Delegate commented that the graph shows a trend to better results for 4 weekly injections and not 8 weekly.

The sponsor clarified that the figure representing the integrated analysis of pooled data from the pivotal studies for mean change in BCVA shows a change from baseline at Week 52 of 9.3 ± 13.3 letters in the Eylea 2Q4 (2 mg every 4 weeks) group and 8.4 ± 14.7 letters in the Eylea 2Q8 (2 mg every 8 weeks) group. In the VIEW 1 study, the change from
baseline at Week 52 was 10.9 ± 13.77 letters and 7.9 ± 15.00 letters in these two Eylea groups, respectively, and in VIEW 2, 7.6 ± 12.6 letters vs. 8.9 ± 14.4 letters, respectively. The sponsor does not consider the observed difference between treatment groups to be of clinical relevance in the context of the studies as a whole and, therefore, stands behind the conclusion that 2 mg Eylea dosed every 8 weeks provides the same efficacy as when dosed every 4 weeks. Minor differences seen between treatment groups in the clinical studies represent random variability and not a clinically meaningful outcome.

The Delegate commented that the sponsor’s justification for the proposed dosing regimen does not cite study data that show a higher rate of local adverse events attributable to more frequent injections and so the sponsor’s suggestion is taken to be “in principle”.

The sponsor acknowledged that this part of the justification is indeed proposed “in principle” because (1) the pivotal studies were not designed (that is, not powered) to show differences in the incidence of adverse events and (2) although subjects in the 2q8 group received fewer “real” injections, they underwent all the same preparatory procedures and a sham injection, which included touching and applying pressure to the eye. Based on logical considerations that fewer injections, each of which carries risk for an adverse event, expose the patient to fewer opportunities for an adverse event, the sponsor believes that Eylea may impart a clinically relevant decrease in the risk of serious complications associated with intravitreal injections. This reduction of risk is by virtue of the bimonthly treatment regimen with Eylea such that the number of injections given over the first year in a 2q8 dosing regimen is reduced by more than 40% compared to monthly treatment and therefore, the risk of any injection-related adverse event, including serious complications such as endophthalmitis, may also be reduced by a similar magnitude.

The Delegate acknowledged that the three regimens of aflibercept are non-inferior in respect of the primary endpoint at 12 months in VIEW 1 and VIEW 2 but commented that the numerous secondary endpoints are harder to interpret, other than qualitatively as showing small differences. The Delegate suggested that perhaps the 24 month data may show statistically significant trends in terms of the statistical plan, noting that the 12 month data was pooled from both studies to support a claim for non-inferiority in the secondary endpoints with consistency or response across various subgroups.

The sponsor clarified that no claim of non-inferiority was made based on the secondary efficacy endpoints.

The VIEW 1 and VIEW 2 studies included four secondary endpoints: change from baseline in BCVA as measured by ETDRS letter score at Week 52, proportion of subjects who gained at least 15 letters of vision from baseline to Week 52, change in total NEI VFQ-25 score from baseline to Week 52, and change in CNV area from baseline to Week 52. All other endpoints were considered to be exploratory and were not subjected to formal statistical analysis. In addition, based on the conditional sequence of statistical hypothesis tests, which controlled for multiplicity in the testing of these four secondary endpoints, the hierarchical testing had to be stopped after the first or second step, because the pairwise comparison failed to show a statistically significant treatment difference between the Eylea 2q4 group and the Lucentis 0.5q4 (0.5 mg every 4 weeks) group. Therefore, the p-values provided for all subsequent steps were for descriptive purposes only and were not used to make a claim of superiority. Regarding the secondary efficacy endpoints, based on the confidence intervals for the differences between Lucentis and Eylea, both studies concluded that all secondary endpoint analyses supported the comparability of the efficacy of Lucentis and all 3 Eylea treatment schedules, including the 2 mg bimonthly regimen.
The pooled efficacy data from Year 1 are presented in the sponsor's Summary of Clinical Efficacy. There is no mention in this document that non-inferiority has been shown in the secondary endpoints. The only mention of non-inferiority is made in reference to the primary endpoint, proportions of subjects who maintained vision at Week 52.

The sponsor clarified further that all primary and secondary endpoint analyses performed on the Year 1 data were repeated for the data covering the whole 2 year study period and all such analyses were considered to be only exploratory in nature.

With respect to safety data and the observed increase in intraocular pressure of around 3.2 mmHg immediately post-treatment that did not increase with subsequent treatments, the Delegate requested clarification around the duration of this increase in intraocular pressure, the proportion that needed treatment, and the time course of the increased intraocular pressure.

The sponsor clarified that a transient increase in intraocular pressure (IOP) immediately post-injection is an expected event with any intravitreal injection. There is no suggestion in the data from the pivotal studies that Eylea is associated with an excessive or durable increase in IOP, as evidenced by the subsequent IOP. No mean increases in pre-dose IOP occurred in any treatment group during the first year of treatment. Increases in IOP were reported as treatment-emergent adverse events at a lower incidence with Eylea (5.2%) than Lucentis (6.9%) and in both treatments, most were considered to be related to the injection procedure (Eylea 3.2%; Lucentis 4.5%) and not the study drug (Eylea 0.5%; Lucentis 1.2%). In subjects with “sustained” increases in IOP, defined as consecutive visits with pre-injection IOP > 21 mmHg or ≥ 25 mmHg, more subjects treated with Lucentis met this definition than those treated with Eylea. This was true for both the study eye as well as the non-injected fellow eye.

The single subject (in the Eylea 2q8 group) who discontinued the study because of an TEAE of IOP increased experienced two non-serious, mild events of IOP increased, once to 28 mmHg and once to 29 mmHg. In both instances the study drug was temporarily withdrawn and the subject recovered. The investigator did not consider the events to be related to study drug or study procedures.

Overall, the need for IOP-lowering interventions with the exception of the routine prophylactic use of IOP lowering medications at some study sites, did not suggest that many subjects in these studies were developing ocular hypertension. IOP increased is listed as an adverse drug reaction (ADR) for the product and, therefore, is adequately handled in the product labelling with regard to patient safety.

In relation to the proposed RMP, the Delegate acknowledged that the planned risk management activities are reasonable but commented that the risk management plan has not been fully accepted by the evaluator.

The sponsor clarified and drew TGA’s and ACPM’s attention to their response of 24 October 2011, which answered the quality evaluator’s question surrounding the potential for overdose from the PFS and vial presentations. The potential risk of multi-patient use by combining residual amounts from several vials is considered to be very low. Given that there is little to no meaningful amount of residual volume following withdrawal of the content to prepare the 50 μL dose, it would be very difficult, if not impossible, to combine the residual contents of multiple vials to obtain a usable volume of the product. As reinforced in the PI, administration must be carried out according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. The PI clearly instructs that each pre-filled syringe or vial should only be used for the treatment of a single eye and that any unused product must be discarded following injection.
The Delegate requested the sponsor to comment on managing the risks associated with not supplying syringes and needles in the vial package and not supplying an injection needle in the syringe pack.

The sponsor believes that injection needles, available from various existing suppliers, would be readily available to the experienced physicians administering Eylea and acknowledges that practicing ophthalmologists often prefer one brand of injection needle over another. Not including an injection needle in the packaging for Eylea therefore provides flexibility to the physician and allows him/her to use the brand with which he/she has the most experience. The PI recommends a 30-G ½-inch injection needle for the administration of Eylea, although there is no risk from using a needle of a slightly different size as long as such a needle was selected based on the experience and standards of the qualified treating physician.

In the event that the vial presentation is marketed, a filter fill needle would be supplied in the packaging as a filter needle may not be readily available to a treating physician. As is the case with the injection needle, the sponsor believes that appropriate syringes, available from various existing suppliers would be readily available to the experienced physicians administering Eylea and therefore, inclusion of a syringe in the vial packaging is not necessary.

Advisory committee considerations

The Advisory Committee on Prescription Medicines (ACPM), having considered the evaluations and the Delegate’s overview, as well as the sponsor’s response to these documents, advised the following:

The ACPM considered this product to have a positive benefit-risk profile for the indication;

*For the treatment of neovascular (wet) age-related macular degeneration (AMD)*.

In making this recommendation, the ACPM considered the dosage regimen, as proposed by the sponsor was appropriate.

The ACPM supported the amendments proposed by the Delegate to the Product Information (PI) and Consumer Medicines Information (CMI) and others which should be considered include;

- a statement in the *Dosage and Administration / Clinical Trial* sections to highlight the absence of evaluated data beyond 12 months of use.

- the reporting of the primary endpoint for each of the two pivotal studies should be the main focus of statements in the *Clinical Trials* section. The secondary endpoints for each study may be listed and, where relevant, described as favourable trends but the statistical limitations should be disclosed. The fact that the studies are planned to run for two years should also be disclosed.

The ACPM advised that the implementation by the sponsor of the recommendations outlined above to the satisfaction of the TGA, in addition to the evidence of efficacy and safety provided would support the safe and effective use of this product.

Outcome

Based on a review of quality, safety and efficacy, TGA approved the registration of Eylea aflibercept (rch) 40 mg/mL solution for intravitreal injection vial and Eylea aflibercept (rch) 40 mg/mL solution for intravitreal injection pre-filled syringe, indicated for:

*Eylea (aflibercept) is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).*
Specific conditions applying to these therapeutic goods:

1. The implementation in Australia of the Eylea (aflibercept) 40 mg/mL solution for intravitreal injection (pre-filled syringe and vial) Risk Management Plan (RMP), dated 21 January 2012 included with the submission and any subsequent revisions, as agreed with the TGA and its Office of Product Review.

Attachment 1. Product Information

The following Product Information was approved at the time this AusPAR was published. For the current Product Information please refer to the TGA website at www.tga.gov.au.
PRODUCT INFORMATION

EYLEA®
afibercept (rch)

NAME OF THE MEDICINE

Active ingredient: Afibercept

Chemical names: Vascular endothelial growth factor receptor type VEGFR-1 (synthetic human immunoglobulin domain 2 fragment) fusion protein with vascular endothelial growth factor receptor type VEGFR-2 (synthetic human immunoglobulin domain 3 fragment) fusion protein with immunoglobulin G1 (synthetic Fc fragment), dimer

des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment) fusion protein with human immunoglobulin G1-(227 C-terminal residues)-peptide (Fc fragment)], (211-211’:214-214’)-bisdisulfide dimer

CAS number: 862111-32-8

Molecular weight: 97 kDa (protein molecular weight)
115 kDa (total molecular weight)

Structure: The secondary and tertiary structures of afibercept as well as the amino acid structure are shown in Figures 1 and 2.
Figure 1: Aflibercept secondary and tertiary structures

Figure 2: Aflibercept amino acid structure

SDTGR PFVEM YSEIP EIIHM TEGRE LVIP RVTSP NITVT
LKKFP LDTLI PDGKR IIWDS RKGFI ISNAT YKEIG LLTCE
ATVNG HLYKT NYLTH RQTNT IIDVV LSPSH GIELS VGEKL
VLNC T ARTEL NVGID FNWEY PSSKH QHKKL VNRDL KTQSG
SEMKK FLSTL TIDGV TRSDQ GLYT AASSG LMTKK NSTFV
RVHEK DKTHT PCCP APELL GGPSV FLFPP KPKDT LMISR
TPEVT CVVVD VSHED PEVKF NWYVD GVEVH NAKTK PREEQ
YNSTY RVVSV LTVLH QDWLN GKEYK CKVSN KALPA PIEKT
ISKAK GQPRE PQVYT LPPSR DELTK NQVSL TCVK GFYPS
DIAVE WESNG QPENN YKTTP PVLDS DGSFF LYSKL TVDKS
RWQQG NVFSC SVMHE ALHNH YTQKS LSLSP GA
DESCRIPTION

EYLEA is a sterile, clear, colourless to pale yellow, preservative-free, iso-osmotic aqueous 40 mg/mL solution for intravitreal injection.

Excipients: Polysorbate 20, sodium phosphate - monobasic monohydrate, sodium phosphate - dibasic heptahydrate, sodium chloride, sucrose, water for injection.

PHARMACOLOGY

Pharmacodynamic properties

Pharmacotherapeutic group: Ophthalmologicals / Antineovascularization agents

ATC Code: S01LA05

Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.

Mechanism of action

Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PIGF binds only to VEGFR-1, which is also present on the surface of leukocytes. Excessive activation of these receptors by VEGF-A can result in pathological neovascularisation and excessive vascular permeability. PIGF can synergise with VEGF-A in these processes, and is also known to promote leukocyte infiltration and vascular inflammation. A variety of ocular diseases, including neovascular (wet) age-related macular degeneration (AMD), are associated with pathologic neovascularisation and vascular leakage, and can result in thickening and oedema of the retina, which is thought to contribute to vision loss.

Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PIGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors. The equilibrium dissociation constant (K_D) for aflibercept binding to human VEGF-A_{165} is 0.5 pM and to human VEGF-A_{121} is 0.36 pM. The K_D for binding to human PIGF-2 is 39 pM.

Pharmacodynamic effects

Wet AMD is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal oedema and/or sub-/intra-retinal haemorrhage, resulting in loss of visual acuity.
In patients treated with EYLEA (one injection per month for three consecutive months, followed by one injection every 2 months), retinal thickness decreased soon after treatment initiation, and the mean CNV lesion size was reduced, consistent with the results seen with ranibizumab 0.5 mg every month.

In pivotal phase III clinical studies, VIEW 1 and VIEW 2, there were mean decreases in retinal thickness on optical coherence tomography (OCT) at week 52: -130 and -129 microns for the EYLEA 2 mg every two months and ranibizumab 0.5 mg every month study groups, respectively, in VIEW 1; -149 and -139 microns for the EYLEA 2 mg every two months, and ranibizumab 0.5 mg every month study groups, respectively, in VIEW 2.

**Pharmacokinetic properties**

EYLEA is administered directly into the vitreous to exert local effects in the eye.

**Absorption / Distribution**

Aflibercept is slowly absorbed from the eye into the systemic circulation after intravitreal administration and is predominately observed in the systemic circulation as an inactive, stable complex with VEGF; however only free aflibercept is able to bind endogenous VEGF.

In a pharmacokinetic sub-study with frequent sampling, maximum plasma concentrations of free aflibercept (systemic C<sub>max</sub>) were low, with a mean of approximately 0.02 µg/mL (range 0 to 0.054) within 1 to 3 days after 2 mg intravitreal injection, and were undetectable two weeks following dosage in almost all patients. Aflibercept does not accumulate in the plasma when administered intravitreally every 4 weeks.

The mean maximum plasma concentration of free aflibercept is approximately 50 to 500 times below the aflibercept concentration required to inhibit the biologic activity of systemic VEGF by 50% in animal models. It is estimated that after intravitreal administration of 2 mg to patients, the mean maximum plasma concentration of free aflibercept is more than 100-fold lower than the concentration of aflibercept required to half-maximally bind systemic VEGF. Therefore, systemic pharmacodynamic effects are unlikely.

**Elimination**

As EYLEA is a protein-based therapeutic, no metabolism studies have been conducted.

Free aflibercept binds VEGF to form a stable, inert complex. As with other large proteins, both free and bound aflibercept are expected to be cleared by proteolytic catabolism.
Patients with renal impairment

No special studies in patients with renal impairment were conducted with EYLEA. Pharmacokinetic analysis of patients in the VIEW 2 study, of which 40% had renal impairment (24% mild, 15% moderate, and 1% severe), revealed no differences with respect to plasma concentrations of active drug after intravitreal administration every 4 or 8 weeks.

CLINICAL TRIALS

The safety and efficacy of EYLEA were assessed in two pivotal phase III randomised, multi-centre, double-masked, active-controlled studies in patients with wet AMD. A total of 2412 patients were treated and evaluable for efficacy (1817 with EYLEA) in the two studies (VIEW 1 and VIEW 2). In each study, patients were randomly assigned in a 1:1:1:1 ratio to 1 of 4 dosing regimens:

1. EYLEA administered at 2 mg every 8 weeks (EYLEA 2Q8) following 3 initial monthly doses
2. EYLEA administered at 2 mg every 4 weeks (EYLEA 2Q4)
3. EYLEA administered at 0.5 mg every 4 weeks (EYLEA 0.5Q4)
4. Ranibizumab administered at 0.5 mg every 4 weeks (Ranibizumab 0.5Q4)

Patient ages ranged from 49 to 99 years with a mean of 76 years. Approximately 89% (1616/1817) of the patients randomised to treatment with EYLEA were 65 years of age or older and approximately 63% (1139/1817) were 75 years of age or older.

Primary efficacy data at 52 weeks have been evaluated for these studies that are planned to run for 96 weeks.

In both studies, the primary efficacy endpoint was the proportion of patients in the Per Protocol Set who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline. The studies were intended to test for non-inferiority against ranibizumab 0.5 mg given every 4 weeks.

In the VIEW 1 study, at week 52, 95.1% of patients in the EYLEA 2Q8 treatment group maintained vision compared to 94.4% of patients in the ranibizumab 0.5Q4 group. EYLEA treatment was shown to be non-inferior to the ranibizumab 0.5Q4 group.

In the VIEW 2 study, at week 52, 95.6% of patients in the EYLEA 2Q8 treatment group maintained vision compared to 94.4% of patients in the ranibizumab 0.5Q4 group.

The VIEW 1 and VIEW 2 studies included four secondary efficacy endpoints: mean change in Best Corrected Visual Acuity (BCVA), proportion of patients who gained ≥15 letters, change in the total National Eye Institute Visual Function Questionnaire (NEI VFQ-25) score, and change in CNV area.
Detailed results from the combined analysis of both studies (primary* and secondary# endpoints) are shown in Table 1 and Figure 3 below.

Table 1: Efficacy outcomes at week 52; combined data from the VIEW 1 and VIEW 2 studies (b)

<table>
<thead>
<tr>
<th>Efficacy outcome</th>
<th>EYLEA 2 mg Q8 (e) (n = 607)</th>
<th>Ranibizumab 0.5 mg Q4 (n = 595)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean number of active injections over 52 weeks</td>
<td>7.6</td>
<td>12.3</td>
</tr>
<tr>
<td>Proportion of patients with maintained visual acuity (&lt;15 letters of BCVA (a) loss) (Per Protocol Set) *</td>
<td>95.33%</td>
<td>94.42%</td>
</tr>
<tr>
<td>Difference (c) (95% CI) (d)</td>
<td>0.9% (-1.7, 3.5)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mean change in BCVA as measured by ETDRS (a) letter score from baseline #</td>
<td>8.40</td>
<td>8.74</td>
</tr>
<tr>
<td>Difference in LS (a) mean (ETDRS letters) (c) (95% CI) (d)</td>
<td>-0.32 (-1.87, 1.23)</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of patients who gained at least 15 letters of vision from baseline #</td>
<td>30.97%</td>
<td>32.44%</td>
</tr>
<tr>
<td>Difference (c) (95% CI) (d)</td>
<td>-1.5% (-6.8, 3.8)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mean change in total score as measured by NEI VFQ-25 from baseline #</td>
<td>5.00</td>
<td>5.56</td>
</tr>
<tr>
<td>Difference in LS (a) mean (NEI VFQ-25 score) (c) (95% CI) (d)</td>
<td>-1.26 (-2.72, 0.20)</td>
<td>N/A</td>
</tr>
<tr>
<td>Mean change in CNV area as measured by FA (a) from baseline #</td>
<td>-4.28</td>
<td>-4.21</td>
</tr>
<tr>
<td>Difference in LS (a) mean (CNV area) (g) (95% CI) (d)</td>
<td>0.08 (-0.46, 0.61)</td>
<td>N/A</td>
</tr>
</tbody>
</table>
(a) BCVA: Best Corrected Visual Acuity  
ETDRS: Early Treatment Diabetic Retinopathy Study  
LS mean: least squares mean  
FA: Fluorescein angiography  

(b) Full Analysis Set (FAS), Last Observation Carried Forward (LOCF); only proportion of patients with maintained visual acuity is shown for the Per Protocol Set (PPS)  

(c) The difference is the value of the EYLEA group minus the value of the ranibizumab group. A positive value favours EYLEA.  

(d) Confidence Interval (CI) calculated by normal approximation  

(e) After treatment initiation with three monthly doses  

(f) A confidence interval lying entirely above -10% indicates a non-inferiority of EYLEA to ranibizumab  

(g) The difference is the value of the EYLEA group minus the value of the ranibizumab group  

* Primary endpoint  
# Secondary endpoint – see statistical comment below
While there were small differences between EYLEA and ranibizumab, no clinically relevant differences were seen between the treatment groups across all four secondary efficacy endpoints, based on the confidence intervals for the differences between EYLEA and ranibizumab. All statistical tests on secondary efficacy endpoints were considered to be exploratory in the combined analysis of both studies. All secondary endpoint analyses supported the comparability of the efficacy of all 3 EYLEA treatment schedules and ranibizumab.

In combined data analysis of the VIEW 1 and VIEW 2 studies EYLEA demonstrated clinically meaningful changes from baseline in NEI VFQ-25 scores and subscales (near activities, distance activities, and vision-specific dependency). The magnitude of these changes was similar to that seen in published studies, which corresponded to a 15-letter gain in BCVA.

Exploratory analyses of efficacy results in all evaluable subgroups (e.g. age, gender, race, baseline visual acuity, lesion type, lesion size) in each study and in the combined analysis were consistent with the results in the overall populations.

**INDICATIONS**

EYLEA (aflibercept) is indicated for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
CONTRAINDICATIONS

- Known hypersensitivity to aflibercept or to any of the excipients
- Ocular or periocular infection
- Active severe intraocular inflammation

PRECAUTIONS

Endophthalmitis

Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis (see ADVERSE EFFECTS). Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay and should be managed appropriately.

Increase in intraocular pressure

Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection, including with EYLEA (see ADVERSE EFFECTS). Special precaution is needed in patients with poorly controlled glaucoma. In all cases both intraocular pressure and the perfusion of the optic nerve head must therefore be monitored and managed appropriately.

Effects on fertility

Effects on male and female fertility were assessed as part of a 6-month study in monkeys with intravenous administration of aflibercept at doses ranging from 3 to 30 mg/kg every one to two weeks. Absent or irregular menses associated with alterations in female reproductive hormone levels and changes in sperm morphology and motility (considered consequential to male fertility) were observed at all dose levels. Based on $C_{\text{max}}$ and AUC for free aflibercept observed at the 3 mg/kg intravenous dose, the systemic exposures were approximately 4900-fold and 1500-fold higher, respectively, than the exposure observed in humans after an intravitreal dose of 2 mg. All changes were reversible.

Use in pregnancy (Category D)

There are no data on the use of aflibercept in pregnant women. Studies in animals have shown reproductive toxicity, including a series of external, visceral, skeletal malformations, after systemic administration. EYLEA is not recommended during pregnancy unless the potential benefit outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.

Aflibercept produced malformations and other fetal abnormalities in pregnant rabbits with intravenous administration (at 3 to 60 mg/kg once every 3 days during the period of organogenesis). A No Observed Effect Level (NOEL) for adverse effects on embryofetal
development was not established. At the lowest dose tested (3 mg/kg), the systemic exposures based on $C_{\text{max}}$ and AUC for free aflibercept were approximately 2900-fold and 600-fold higher, respectively, when compared to corresponding values observed in humans after an intravitreal dose of 2 mg.

Use in lactation

It is unknown whether aflibercept is excreted in human milk. A risk to the breast-fed child cannot be excluded. EYLEA is not recommended during breast-feeding. A decision must be made whether to discontinue breast-feeding or to abstain from EYLEA therapy.

Paediatric use

Wet AMD does not occur in children and adolescents. Therefore the safety and efficacy of EYLEA have not been studied in these age groups.

Use in the elderly

No special considerations are needed.

Genotoxicity

No studies have been conducted on the mutagenic or clastogenic potential of aflibercept. As a large protein molecule, aflibercept is not expected to interact directly with DNA or other chromosomal material.

Carcinogenicity

No studies have been conducted on the carcinogenic potential of aflibercept.

Effects on ability to drive or use machines

Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA and the associated eye examinations. They should not drive or use machinery until visual function has recovered sufficiently.

INTERACTIONS WITH OTHER MEDICINES

No formal drug interaction studies have been performed with EYLEA.

ADVERSE EFFECTS

A total of 1824 patients constituted the safety population in the two phase III studies with up to 96 weeks of exposure to EYLEA, and 1223 patients were treated with the 2 mg dose.
Summary of the safety profile

Serious adverse reactions related to the injection procedure have occurred in less than 1 in 1,000 intravitreal injections with EYLEA and included endophthalmitis, traumatic cataract and transient increased intraocular pressure (see PRECAUTIONS).

The most common adverse reactions (in at least 5% of patients treated with EYLEA) were conjunctival haemorrhage (26.7%), cataract (12.8%), eye pain (10.3%), vitreous detachment (8.4%), vitreous floaters (7.6%), and increased intraocular pressure (7.2%). These adverse reactions occurred with a similar incidence in the ranibizumab treatment group.

Tabulated list of adverse reactions

The safety data described below include all adverse reactions (serious and non-serious) with a reasonable possibility of causality to the injection procedure or medicinal product over the 96 weeks study duration.

The adverse reactions are listed by system organ class and frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100).

Table 2: Adverse reactions in phase III wet AMD studies

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Very common (≥1/10)</th>
<th>Common (≥1/100 to &lt;1/10)</th>
<th>Uncommon (≥1/1,000 to &lt;1/100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye disorders</td>
<td>Cataract,</td>
<td>Retinal detachment,</td>
<td>Endophthalmitis,</td>
</tr>
<tr>
<td></td>
<td>Conjunctival haemorrhage,</td>
<td>Retinal pigment epithelium tear,</td>
<td>Retinal tear</td>
</tr>
<tr>
<td></td>
<td>Eye pain</td>
<td>Detachment of the retinal pigment epithelium,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Corneal erosion,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intraocular pressure increased,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vision blurred,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitreous floaters,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Corneal oedema,</td>
<td></td>
</tr>
</tbody>
</table>
## System Organ Class

<table>
<thead>
<tr>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>(≥1/10)</td>
<td>(≥1/100 to &lt;1/10)</td>
<td>(≥1/1,000 to &lt;1/100)</td>
</tr>
</tbody>
</table>

### Adverse Event Descriptions

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitreous detachment,</td>
<td>Injection site pain,</td>
</tr>
</tbody>
</table>
| Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.

ATEs, as defined by Antiplatelet Trialists' Collaboration (APTC) criteria, include nonfatal myocardial infarction, nonfatal stroke, or vascular death (including deaths of unknown cause). The incidence in the VIEW 1 and VIEW 2 wet AMD studies during the 96 weeks study period was 3.3% (61 out of 1824) in the combined group of patients treated with EYLEA compared with 3.2% (19 out of 595) in patients treated with ranibizumab.

As with all therapeutic proteins, there is a potential for immunogenicity with EYLEA.

### DOSAGE AND ADMINISTRATION

EYLEA is for intravitreal injection only.

It must only be administered by a qualified physician experienced in administering intravitreal injections.

#### Dosage regimen

The injection volume is 50 µL of EYLEA (equivalent to 2 mg aflibercept).
EYLEA treatment is initiated with one injection per month for three consecutive months, followed by one injection every two months. (See CLINICAL TRIALS for dosing experience).

**Special populations**

**Patients with hepatic and/or renal impairment**

No specific studies in patients with hepatic and/or renal impairment were conducted with EYLEA. Available data do not suggest a need for a dose adjustment with EYLEA in these patients (see Pharmacokinetic properties).

**Method of administration**

Intravitreal injections must be carried out according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. In general, adequate anaesthesia and asepsis, including topical broad spectrum microbiocide, have to be ensured. Surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent) are recommended. RANZCO’s guidelines for performing intravitreal therapy (August 2006) recommend the use of antimicrobial drops for 3-5 days following each injection.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis should be available.

Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye, photophobia, blurring of vision) without delay.

Each pre-filled syringe or vial should only be used for the treatment of a single eye.

After injection any unused product must be discarded.

**Instructions for use / handling**

The pre-filled syringe and the vial are for single use only.

Prior to administration visually inspect the solution for injection. Do not use the vial or pre-filled syringe if particulates, cloudiness, or discolouration are visible.

Prior to usage, the EYLEA unopened vial or pre-filled syringe blister pack may be stored at room temperature (25°C) for up to 24 hours. After opening the vial or blister pack, proceed under aseptic conditions.

For the intravitreal injection a 30 G x ½ inch injection needle should be used.
Pre-filled syringe

1. When ready to administer EYLEA, open the carton and remove the sterilised blister pack. Carefully peel open the blister pack ensuring the sterility of its contents. Keep the syringe in the sterile tray until you are ready for assembly.

2. Using aseptic technique, remove the syringe from the sterilised blister pack.

3. To remove the syringe cap, hold the syringe in one hand while using your other hand to grasp the syringe cap with the thumb and forefinger. Please note: Snap off (do not turn or twist) the syringe cap.

4. To avoid compromising the sterility of the product, do not pull back on the plunger.

5. Using aseptic technique, firmly twist the injection needle onto the Luer-lock syringe tip.

6. Remove the plastic needle shield.
7. Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top.

8. To eliminate all bubbles and to expel excess drug, slowly depress the plunger to align the cylindrical base of the dome tip with the black dosing line on the syringe (equivalent to 50 µL).
**Vial**

1. Remove the plastic cap and disinfect the outer part of the rubber stopper of the vial.

2. Attach the 18 G, 5-micron filter needle supplied in the carton to a 1 mL sterile, Luer-lock syringe.

3. Push the filter needle into the centre of the vial stopper until the needle touches the bottom edge of the vial.

4. Using aseptic technique withdraw all of the EYLEA vial contents into the syringe, keeping the vial in an upright position, slightly inclined to ease complete withdrawal.

5. Ensure that the plunger rod is drawn sufficiently back when emptying the vial in
order to completely empty the filter needle.

6. Remove the filter needle and properly dispose of it. Note: Filter needle is not to be used for intravitreal injection.

7. Using aseptic technique, firmly twist a 30 G x ½ inch injection needle to the Luer-lock syringe tip.

8. When ready to administer EYLEA, remove the plastic needle shield.

9. Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top.

10. Eliminate all bubbles and expel excess drug by slowly depressing the plunger so that the plunger tip aligns with the line that marks 0.05 mL (equivalent to 50 µL) on the syringe.
Incompatibilities

EYLEA must not be mixed with other medicinal products.

OVERDOSAGE

In clinical trials doses of up to 4 mg in monthly intervals and isolated cases of overdoses with 8 mg were generally well tolerated. Overdosing was associated with increased injection volume and subsequently with increased intraocular pressure. Therefore, in case of overdosage intraocular pressure should be monitored and if deemed necessary by the treating physician, adequate treatment should be initiated. It is advisable to contact the Poisons Information Centre (131126) for recommendations on the management and treatment of overdose.

PRESENTATION AND STORAGE CONDITIONS

Presentation

EYLEA is a sterile, clear, colourless to pale yellow, preservative-free, iso-osmotic aqueous 40 mg/mL solution for intravitreal injection.

EYLEA is supplied in a single-use vial or pre-filled syringe.

Each vial and pre-filled syringe provides a usable amount to deliver a single dose of 50 µL solution for intravitreal injection containing 2 mg aflibercept.

Pre-filled syringe

Each carton includes a sealed blister pack with a sterile pre-filled type I glass syringe, containing approximately 90 µL of extractable volume, sealed with an elastomeric
plunger stopper and an elastomeric tip cap that is part of a closure system with Luer lock adaptor. The syringe has a pre-attached plunger rod and a finger plate.

**Vial**

Each carton includes a type I glass vial containing approximately 100 µL of extractable volume, with an elastomeric rubber stopper, and an 18 G filter needle.

**Shelf life and storage conditions**

Shelf life: 12 months

Store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light.

Keep the pre-filled syringe in its blister pack and carton in order to protect from light.

Keep the vial in its carton in order to protect from light.

**NAME AND ADDRESS OF THE SPONSOR**

Bayer Australia Limited  
ABN 22 000 138 714  
875 Pacific Highway  
Pymble, NSW 2073

**POISON SCHEDULE OF THE MEDICINE**

PRESCRIPTION ONLY MEDICINE (S4)

**DATE OF FIRST INCLUSION IN THE ARTG**